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ABSTRACT 
The dengue virus protein NS1, is the first non-structural protein to be translated in 
the dengue virus genome. It is glycosylated, which is unusual for a viral non-
structural protein and exists as an oligomer in its native form. The function of NS1 is 
still largely unknown however there is evidence that it is involved in RNA replication. 
It is also capable of inducing an immune response in experimental animals, with 
antibodies to NS1 being able to confer passive protection against lethal virus 
challenge. The work that comprises this thesis sought to expand our understanding 
of NS1 by exploring the human immune response to dengue virus infection and the 
role of NS1 in pathogenesis, and to analyze in detail the antigenicity and structure 
of the protein by building on our existing data. 
Both the human immune response to NS1 and the circulation of NS1 in the serum 
of dengue virus infected patients was examined. An antigen capture ELISA was 
first developed for the detection of dengue virus NS1 based on the selection of 
monoclonal and polyclonal antibodies as the probe and capture reagents 
respectively. The limit of detection for NS1 with the method developed was 4 ng / 
mL for dengue-2 virus infections and 15 ng / mL for other dengue serotypes 
detected with a cross - reactive monoclonal antibody (MAb) probe. Sera were 
obtained from dengue virus infected patients in Thailand and screened for the 
presence of NS1 and antibody to NS1. Examination of clinical samples 
demonstrated that the assay was able to detect NS1 with minimal interference from 
serum components at the test dilutions routinely used, suggesting that it could form 
the basis of a useful additional diagnostic test for dengue virus infection. The 
presence of high levels of secreted NS1 in the sera of patients experiencing 
secondary dengue virus infections in addition to high NS1 antibody concentrations, 
suggests that NS1 may be a significant contributor to the formation of circulating 
immune complexes that are hypothesized to play an important role in the 
pathogenesis of severe dengue disease. 
Although NS1 has been reported to be immunogenic, little detailed information 
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exists regarding the antigenic epitopes on the native dimeric form of the protein. In 
this thesis, using a panel of anti - NS1 MAbs in a competitive ELISA, five major 
antigenic domains and several sub - domains were defined for the secreted form of 
NS1. Together with PEPSCAN data obtained previously in this laboratory, important 
protective and antigenic epitopes in the primary and tertiary sequence of NS1 were 
mapped. Using NS1 derived from both mammalian (Vero) and insect (mosquito) 
cells, and in both soluble and membrane - associated forms, it was found that the 
membrane-associated NS1 produced in Vero cells lacked one important antigenic 
and protective epitope. This may explain differences noted in protection of lethally 
challenged mice by the different forms of NS1. Partial enzymatic digestions of 
purified NS1 combined with N-terminal sequencing of the protein fragments 
obtained and an analysis of their reactivity with the panel of MAbs, provided further 
insights into the antigenic structure of NS1 at the amino acid sequence level. 
Detergent phase separation experiments carried out on these proteolytic fragments 
have identified that the hydrophobic character of NS1 resides in the N-terminal half 
of the molecule. All of this data has collectively enabled the construction of a 
structural model for NS1 that is presented in Chapter 4. 
Progress was made toward identifying the parameters required for crystallization of 
dengue-2 NS1 with the expectation that a crystal structure would assist in defining 
the function of the protein. As the amount of NS1 secreted from dengue virus 
infected cells is not produced in sufficient quantities to purify for crystallography 
studies, NS1 was expressed as a recombinant protein in the baculovirus expression 
system. Pulse-chase experiments defined the optimum conditions for expression of 
recombinant secreted NS1 from Spodoptera frugiperda cells. Recombinant NS1 
was immunoaffinty purified and found experimentally to resemble the authentic 
protein in terms of cellular localization, secretion, oligomerization, glycosylation and 
antigenicity (using the antigenic epitopes defined in Chapter 4). Cross-linking and 
electron microscopy studies provided support for the hexameric structure of both 
native and recombinant NS1. The isoelectric point of NS1 was determined to be 5.7 
and concentrated protein (from 5 - 7 mg / mL) was used in crystallography trials. 
Both microcrystals and crystals were obtained under specific buffer conditions after 
ten weeks and nine months of incubation respectively. Unfortunately, these crystals 
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did not diffract and are therefore not useful in collating structural information. 
However, the successful establishment of a purification regime for NS1 has been 
achieved and is an important step towards successful crystallization and ultimately 
structure resolution. 
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CHAPTER 1 
INTRODUCTION 
1.1 FLAVIVIRUSES 
(a) General properties and classification 
In 1984 the International Committee for the Nomenclature of Viruses voted to make 
the Flaviviridae (from the Latin flavus, meaning yellow) a separate family 
(Westaway et al, 1986). Within this family there are currently three genera: the 
flaviviruses, the pestiviruses and hepaciviruses (which includes hepatitis C virus) 
(Ruggli and Rice, 1999) that show no serological cross-reactivity. These three 
groups have shared properties including a lipid envelope and a single stranded 
positive sense RNA genome containing a single open reading frame (ORF). Within 
the flaviviruses, eight serological sub-groups are recognized based on cross 
neutralization tests (Monath and Heinz, 1986; Calisher et al, 1989). Yellow fever 
(YF) virus is the prototype virus of the flavivirus group that comprises 68 members. 
Nucleotide sequence analysis of different flaviviruses has shown that they are 
closely related and have evolved from a common ancestor (Gould et al, 1985; 
Deubel etal, 1986; Rice etal, 1986; Hahn et al, 1988). 
The majority of flaviviruses are human or veterinary pathogens (Westaway et al, 
1985). Approximately 70% of these viruses are transmitted by infected mosquitoes 
or ticks to vertebrate hosts (Schlesinger and Schlesinger, 1990) and are therefore 
termed arboviruses (arthropod-borne viruses). The significant spread of these 
viruses over the previous few decades has been a consequence of the disruption of 
the vector-vertebrate equilibrium (Chambers etal, 1990) with worldwide eradication 
considered unlikely due to their maintenance in animal reservoirs and transovarial 
transmission in arthropods (LeDuc, 1989). Combined, these viruses are a major 
public health problem although the dengue viruses are considered to be the most 
significant with up to 100 million infections occurring annually (Halstead, 1988; 
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Jacobs and Young, 1998) and over two billion people at risk of dengue infection in 
tropical areas (WHO, 1999). 
(b) Historical Background 
The study of flaviviruses began with the discovery by Walter Reed and colleagues 
in 1900 that the disease yellow fever was caused by a filterable agent and 
transmitted to humans by mosquitoes (Kelly, 1907). For more than two hundred 
years, yellow fever was one of the great plagues of the world (Strode, 1951; Theiler 
and Downs, 1973; WHO, 1971; WHO, 1986) that decimated populations and 
paralysed industry and trade (Tomori, 1999). The tropical and subtropical regions of 
the Americas were subjected to devastating epidemics and serious outbreaks were 
recorded in Spain, France, England and Italy (Strode, 1951). A large outbreak of 
yellow fever occurred in Ethiopia between 1960 and 1962 with 15 000 - 30 000 
estimated deaths (Monath etal, 1980; WHO 1986). Similar outbreaks still occur in 
Africa (Anon, 1994) primarily in areas contiguous with rainforest regions (Soper, 
1936) where jungle yellow fever is enzootic (Tomori, 1999). 
Dengue fever is a very old disease with the earliest record of dengue-like illness 
found in a Chinese encyclopaedia of disease symptoms and remedies first 
published during the Chin dynasty (265-420 AD) (Gubler, 1999). Dengue was the 
second human disease (after yellow fever) whose etiology was identified as a 
"filterable virus" (Ashburn and Craig, 1907). Early authors have assumed that 
dengue virus was spread with the slave trade from East Africa to the Carribean, 
with an extensive outbreak occurring in the West Indies between 1827 and 1828 
(Brown, 1977). During the 19th and 20th centuries, outbreaks have occurred on all 
continents and on the islands of the South Pacific and in the Carribean (Brown, 
1977; Gratz and Knudsen, 1996). This extensive spread has continued to the 
present day. The first outbreak of DSS may have occurred in 1897 in Queensland 
(Hare, 1898). Dengue was a major cause of death in northern Australia until the 
beginning of World War I (Lumley and Taylor, 1943). During the last century major 
epidemics outside of the South East Asian region, where it has been endemic for 
more than 50 years, were recorded in the southern US (1920,1922) (Chandler and 
Rice, 1923), Australia (1925 - 26, 1942, 1954 - 55) (McCallum and Dwyer, 1927), 
South Africa (1926 -1927) (Kokernut etal, 1956), Greece (1927 - 28) (Copanaris, 
1928), Japan (1942 - 45) (Yamada et al, 1943) and the Carribean (1963 - 69) 
(Downs, 1964). Although classical dengue is endemic in the Carribean, an outbreak 
in Cuba in 1981 with over 340 000 cases and 156 recorded deaths was the first 
outbreak in the Americas of the disease in its haemorrhagic form (Kouri et al, 
1986). The Pacific phases of World War II brought the disease to prominence when 
dengue fever debilitated US army combat forces with the transport of previously 
unexposed personnel into endemic areas (Gilbertson, 1945; Gubler, 2002). This 
was the stimulus for the investigation of the disease and its causative agent(s). The 
major factors contributing to the expansion of the distribution of dengue viruses 
include the expanding urban population and environment (Gubler, 1999), an 
increase in vector density and the ease and frequency of rapid air travel allowing 
the daily movement of viremic individuals (Gubler and Clark, 1995; Gratz and 
Knudsen, 1996). Dengue viruses have since spread to many of the tropical 
countries of the world including Asia, Oceania, Africa, the Americas and Australia 
(Gubler, 2002). Significantly, several outbreaks of dengue fever have been 
documented in north Queensland over the last ten years (Mackenzie JS et al, 
1998). 
Hotta and his colleagues established three Swiss albino mouse-adapted strains of 
the virus from dengue epidemics in Japan in 1943 and 1944 (Kimura and Hotta, 
1944). All four serotypes were subsequently adapted for growth in mice (Hammon 
etal, 1960; Meiklejohn etal, 1952). This was a very significant milestone in dengue 
virus research allowing the circumvention of humans as the only available host and 
facilitated subsequent developments in the propagation and quantitation of the 
viruses in in vitro cell cultures. 
1.2 DISEASE AND TRANSMISSION 
(a) Flaviviruses 
Flaviviruses replicate in a wide range of vertebrate and invertebrate hosts 
(Karabatsos, 1980; Kuno, 1982). The vector species of mosquitoes or ticks appear 
to be restricted for individual viruses (Monath, 1986). Humans are usually an 
incidental host in the arthropod-vertebrate cycle that maintains the viruses in nature 
(Monath and Heinz, 1996). The incubation period for vertebrates is several days 
and involves a short viremia. The pathogenesis and tissue tropism of flaviviruses 
vary from silent infections, fever with malaise, through to jaundice, haemorrhage 
and encephalitis (Monath and Heinz, 1996). Yellow fever (YF), Japanese 
encephalitis (JE), Saint Louis encephalitis (SLE), tick-borne encephalitis (TBE), 
Murray Valley encephalitis (MVE), West Nile (WN) and Kyasanur Forest Disease 
viruses are all important agents of regional endemic or epidemic disease (Monath, 
1986). Recent topical flavivirus infections include West Nile virus encephalitis, due 
to an outbreak in New York (Lanciotti et al, 1999), and the recent emergence of 
Japanese encephalitis virus in northern Australia (Hanna etal, 1999). 
(i) Dengue 
Pathogenesis 
Dengue fever (DF) can lead to the less common but potentially fatal dengue 
haemorrhagic fever (DHF) with or without dengue shock syndrome (DSS) (Gibson 
et al, 1988). In 1999 dengue and DHF were the second most important tropical 
infectious disease (after malaria), with over half the world's population (2.5 billion) 
living in areas at risk for dengue transmission (Gubler, 1999; 2002). It has been 
estimated that each year there are 50-100 million cases of dengue (Clarke, 2002), 
500 000 hospitalizations and 25 000 deaths (WHO, 1999). There are four dengue 
serotypes that cause these disease epidemics of major proportions worldwide. 
They can be distinguished via complement fixation, haemagglutination inhibition 
and neutralization assays (Smithburn, 1954; Sabin and Schlesinger, 1954; Russell 
and Nisalak, 1967). The mosquito, Aedes aegypti is the primary vector for dengue 
virus transmission in urban environments (Simmons et al, 1931; Shope, 1980) 
although Aedes albopictus is also able to spread the disease (Gubler, 1988). 
Mosquitoes remain chronically infected for life (Gubler, 1999) and produce high 
levels of infectious virus particles in their salivary glands (Whitfield et al, 1973). 
Zoonotic cycles of dengue virus transmission involving monkeys and forest Aedes 
sp. {Ae. albopictus, Ae. polynesiensis and other members of the Ae. scutellaris 
group) (Gubler and Meltzer, 1999) have been reported in Malaysia (Rudnick etal, 
1967) and the west coast of Africa (Roche etal, 1983). The presence of the virus in 
the invertebrate host doesn't result in any apparent disease and replication in 
invertebrate cell culture shows demonstrably less cytopathic effect than in 
mammalian cell lines (Mussgay et al, 1975). When the mosquito takes a 
subsequent blood meal, virus is injected into the human along with salivary fluids 
(Gubler, 1999). The virus enters the bloodstream and is spread via lymphatics and 
peripheral blood mononuclear cells (PBMC), especially monocytes which support 
dengue virus replication. Virus can be isolated from the peripheral blood of infected 
patients during the febrile phase of the illness (Scott et al, 1980). Gubler et al 
(1981) reported that there was no difference in the amount of circulating virus in 
mild and severe disease however Vaughn et al (2000) recently demonstrated by 
mosquito inoculation, that for dengue-1 and dengue-2 infected patients a direct 
correlation existed between high viremia titres and disease severity. Viral antigens 
have been identified in mononuclear phagocytes in the skin, thymus, lymph nodes, 
Kupffer liver cells and the spleen (Bhamarapravati, 1981). 
Dengue fever (DF) is the most common result of a dengue virus infection, a self-
limiting flu-like illness. In a typical patient, symptoms commence abruptly after a two 
to seven day incubation period. This illness in humans is characterized by high 
fever, headache, pains in various parts of the body which may range from mild to 
severe, a generalized mottled rash, lymphadenopathy and leukopenia (Simmons et 
al, 1931; Siler etal, 1926; Shope, 1980). These initial symptoms are followed by 
bone pain of increasing severity (thus dengue is often referred to as "break-bone 
fever"), anorexia, vomiting, weakness and prostration. Respiratory symptoms are 
also common in children at this stage. These disease manifestations generally last 
from three to seven days whereupon the patient recovers without any complications 
(Shope, 1980). Treatment is supportive and includes bed rest, antipyretics and 
analgesics together with electrolyte replacement. Uncomplicated, primary dengue in 
a previously healthy individual is rarely, if ever, fatal. However the more severe 
complications of DHF and DSS which are characterized by haemorrhage and shock 
(Cohen and Halstead, 1966; Halstead, 1980) are potentially life-threatening. WHO 
has categorized DHF / DSS into four clinical grades based on symptomatology 
(Table 1.1). Grade I is the mild febrile form of the disease without haemorrhagic 
symptoms. Shock is the only criteria that differentiates grade IV from grade III. The 
molecular basis of the pathogenesis of DF and DHF / DSS has yet to be fully 
elucidated. 
Table 1.1 World Health Organization criteria for classification of DHF patients. 
Grade of disease Signs and symptoms 
I Fever accompanied by non-specific constitutional symptonns with a 
positive tournique test as the only haemorrhagic manifestation. 
II Same as grade I, except with spontaneous haemorrhagic 
manifestations. 
III Circulatory failure manifested by rapid, weak pulse with narrowing of 
the pulse pressure (< 20 mm Hg) or hypotension. 
IV Profound shock with undetectable blood pressure and pulse. 
Modified from Henchal and Putnak (1990). 
At the onset of symptoms DHF and DSS are indistinguishable from DF, however 
several days later there is a rapid deterioration. The clinical features of DHF include 
plasma leakage, bleeding and liver involvement as demonstrated by hepatomegaly 
and elevated serum transaminase levels (Rothman and Ennis, 1999). Plasma 
leakage is caused by a diffuse increase in capillary permeability (Kalayanarooj etal, 
1997). As a consequence, fluid supplementation is required to prevent the 
circulating blood volume from dropping and causing shock. Bleeding manifestations 
are variable, ranging from a positive tourniquet test to life-threatening 
gastrointestinal haemorrhage (Gubler, 2002). 
Antibody-dependent enhancement 
Both type-specific and cross-reactive antibody responses are elicited in individuals 
following natural infection (Scott et al, 1972). Neutralizing antibodies against the 
flavivirus envelope proteins are generated and have been shown to confer long-
lasting immunity against homologous serotypes of dengue (Sangkawibhaet et al, 
1984; Kaufman et al, 1987), JE (Kimura-Kuroda and Yasui, 1988; Mason et al, 
1989), and YF (Gould et al, 1986). In most cases, passive protection has been 
correlated with the ability of these anti-E antibodies to neutralize the virus in vitro. 
Kaufman et al (1989) have demonstrated that passive protection can also be 
produced with prM specific monoclonal antibodies that exhibit weak or undetectable 
neutralizing activity in vitro. The ability of structural protein specific MAbs to protect 
experimental animals from infection is consistent with the conventional hypothesis 
that structural protein antibodies attenuate viral infection by blocking virus binding 
and/or entry to target cells. 
Despite protection against homologous infection, secondary infection with a 
heterologous strain can in some cases result in the potentially life threatening 
manifestations of DHF or DSS (Halstead, 1981). A number of prospective studies 
provide independent support for this hypothesis (Burke etal, 1988; Sangkawibhaet 
etal, 1984; Thein etal, 1997). The mortality rate of patients suffering haemorrhagic 
shock syndrome may be as high as 2 to 10% (Halstead, 1988) and affects 
predominantly young indigenous children (Rehle, 1989), those who have had a 
previous dengue infection and infants born to immune mothers (Halstead, 1980; 
Kliks etal, 1989; Halstead, 1981; Burke etal, 1988). Infection with a third serotype, 
does not appear to be related to the occurrence of overt disease (Fischer and 
Halstead, 1970) but rather a subclinical infection as repeated cases of DSS have 
not been reported (Halstead, 1981). Although it has been postulated that there is a 
role for dengue specific T cells in the pathogenesis of DHF / DSS, such specific T 
cell memory responses do not explain these complications when they occur during 
primary infections (Kurane etal, 1989b; Rothman and Ennis, 1999). 
Host factors may also contribute to the severity of DHF / DSS. During the dengue 
epidemic in Cuba in 1981, chronic diseases (eg. bronchial asthma, diabetes 
mellitus and sickle cell anemia) were additional risk factors contributing to DHF / 
DSS (Terval-Lopez, 1991). Significantly more Caucasians than those of African 
descent developed DHF (Bravo etal, 1987) indicating that a genetic factor may be 
responsible for these observed differences. In 1946, in Madagascar, dengue 
disease was reported more frequently among Europeans than among Africans 
(Cullinan, 1946). Likewise it has been demonstrated that DHF / DSS is more 
prevalent amongst females than males at, and after, the age of four years. It is 
thought that this reflects a more vigorous immune response in females rather than 
differences in exposure to infected mosquitoes (Halstead, 1980; Vaughn et al, 
2000). Nutritional status may also be a contributing factor (Halstead, 1980; Vaughn 
etal, 2000), as good nutrition has an adverse effect on the outcome of DHF/ DSS. 
In countries where the urban poor are clinically undernourished, DHF / DSS is 
predominantly a disease of the middle and upper classes. This epidemiological 
data reinforces the potential of a vigorous immune response to potentiate disease. 
Differences between viral strains are also important in determining the incidence of 
DHF in a susceptible community (Rico-Hesse et al, 1997). 
A single autosomal-dominant locus in mice has been shown to confer resistance to 
flavivirus infection (Brinton, 1986; Sangster, 1993). Flaviviruses can replicate in 
these resistant mice however the spread of infection is slower and peak viremias 
are considerably lower than in susceptible mice. This indicates that a specific host 
gene may alter flavivirus replication competence. Characterization of this gene in 
humans may add further evidence to epidemiological data that suggests that the 
genetic constitution of the host may contribute to dengue virus resistance. 
No specific receptors for the flaviviruses have been identified to date, apart from the 
generalized binding to glycosaminoglycans (GAGs) (Chen et al, 1997) however 
these molecules are likely to be co-receptors. Another unidentified high affinity 
receptor may be required to trigger endocytosis (Jacobs and Young, 1998), such as 
the recently reported 74 kDa protein in Vero cells (de Jesus Martinez-Barragan and 
del Angel, 2001). It has been shown that antibodies which bind to the virion have 
the ability to enhance replication of heterologous virus in cells of lymphoid lineage 
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in vitro (Daughaday et al, 1981). The phenomenon of antibody-dependent 
enhancement (ADE) has been demonstrated for viruses of various taxonomic 
groups (Gotoff etal, 1994; Weiss and Scott, 1981). Ferguson ef a/(1999) studied 
the effect of ADE on the transmission dynamics of multistrain pathogen populations 
by mathematical modelling and concluded that ADE acts to induce cyclical 
epidemics of all cocirculating strains where in its absence only one or a subset 
would persist. 
Entry of antibody-virus complexes into cells has been reported for a range of 
flaviviruses (Halstead, 1981; Phillpotts etal, 1985; Collins and Porterfield, 1985). 
The enhancement of virus production in these cells is due to an increased number 
of infected cells in the presence of antiviral antibodies (Hotta et al, 1984). 
Experimental evidence has demonstrated the role of antibody enhancement of 
infection (100 -1 000 fold increase in titre) with all four dengue serotypes (Morens 
and Halstead, 1990). Antibody concentration dependent patterns of enhanced virus 
production was observed in murine macrophages infected with each of the four 
dengue serotypes, pre-incubated with either immune monkey sera, human immune 
cord blood sera, or dengue monoclonal antibodies (MAbs) directed to flavivirus 
glycoprotein specific envelope (E) epitopes (Morens and Halstead, 1990). It has 
been reported that the best dengue-2 enhancing MAb was dengue-4 derived, 
further supporting the theory of heterologous serotype enhancement of dengue 
virus infections. Monkeys infected with dengue-2 virus developed higher levels of 
viremia if they had actively or passively acquired antibody to heterologous dengue 
virus than if they had no such antibody (Halstead et al, 1993; Halstead, 1979). 
Antibody enhanced binding of dengue virus to human platelets has been reported 
by Wang etal{^ 995) and is consistent with epidemiological and experimental data 
linking preexisting host antibodies to an increased risk of DHF / DSS. The 
exacerbation of dengue infection by sequential infections indicates that it would be 
unwise to vaccinate individuals unless protection against all four dengue serotypes 
can be conferred simultaneously (Rosen, 1989). 
In contrast to the theory that DHF / DSS has an imunological basis it has been 
proposed that dengue virus variants of increased pathogenic potential cause DHF/ 
DSS (Rosen, 1977; Hammon, 1973) based on patients who acquired dengue with 
no evidence of a previous dengue infection. The high mutation rate of RNA viruses 
is an established fact (Holland etal, 1982) and combined with alternative replication 
in two different hosts (ie. vertebrates and arthropods) strong selection pressure for 
virus variants is likely to exist (Igarashi, 1984). Although it has not yet been 
determined whether these variants alter the virulence of dengue viruses, higher 
replication of virus strains isolated from DHF patients in macrophage lines has been 
observed (Kliks etal, 1989). Nevertheless, disease severity is likely to be a result of 
a combination of various factors in each individual. 
Complement activation 
A role for complement activation in the pathogenesis of dengue virus infection, 
particularly plasma leakage in DHF, has been implicated in several published 
reports (Bokisch etal, 1973; Sobel etal, 1975; Ruangirachuporn etal, 1979; 
Cornain etal, 1987; Suvatte, 1987; Malasit, 1987; Rothman and Ennis, 1999). 
Decreased levels of C3, C4 and C5 in the sera of patients with DHF was reported 
as long ago as 1973, with an increased metabolism of C3 and C lq being most 
evident in patients with clinical grades III and grade IV disease (see Table 1.1) 
(Bokisch et al, 1973). Elevated plasma levels of C3a and C5a (products of 
complement activation) have been observed in DHF patients (Malasit, 1987) with 
maximal levels of C3a appearing at the time of defervesence and correlating with 
the severity of disease. These reports are consistent with the hypothesis that 
complement activation is likely to play a contributory role in plasma leakage 
(Rothman and Ennis, 1999). 
Many studies have also reported circulating immune complexes in the sera of DHF 
patients, although the presence of dengue virus or dengue virus antigens in these 
complexes has never been demonstrated conclusively (Ruangirachuporn et al, 
1976; Sobel etal, 1975; Rothman and Ennis, 1999). The complement pathway may 
be activated by these immune complexes in secondary infections and explain the 
massive complement depletion that is reported as a hallmark of dengue virus 
infection (Halstead, 1988; Jacobs and Young, 1998). 
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Cell-Mediated Immunity 
To enable the design of a safe and effective vaccine and to understand the 
pathogenesis of DSS, it is of paramount importance to determine which dengue 
virus proteins induce protective T cell responses and which responses may lead to 
DHF/DSS. 
Antibody may eliminate virus infected cells by antibody-dependent, cell-mediated 
cytotoxicity (ADCC). ADCC has been reported to lyse infected cells in wfroalthough 
an in vivo role has yet to be conclusively demonstrated (Kurane etal, 1984; 1986). 
Other cell-mediated immune responses have been found to be effective in the lysis 
of virus infected cells in vitro including macrophages, natural killer cells and 
cytotoxic T cells. Cellular effector functions have been evaluated in dengue virus 
infections by several groups (Hober etal, 1996; Anderson etal, 1997; Chang and 
Shaio, 1994; Shaio et al, 1995) demonstrating that dengue virus infection of human 
monocytes (particularly in the presence of enhancing antibodies), induces the 
production of vasoactive factors. 
Production of IFNy (interferon-gamma) by CD4+ CTL (cytotoxic T-lymphocytes) 
(Kurane et al, 1989b; 1989c) leads to an increase in Fc receptor expression on 
monocytes (Guyre et al, 1983), which results in a greater number of monocytes 
infected by virus-antibody complexes (Kotny etal, 1988). These monocytes may in 
turn be susceptible to lysis by class I and class II CTL, culminating in the release of 
vasoactive factors such as complement components (Bokish et al, 1973) and 
vasoactive cytokines such as tumour necrosis factor (TNF). T cells may also play a 
role in DHF / DSS by producing interleukin - 2. Interkeukin - 2 augments NK 
(natural killer) cell activity and proliferation and NK cells can mediate ADCC 
(Kurane etal, 1984) and produce IFNy and tumour necrosis factor (TNF) possibly 
further contributing to DHF / DSS. Dengue virus infection of THP-1 cells (a 
monocytic cell line) or exposure to inactivated dengue virus has also been shown to 
induce TNFa production (Hober etal, 1996). Chang and Shaio (1994) found that IL-
1P production (but not TNFa) by primary monocytes was enhanced when infected 
with dengue virus in the presence of enhancing antibody. More recently Anderson 
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et al (1997) demonstrated that tissue culture supernatants from primary human 
monocytes infected with dengue virus, activated endothelial cells in vitro and that 
this effect could be suppressed by antibody to TNFa. A prospective study of Thai 
children with DHF showed elevated levels of IFNy, TNFa and soluble TNF 
receptors (sTNFRs) in patients with DHF and appeared to be associated with the 
severity of the dengue illness (Green etal, 1999). Collectively these studies indicate 
that infection of human monocytes induces the production of vasoactive factors, 
especially in the presence of enhancing antibodies. 
Given that T lymphocyte responses to peptide antigens demonstrate MHC 
haplotype preference, candidate vaccines will need to induce protective immune 
responses in a wide variety of individuals possessing different histocompatibility 
antigens. The potential concern in using vaccines which elicit responses to the 
virion surface proteins because of the enhancement phenomenon could be 
significant, as a vaccine that failed to induce immunity, or that waned over time 
could lead to serious complications in the event of a natural dengue infection. The 
absence of non structural proteins from the virion make them candidates for a 
subunit vaccine approach. It follows therefore, that the elucidation of which non 
structural proteins are recognized by cross reactive T cells, and which are targets 
for CTL mediated clearance, will be invaluable in vaccine design strategies. 
1.3 VIRION MORPHOLOGY AND ASSEMBLY 
The three structural proteins that comprise the flavivirus virion are encoded in the 5' 
end of the genome (Figure 1.1 A). Flaviviruses have a central isometric 
ribonucleoprotein core composed of a single stranded positive sense RNA genome 
complexed with a single species of capsid protein. This protein is a highly basic 
polypeptide that is not conserved among flaviviruses (Schlesinger and Schlesinger, 
1990). Surrounding the nucleocapsid is a lipid bilayer derived from host cell 
membranes in which is embedded the virus specific membrane (M) and envelope 
(E) proteins (Russell et al, 1980) that protect the genome from extra-cellular 
nucleases (Figure L IB) . Virions are spherical and have a diameter of 
approximately 40 - 50 nm (Figure 1 .IC i) (Brinton, 1986) with a dense 30 nm core 
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The structure of the dengue virion has recently been resolved to 2.4A by cryo-
electron microscopy (Figure 1.1D and E) (Kuhn et al, 2002). The surface of the 
dengue virion also reveals a lattice like network of E homodimers, however the 
arrangement of these is different to those reported for the TBE recombinant 
subviral particle (Ferlenghi et al, 2001). Kuhn et al (2002) suggested that this 
difference may simply reflect the different fusogenic states of the particles under 
study. The dengue virion is labile at 4°C for extended periods, upon freeze-thawing, 
as a result of pH changes and, due to the lipid envelope, is sensitive to organic 
solvents and detergents (Russell et al, 1980). Two virion forms have been 
characterized although they are indistinguishable morphologically: intracellular 
virions contain a precursor glycoprotein prM, and an extracellular form with the 
processed M protein (Shapiro etal, 1972). 
Virion entry appears to utilize clathrin coated pits on the cell surface (Collins and 
Porterfield, 1986a). Later they are found in prelysosomal vesicles where acid-
catalyzed membrane fusion is proposed as the mechanism of release for the 
nucleocapsid (Collins and Porterfield, 1986a; 1986b; Heinz ef a/, 1994). At low pH, 
a conformational change in the E protein occurs exposing a fusogenic domain 
(Roehrig etal, 1989), which is thought to be a highly conserved loop at the distal tip 
of each subunit of the E homodimer (Stiasny etal, 1996; Stiasny etal, 2001; Allison 
etal, 200^). 
Cell tropism for flaviviruses is still poorly understood. Viral entry is thought to be by 
an endoctyic mechanism following virus binding as described above (Collins and 
Porterfield, 1985), although evidence for an alternative plasma membrane 
penetration process has been presented (Hase et al, 1989). The cell surface 
receptor is presumed to involve the envelope glycoprotein E (Guirakhoo etal, 1991; 
Anderson etal, 1992; Heinz etal, 1994; Marianneau etal, 1996). Anderson etal 
(1992) showed that the degree of binding of the envelope protein correlated with 
cell susceptibility to dengue virus and suggested that cell tropism is determined in 
several cell types by the presence of an E protein receptor. Chen et al (1997) 
reported that heparan sulfate is the dengue-2 receptor in Vero cells, although the 
ability of dengue virus to replicate in cells of both vertebrate and invertebrate cell 
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lines indicate that more than one receptor could bind dengue viruses. The 
significance of heparan sulfate in both dengue and yellow fever virus binding has 
been confirmed by Germi et al (2002). A region between ^^ '^ E and ^^°E was 
proposed as being the binding domain (Chen et al, 1997). It has also been 
suggested however, that heparan sulfate may simply play a role in concentrating 
virus particles at the cell surface allowing more effective interaction with some other 
surface molecule(s) (Putnak etal, 1997; Jacobs and Young, 1998). 
Ultrastructural studies indicate that morphogenesis occurs in association with 
intracellular membranes (Monath, 1990). Studies have consistently obsen/ed 
mature virions first within the lumen oftheER (Hase ef a/, 1989a; \shak etal, 1988; 
Ko etal, 1979). Budding intermediates and cytoplasmic nucleocapsids have rarely 
been observed indicating that the assembly process occurs rapidly. Virions tend to 
accumulate within disorderly arrays of membrane bound vesicles prior to 
transportation through the secretory pathway and final release from the cell 
(Mackenzie etal, 2001). 
1.4 GENOME STRUCTURE AND ORGANIZATION 
The flavivirus genome consists of single stranded positive sense RNA that is nearly 
11 kilobases long (Rice et al, 1986). The RNA has a type 1 cap at the 5' end 
(m^GpppAmpNp), (Wengler, 1978) and is not polyadenylated at the 3' terminus in 
dengue and other mosquito borne flaviviruses (Vezza et al, 1980). Cells infected 
with flaviviruses contain no subgenomic RNA (Boulton and Westaway, 1977; Naeve 
and Trent, 1978; Westaway, 1980). The viral RNA is the only mRNA which serves 
as messenger for all viral structural and nonstructural proteins (Rice, 1990). 
Complete sequences of the cDNAs of all four serotypes of dengue virus have been 
determined: dengue-1 (Mason etal, 1987b; Fu etal, 1992), dengue-2 (Mackow et 
al, 1987; Zhao etal, 1986; Hahn etal, 1988; Gualano etal, 1998; Irie etal, 1989), 
dengue-3 (Osatomi and Sumiyoshi, 1990; Yuan etal, AF3217645), and dengue-4 
(Deubel et al, 1986). This has revealed the presence of an open reading frame 
(ORF) which encodes at its 5' end the three structural proteins: the capsid (or core) 
protein (C), the precursor (prM) of the membrane protein (M) and the envelope 
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protein (E). The nonstructural proteins are encoded in the remaining two thirds of 
the genome (Figure 1.1 A). Flanking the long ORF are 5' (95 - 132 base pairs in 
length) and 3' (114 - 624 base pairs in length) noncoding regions. Flavivirus gene 
products are synthesized as one long polypeptide with co-translational proteolytic 
processing by both cellular and viral proteases (Rice etal, 1986; Westaway, 1987). 
The non-coding regions at the 5' and 3' ends of the flavivirus genome form complex 
secondary structures (Brinton etal, 1986; Zhao etal, 1986; Brinton and Dispoto, 
1988) and have been shown to function in the regulation of translation, RNA 
replication and encapsidation (Brinton etal, 1986; Zhao et al, 1986; Rice etal, 
1986a, Hahn etal, 1987; You and Padmanabhan, 1999; You etal, 2001; Khromykh 
etal, 2001). The length of these regions vary among the flaviviruses however they 
all contain putative stem and loop structures (Brinton etal, 1986; Zhao etal, 1986; 
Brinton and Dispoto, 1988). Interestingly, the variation in the non-coding regions 
between the mosquito and tick borne flaviviruses has been suggested may reflect 
transmission by the different insect vectors (Hahn etal, 1987). A sequence motif 
consen/ed among all flaviviruses and located at the 3' terminus has been 
postulated by Mandl et a/ (1993) to act as a recognition signal for a viral or cellular 
transcription factor. A role in RNA replication for consen/ed complementary 
(cyclization) sequences in the 5' and 3' terminal regions of Kunjin flavivirus RNA 
has been shown by Khromykh et al (2001) by mutating the base pairing either 
separately or simultaneously to restore complementarity with a replicon RNA. None 
of the RNAs with separate mutations in only 5' or 3' cyclization sequences were 
able to replicate after transfection, whereas RNA with compensatory mutations in 
both cyclization sequences was replication competent. These cyclization 
sequences have also been shown for dengue virus (You and Padmanabhan, 1999; 
You ef a/, 2001). 
(a) Genome Replication 
Virions are taken up in coated pits with subsequent fusion of virion and cellular 
membranes occurring within minutes. Following fusion, the viral RNA is presumably 
released from endosomes and translation commences in association with the rough 
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endoplasmic reticulum (ER). A long latent period follows (12-16 hours) during 
which input virion RNA acts as mRNA to initiate synthesis of proteins such as the 
RNA-dependent RNA polymerase (NS5) and other proteins necessary for viral 
replication. At this time RNA synthesis can be detected in infected cells (Leary and 
Blair, 1983) and cell extracts have been shown to have RNA dependent RNA 
polymerase activity in vitro (Chu and Westaway, 1985; 1987). 
Three RNA species have been detected in infected cells: a 20 - 28S partially double 
stranded replicative intermediate (Rl), a 20 - 22S completely double-stranded 
replicative form (RF) and a 40 - 44S positive-strand genomic RNA (Stellar et al, 
1967; Trent etal, 1969; Cleaves etal, 1981; Wengler etal, 1978). The nature of 
these species was supported by reports from Cleaves ef a/(1981) and Chu and 
Westaway (1985) that demonstrated that the Rl is RNase sensitive and the RF is 
RNase resistant. 
After translation of the incoming genomic mRNA, RNA is synthesized 
asymmetically in a semiconservative manner with the double stranded replicative 
form serving as a recycling template on which only one nascent strand is 
synthesized. After the latent period, RNA of positive polarity is the major product of 
viral RNA synthesis (Westaway, 1987; Gong etal, 1998). This RNA can then be 
used either for translation of structural and nonstructural polypeptides, minus strand 
synthesis, or be encapsidated into virions (Westaway, 1987). 
Translation is initiated close to the 5' end of the genome, as indicated by homology 
of predicted open reading frames in the nucleotide sequence and N-terminal 
sequencing of translation products. The sequence of translation is NH2- C - prM 
(M) - E - NS1 -NS2A - NS2B - NS3 - NS4A - NS4B - NS5 - COOH. (Rice et al, 
1985; Biedrzycka etal, 1987). 
(b) Co-translational Processing 
Proteolytic cleavage sites were identified by N-terminal sequence analysis of the 
final protein products (Speight and Westaway, 1989b; Chambers et al, 1989; 
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Biedrzycka et al, 1987) and from alignment of homologous sequences. Cell-free 
and in vivo studies have also been used to study flavivirus polyprotein processing. 
(Svitkin etal, 1981; Markoff, 1989; Nowak etal, 1989). Translation takes place in 
association with the rough ER with some proteins being translocated into the lumen 
and others remaining localized on the cytoplasmic side. No carboxy terminal post-
translational processing has been reported to occur (Speight and Westaway, 
1989a, Wright etal, 1989) although recent evidence from the Young laboratory has 
suggested that a proportion of dengue virus NS1 undergoes glycosylphosphatidyl-
inositol (GPI) addition at the C-terminus (Jacobs etal, 2000). 
The processing of core (C) involves removal of the initial methionine from the amino 
terminus by a cellullar methionine aminopeptidase (Coia etal, 1988; Nowak etal, 
1989; Rice etal, 1986b; Boege etal, 1983), although this is not universal among 
flaviviruses (Bell et al, 1985). Regions of hydrophobicity and hydrophilicity within 
core are consen/ed (Mandl et al, 1998). A C-terminal hydrophobic region acts as a 
signal sequence for translocation of prM into the lumen of the ER. Cleavage at this 
site has been implicated in the efficient generation of the amino terminus of prM 
(Lobigs, 1993; Stocks and Lobigs, 1995). This subsequent cleavage, converts core 
from a membrane-anchored intracellular form to its virion form and has been shown 
to be an essential component of virion maturation (Lobigs, 1993; Yamshchikov and 
Copans, 1993) and the flavivirus life cycle (Amberg and Rice, 1999; Lee et al, 
2000). Virion core had been commonly considered to be free in the cytoplasm of 
infected cells, but evidence suggests that if is in fact anchored in the ER membrane 
by a structurally conserved, internal hydrophobic domain (Markoff et al, 1997). It 
thus takes up a hairpin conformation with positively charged regions amino- and 
carboxy-terminal to this anchor accessible to interact with RNA in the cytoplasm. 
Cleavage of prM occurs immediately after the sequence motif Arg - X - Arg / Lys -
Arg (where X is variable) (Randolph etal, 1990). prM cleavage was first postulated 
to be mediated by the host enzyme furin (Hallenberger et al, 1992) and has 
subsequently been confirmed for TBE by Stadler ef a/(1997). The cleavage of prM 
from E occurs rapidly as no higher molecular weight precursors have been 
identified (Chambers etal, 1990c) although a C - prM precursor has been reported 
in cell-free translation systems (Svitkin et al, 1981; Markoff, 1989; Nowak et al, 
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1989) and in dengue-2 infected mosquito cells (Murray etal, 1993). It has been 
postulated that the inefficiency of the C / prM cleavage in mosquito cells may be a 
consequence of the lower incubation temperature required for these cells (Murray 
etal, 1993). 
At the C-terminus of prM are two hydrophobic domains separated by a single basic 
residue (Rice et al, 1985). The first is likely to anchor prM in the virion envelope 
(Nowak et al, 1989; Wright et al, 1989) whereas the second acts as a signal 
sequence for translocation of E across the ER (Coia et al, 1988; Gruenberg and 
Wright, 1992). 
The N termini of prM, E, NS1 and NS4B follow predicted signalase cleavage sites 
(von Heijne, 1984) contributed by the C-terminal hydrophobic regions of anchored 
C, prM, E and NS4A respectively. A signal sequence also precedes the N-terminus 
of NS4B, suggesting that this hydrophobic protein is processed in association with 
membranes of the ER. The N-terminus of NS2A follows a cleavage site defined by 
the sequence (Val - X - Ala; X = Ser, Thr, Gin, Asp, Asp). Although this fulfills the 
rule for a signalase (von Heijne, 1984), sequence analysis indicates that the site 
lacks a requisite upstream hydrophobic region, thus the source and specificity of 
the protease responsible for cleavage between NS1 and NS2A remains to be 
determined. A role for NS2A in the NS1 - NS2A cleavage is suggested by studies 
with dengue-4 vaccinia recombinants in which progressive C-terminal deletions of 
the NS2A region generated uncleaved but glycosylated NS1 - NS2A related 
proteins (Falgout etal, 1989). It has also been shown that efficient cleavage at the 
dengue-4 virus NS1 - NS2A junction of the viral polypeptide requires the N-terminal 
hydrophobic signal of NS1 and downstream NS2A in cis (Falgout et al, 1989). 
Deletion analysis has shown that a minimum of eight amino acids at the C-terminus 
of NS1, preceding NS2A, is also required for efficient cleavage at this junction (Hori 
and Lai, 1990). It was also shown that in the 12 flavivirus amino acid sequences 
analysed there was a degree of homology within this octapeptide sequence, and a 
conserved sequence was derived: Leu/Met-Val-Xaa-Ser-Xaa-Val-Xaa-Ala. 
Substitutions at each of these amino acids were analysed by Pethel et al (1992) 
and tended to indicate a possible structural requirement around this region, which 
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may or may not include the hydrophobic region downstream. This is discussed in 
more detail in Chapter 1.5b. 
Cleavage sites generating the N termini of NS2B, NS3, NS4A and NS5 are highly 
conserved among flaviviruses and there does not appear to be any obligate order 
for processing in the non-structural region (Lin etal, 1993; Preugshat and Strauss, 
1991). The flavivirus encoded protease (NS2B/NS3) has been shown to mediate 
cleavage at di-basic amino acid residues (Lys-Arg, Arg-Arg or Arg-Lys) or 
occasionally between GIn-Arg (dengue-2 and dengue-4 NS3). These sites are 
usually flanked by short chain amino acids (Rice etal, 1988). 
1.5 VIRAL PROTEINS 
(a) Structural Proteins 
The Capsid Protein (C) 
The C protein present in virions is a small (12 - 14 kDa) highly positively charged 
protein (due to a high proportion of lysine and arginine residues) that forms the 
structural component of the nucleocapsid. Rice et al (1985) suggested that the 
likely function of this positive charge is to partially stabilize the negative charges of 
the RNA. There is a hydrophobic stretch of uncharged amino acids in the middle of 
the C protein, which is conserved among flaviviruses (Rice etal, 1985; Dalgarno et 
al, 1986) and a conserved amino terminal hydrophilic region (Mandl etal, 1988). It 
is likely that as the charged residues of the C protein complex with the genomic 
RNA, a nucleoprotein is formed with the external surface consisting of the 
hydrophobic portion of the C protein. As a result of this surface hydrophobocity the 
nucleocapsid may act as a membrane vesicle and move along a lipid gradient in 
the cytoplasm towards the membrane (Hase etal, 1989). 
Two epitopes have been identified on the dengue-4 virus capsid protein which are 
recognized by a serotype-specific (between amino acids 47 and 55) and serotype 
cross-reactive (between amino acids 83 and 92) human CD4+ cytotoxic T-
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lymphocyte clone (Gagnon et al, 1996). This was the first report that the capsid 
protein is a target of an antiviral T-cell response in dengue virus infections. 
Thie pre Membrane Protein (prM) 
The prM protein is a glycoprotein precursor (18-19 kDa) to the structural protein M 
(8 kDa). This precursor undergoes a delayed cleavage to form M and the N-
terminal pr segment (Shapiro et al, 1972) that is secreted (Murray etal, 1993). M 
and prM are found on extracellular and intracellular virions respectively, and thus 
this cleavage is presumably linked to virus maturation and release. Inhibitory effects 
of weak bases and lysosotrophic amines on prM cleavage have been 
demonstrated, and this has suggested a specific role for prM in maintenance of the 
conformation of the E protein during virus passage through acidified sorting 
compartments (Randolph etal, 1990), since flaviviruses are generally inactivated at 
low pH. 
The N-terminal pr segment is predominantly hydrophilic, containing six conserved 
cysteine residues all of which participate in disulfide bridging (Norwak and Wengler, 
1987). Glycosylation of prM presumably has an important role in virion assembly 
and release as serologically related viruses show position conservation of N-linked 
glycosylation sites (Wright etal, 1980; Markoff, 1989; Ruiz-Linares etal, 1989). 
Monoclonal antibodies against prM of dengue virus can be protective against 
challenge with both homologous and heterologous virus (Kaufman et al, 1989; 
Takegami etal, 1982). 
Ttie Envelope Protein (E) 
The E protein is the major virion envelope protein (50 - 60 kDa) (a type I membrane 
protein) and displays both the virus haemagglutinin activity and the major 
neutralization epitopes (Gould et al, 1990). It is also involved in a number of 
additional viral functions such as receptor binding and low pH induced membrane 
fusion (Collins and Porterfield, 1986; Summers et al, 1989). It has been 
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demonstrated that infection with West Nile virus involves an endosomal acid 
catalyzed fusion process (Collins and Porterfield, 1986) and it has been suggested 
that the conserved region from amino acid residues 98 - 111 is the fusion 
sequence, based on similarities with other viral fusion domains (Roehrig et al, 
1990). This hypothesis has been supported by the finding that a monoclonal 
antibody that recognizes the TBE E protein fusion sequence is able to block fusion 
(Volkova et al, 1999) and recent experimental evidence using site-directed 
mutagenesis confirms the role of this domain in TBE E-mediated fusion (Allison et 
al, 2001). The E proteins of most of the flaviviruses are glycosylated as shown by 
the incorporation of labeled sugars (Shapiro etal, 1971; Westaway, 1975) and its 
reactivity with concancalin A (Stohlman et al, 1976; Clegg, 1982). Notable 
exceptions are some isolates of Kunjin virus (Wright, 1982) and West Nile virus 
(Wengler et al, 1985). Evidence exists for both simple and complex glycans 
(Winkler etal, 1987; Zhao etal, 1987) with apparent host specific differences. The 
dengue-2 E protein is glycosylated at ^''Asn and ^^^Asn (Smith and Wright, 1985; 
Deubel etal, 1986; Irie etal, 1989). A mutation that eliminated the glycosylation site 
in the dengue-2 E protein led to a higher pH threshold for fusion (Guirakhoo etal, 
1993), consistent with the oligosaccharide participating in oligomerization. SDS 
denaturation resistance was lost when the protein was deglycosylated indicating 
that the carbohydrate side chain contributed to the stability of the molecule (Winkler 
et al, 1987). For the E protein, correct folding is probably required for eliciting a 
protective immune response since E protein antigens produced in E. co//(Mason et 
al, 1989), and the authentic protein produced under denaturing conditions (Wengler 
and Wengler, 1989) failed to induce neutralizing antibodies. 
The genome sequence of the E glycoprotein of all the flaviviruses examined, show 
that each of the twelve cysteines forming six disulphide bridges are perfectly 
conserved in the E ectodomain (Deubel et al, 1986; Nowak and Wengler, 1987; 
Chambers et al, 1990a). Combined with virtually superimposable hydrophilicity 
profiles it is likely that all flavivirus E proteins share a common structure. There is 
however a high degree of diversity at antigenically important sites which exist 
without impairing its principal functions (Heinz, 1986). 
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Structural models for E were originally proposed by Nowak and Wengler (1987) and 
Mandl et al (1989) prior to the publication of the crystal structure for the trypsin 
released ectodomain of E derived from TBE (Rey etal, 1995). The crystallization of 
the E protein has revealed that the E dimer is a rod shaped head-to-tail oligomer of 
170A that is anchored in the bilayer at each end. The slight curvature of the dimer 
suggested that these proteins do not form projections as previously reported 
(Murphy, 1980) but lie parallel to the virion surface (Rey et al, 1995). The active 
fusogenic form has been shown to be a trimer (Allison et al, 1995) that forms by 
reorganization of the virion surface upon exposure to low pH. As noted above, the 
conserved nature of the disulfide bridges suggests that the three-dimensional 
structure of other flavivirus E proteins may be similar to that of TBE. This likely 
homology was used by Kuhn et al (2002) in mapping the position of the dengue 
virus E protein on the surface of the dengue virion structure resolved by cryo-
electron microscopy (Figure 1.1D). 
Three antigenic domains (A, B and C) have been described within the E protein 
(Heinz, 1986) and correspond well to the three structural regions identified by Rey 
etal{^ 995) as domains 11,111 and I respectively. Domain A contains flavivirus cross-
reactive epitopes along the putative fusion domain (amino acids 98 -111). Regions 
postulated to modulate pathogenicity have been localized to domain B (amino acids 
300 - 395) which is dependent on an intact disulfide bridge. Lobigs ef a/(1990) and 
Rey et al (1995) proposed that this domain may be involved in tissue tropism and 
receptor recognition due to published reports for various flaviviruses including JE 
(Cecilia and Gould, 1991; Hasegawa etal, 1992), Louping III (Jiang etal, 1993; 
Gao etal, 1994), TBE (Holzmann etal, 1989) and dengue-2 viruses (Hiramatsu et 
al, 1996; Sanchez and Ruiz, 1996). Domain C (amino acids 132 -177), while not a 
highly conserved domain, is known to contain a conserved glycosylation site 
(Guirakhoo etal, 1989). 
(b) NON STRUCTURAL PROTEINS 
TAie Non Structural Protein, NS1 
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The gene product NS1 follows E in the polyprotein sequence. It encodes at its C-
terminus, a hydrophobic signal sequence that functions as a translocation signal for 
entry of NS1 into the ER (Rice etal, 1985; Biedrzycka etal, 1987; Speight etal, 
1988). Dengue-2 NS1 is a glycoprotein with a molecular weight of 46K and contains 
two N-linked glycans (Smith and Wright, 1985). Processing of NS1 involves a host 
signalase cleavage at the amino terminus and a unique cleavage at the carboxy 
terminus (Speight etal, 1988; Chambers etal, 1989, Falgout etal, 1989; Nowak et 
al, 1989). The enzyme responsible for NS1/NS2A cleavage is unknown, but there is 
strong evidence that it is a host-encoded enzyme that acts within the ER and 
requires a consensus sequence motif of eight amino acids (L/M-V-X-S-X-V-X-A) at 
the carboxy terminus of NS1 (Hori and Lai, 1990) as described previously. Site 
directed mutagenesis experiments confirmed that the amino acids at positions -8, -
7, -5, -3 and -1 were important for cleavage. The lines of evidence suggesting that 
the enzyme responsible for cleavage of NS1/NS2A resides within the ER; are that it 
is not abrogated by brefeldin A (Falgout and Markoff, 1995), which blocks 
membrane traffic from the ER to the Golgi (Klausner etal, 1992) and, isolated dog 
pancreas microsomes, which contain membrane organelles with properties of the 
ER (Walter and Blobel, 1983), can effect NS1-NS2A cleavage (Falgout and 
Markoff, 1995). Furthermore, disruption followed by releasing of these microsomes 
removes the lumenal contents yet does not affect NS1-NS2A cleavage, implying a 
membrane-bound localization for the putative host protease which cleaves NS1-
NS2A (Falgout and Markoff, 1995). 
The various unique characteristics of the NS1 protein will be described later in this 
Chapter (Section 1.6). 
The Non Structural Protein, NS2A 
The NS2A protein is a relatively small (25 kDa) hydrophobic protein which migrates 
anomalously on SDS-PAGE gels at approximately 20 kDa (Coia et al, 1988; 
Chambers etal, 1989). The function of this protein is unknown. Studies by Wengler 
ef a/(1990) on West Nile virus infected cells showed that NS2A remained attached 
to membranes despite high stringency washes and interestingly, NS2A has been 
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found associated with fractions containing RDRP activity in Kunjin virus infected 
cells (Chu and Westaway, 1992). Mackenzie etal{^ 998) suggested that NS2A may 
be involved in targeting the replication complex to cytoplasmic membranes as 
binding assays indicated that it associates strongly with NS3, NS5 and NS1, which 
were localized to separate sides of the membrane. As previously described, NS2A 
has been implicated in the processing of NS1 (Chambers etal, 1989). Two forms of 
NS2A have been observed for some flaviviruses, including YF, JE, KUN and MVE, 
but not dengue virus NS1. The higher molecular weight form of NS2A referred to as 
NSr, was demonstrated to be a fusion protein with NS1 (Mason etal, 1987). 
The Non Structural Protein, NS3 
NS3 is the second largest viral protein (68-70 kDa) encoded by dengue viruses. It is 
highly conserved among flaviviruses (Rice et al, 1986) and is hydrophilic. The 
protease function of NS3 has been experimentally verified (Chambers etal, 1990; 
Preugschat et al, 1990; Wengler et al, 1991; Pugachev etal, 1993). Sequence 
comparisons suggest that it comprises three separate enzymatic functions; serine 
protease (Chambers etal, 1990; Preugschat etal, 1990; Falgout etal, 1990) as 
well as a nucleotide triphosphatase and helicase activity) thought to be involved in 
nucleotide cofactor binding and hydrolysis (Gorbalenya etal, 1989; Wengler and 
Wengler, 1991) hence a role for NS3 in viral RNA replication was postulated. 
Processsing of the 2A-2B, 2B-3, 3-4A and 4B-5 sites is catalyzed by a two 
component viral proteinase (NS2B/NS3) (Bazan and Fletterick, 1989; Gorbalenya 
etal, 1989). RNA-stimulated NTPase activity has been demonstrated for purified 
NS3 of yellow fever (Warrener etal, 1993), West Nile (Wengler and Wengler, 1991) 
and dengue-2 viruses (Li et al, 1999). The RNA triphosphatase activity is thought to 
aid in the formation of the cap structure at the 5' end of the flavivirus genomic RNA 
(Wengler and Wengler, 1993). These properties therefore suggest a cytoplasmic 
location for NS3. Westaway etal{^ 997) showed Kunjin virus NS3 associated with 
double-stranded RNA within vesicle packets. The recently published crystal 
structure of the proteolytic domain of dengue-2 NS3 suggests that 
heterodimerization with NS2B may be involved in the specificity of substrate binding 
(Krishna-Murthy et al, 1999; 2000). Detailed in vitro kinetics, and preliminary 
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inhibitors were recently reported for a recombinant form of NS3 co-expressed with 
its co-factor NS2B (Leung etal, 2001). 
Antibodies to NS3 have been shown to play a role in the immune response to 
dengue virus infection (Tan et al, 1990) with antibodies detectable in dengue 
patient sera by western blot analysis. In addition, Kurane efa/(1989) have reported 
that NS3 is a major target of a CTL mediated immune response. 
The Non Structural Proteins, NS2B, NS4A and NS4B 
These small proteins, like NS2A, are poorly conserved among flaviviruses (Rice et 
al, 1986; Mandl et al, 1989) but contain similar structural features consisting of 
multiple hydrophobic domains which could potentially span membranes. It has been 
postulated that they may serve to anchor the viral replicase to cellular membranes 
(Chambers etal, 1989). NS2B and NS4B are readily identifiable in infected cells, 
but NS4A (16 kDa) has been definitively identified only for Kunjin virus by Speight 
and Westaway (1989). In Kunjin virus infected cells, NS2A and possibly NS4A have 
been shown to be associated with "heavy" membranes isolated by sedimentation in 
sucrose gradients (Chu and Westaway, 1992). NS4A binds strongly to the replicase 
components NS5, NS3 and NS1 as well as the other protease component NS2B 
(Mackenzie et al, 1998, Westaway et al, 1997a; 1997b). Coupled with its 
localization at the putative site of RNA replication (vesicle packets), and proteolytic 
processing (the precursor membranes and paracrystalline arrays), it seems likely 
that NS4A is involved with both processes. It may act by anchoring these 
complexes to the membrane (Mackenzie et al, 1998; Rice, 1996) although 
biochemical data on the topology of this protein are lacking. No post-translational 
modifications of these proteins are known, despite the presence of a conserved 
potential N-linked glycosylation site in the C-terminal portion of NS4B (Lee et al, 
1990). Evidence from Lindenbach and Rice (1999) indicate that NS4A is involved in 
the process of RNA,replication possibly through a direct interation with NS1. NS4A 
is produced via cleavage at its N- and C-termini by the viral serine protease NS2B-
NS3. Both cleavage events appear to be delayed or regulated as the putative NS4A 
precursors NS3-4A and NS4A-4B have been identified in flavivirus infected cells 
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(Chambers et al, 1990c; Svitkin et al, 1981; Cahour et al, 1992; Lobigs, 1992; 
Zhang etal, 1992; Preuschat etal, 1990). 
NS4B shows as little as 3 1 % homology with other flaviviruses (Coia etal, 1988) and 
contains six hydrophobic regions that contribute to its sedimentation with the 
membrane fraction of infected West Nile virus cell lysates (Wengler etal, 1990). 
However, in dengue-2 and Kunjin viral extracts, NS4B has been reported to be 
trypsin sensitive and therefore unprotected by membranes (Cauchi et al, 1991). 
NS4B has been shown to be localized to the nucleus by immunoelectron 
microscopy (Westaway etal, 1997a) which is unusual as NS4B does not contain a 
known nuclear localization signal. It is possible that these proteins form membrane 
components of the viral replication complexes and could be involved in membrane 
localization of NS3 and NS5 via protein-protein interactions (Westaway etal, 1999). 
The Non Structural Protein, NS5 
NS5 is the largest (103 -104 kd) and most highly conserved of all flavivirus proteins 
(Mandl et al, 1989; Rice, 1996). C-terminal sequence data for Kunjin virus indicate 
that the protein extends to the predicted end of the ORF (Speight and Westaway, 
1989). NS5 is a basic protein and does not contain any long hydrophobic domains. 
The role of NS5 as the viral RNA-dependent RNA polymerase (RDRP) was 
originally predicted based on sequence homology with known RDRPs (Koonin 
1991; Poch et al, 1989). This has since been shown by Khromykh et al (1998; 
1999a; 1999b) through complementation studies. The generation of its N-terminus 
by cleavage in the cytoplasmic compartment (presumably by NS3 or an alternative 
protease) suggests that NS5 is located in the cytoplasm, although it is associated 
with membranes (Cauchi et al, 1991; Chu and Westaway, 1992). A highly 
consen/ed domain in NS5 (YF residues 521 - 675), contains a sequence motif (Rice 
et al, 1985; 1986) which is present in nonstructural proteins from a number of 
positive-strand RNA viruses and is believed to play a role in RNA-dependent RNA 
synthesis (Kamer and Argos, 1984; Rice et al, 1986). NS5 is also a putative 
methyltransferase which is involved in the formation of the RNA cap (Chambers et 
al, 1990a; Tan et al, 1996; Koonin, 1993). Motifs are also present for substrate 
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binding, RNA binding, catalytic activity and formation of secondary structure of 
RdRps (Koonin, 1991; O'Reilly and Kao, 1998). 
The conserved coding sequences in the N-terminal half of NS5 have a possible role 
in RNA replication by initiating formation of the replication complex. There is a 
requirement for an association of NS5 with other non-structural proteins (Khromykh 
et al, 1999a) that is thought to be due to binding of NS3 to the N-terminal half of 
NS5 during replication complex assembly. The replication complex then attaches to 
the adjacent 3'UTR on completion of translation and moves to the proposed 
membrane attachment site involving NS4A and NS1 (Khromykh etal, 1999b). 
1.6THENS1 PROTEIN 
NS1 was first identified in flavivirus infected suckling mouse brain extracts and was 
originally referred to as the soluble complement fixing (SCF) antigen. (Russell etal, 
1970). Since then it has been recognized as being important for its immunogenicity 
and in being unusual as a glycosylated nonstructural protein. NS1 is located in 
various regions in infected cells: in association with membranes in the cytoplasm 
(Stohlman et al, 1975; 1978), at the cell surface in association with the plasma 
membrane (Cardiff and Lund 1976; Gould etal, 1985; Westaway and Goodman, 
1987) and in infected culture supernatants as a secreted species (Winkler et al, 
1989; Mason 1989; Despres et al, 1991) (Figure 1.2A). NS1 has also been shown 
in the perinuclear region of infected cells and as cytoplasmic foci in 
immunofluorescence studies (Ng et al, 1992; Ng and Corner, 1989), initially 
suggesting a role in virus assembly and release (Rice etal, 1986b; Mason 1989). 
The dengue NS1 protein is translated from 1056 nucleotides into 352 amino acids 
that encode a protein backbone of 40 kDa (Deubel et al, 1988). NS1 nucleotide 
sequence data for various flaviviruses has been compared and a high degree of 
homology exists (Mackow et al, 1987; Mandl etal, 1989). Cysteine residues in 
flavivirus NS1 have been found to be totally consen/ed in both number and position 
suggesting a common structural organization (Rice etal, 1986; Gibson etal, 1988; 
Wang etal, 2001). There are a number of amino acid substitutions and deletions 
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between the NS1 proteins although the majority are semi-conservative thus 
maintaining the overall hydrophilic nature of the protein. Amino acid conservation 
also suggests preservation of potential antigenic sites and serological data also 
supports this view. NS1 lacks a membrane anchoring domain at the amino or 
carboxy termini (Speight etal, 1988; Wright etal, 1989) despite the fact that it has 
been shown to be membrane-associated (Cardiff and Lund, 1976; Schlesinger et 
al, 1990) by ultracentrifugation (Stohlman etal, 1975) and immunochemical studies 
(Cardiff and Lund, 1976; Gould et al, 1976; Gould et al, 1985; Westaway and 
Goodman, 1987). A portion of NS1 has been reported to be anchored to cellular 
membranes via a glycosyl phosphatidylinositol (GPI) anchor in some cell types 
(Jacobs et al, 2000). Crystallographic structural resolution of NS1 has yet to be 
reported and is the basis of studies in Chapter 5 of this thesis. 
(a) Oligomerisation of NS1 
NS1 exists as both a monomer (46 kDa) and a dimer (86 kDa) in flavivirus infected 
cells (Winkler ef a/, 1988; Chambers ef a/, 1989; Mason, 1989). The dengue-2 NS1 
dimer was first identified when infected cell lysates were left unboiled prior to SDS-
PAGE (Winkler etal, 1988). A homodimeric structure was proposed based on both 
carbohydrate and monomerization analyses (Winkler et al, 1988). Although the 
dengue NS1 dimer is heat sensitive, it is resistant to reducing agents (Winkler etal, 
1988). It should be noted however that the NS1 dimer of JE virus is partially 
sensitive to reducing agents (Fan and Mason, 1990). A hexameric form of secreted 
TBE NS1 has been described from column chromatography studies (Crooks etal, 
1990) and from gel filtration experiments of dengue-1 NS1 (Flamand etal, 1999). 
The sensitivity of the hexameric form of NS1 to detergents has meant that most 
studies have focused on the detergent stable dimeric form of the native oligomeric 
structure. The secreted form of NS1 would appear to be a hexamer. The oligomeric 
state of the membrane-associated form remains to be determined as purification 
strategies usually involve the use of detergents. 
The oligomer is thought to represent the functional form of the protein (Winkler et 
al, 1988) and has been reported to be more immunogenic in mice than its 
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monomeric counterpart (Falconar and Young, 1990). Flavivirus NS1 dimers have 
been detected in both insect and mammalian cells however Flamand ef a/(1992) 
have reported that the process of dimerization takes considerably longer in 
mosquito cells. The types of interactions involved in the formation and maintenance 
of the dimer are not well defined (Pryor and Wright, 1993) although they are non-
covalent in nature. 
Studies using recombinant cDNA demonstrate that NS1 (preceded by its ER 
translocation signal sequence) forms dimers in the absence of any other viral 
protein (Parrish et al, 1991; Pryor and Wright, 1993; 1994; Leblois and Young, 
1995), implying that NS1 itself contains all the essential information for 
dimerization. Maintenance of the dimer may only require one half of the protein, 
since a truncated dimer was isolated following trypsin digestion of membrane-
associated NS1 (Cauchi etal, 1991). However sequence requirements for dimer 
formation and maintenance are not necessarily the same. Dimer formation has 
been addressed using recombinant, mutagenized cDNA expression and it seems 
that the carboxy-terminal end of the protein is important in dimer formation, and 
more so than the amino-terminal end. Deletion of the last 79 amino acids of NS1 
abolishes dimer formation (Parrish etal, 1991), either because this region is directly 
involved in dimer formation or because the conformation of distant sites required for 
dimer formation is altered. Substitution within the conserved octapeptide C-terminal 
sequence did not prevent dimer formation (Parrish etal, 1991), consistent with its 
role as a specific cleavage recognition sequence. However the importance of the 
other carboxy-terminal amino acids has been supported by further work. 
Substitution of any of the last three cysteine residues, located within the carboxy-
terminal 40 amino acids of the protein, prevents dimer formation whereas 
substitutions of the first three cysteine residues do not (Pryor and Wright, 1993). 
Moreover, mutation of a small hydrophobic domain near the C-terminus, but not 
similar domains near the N-terminus or in the middle of the protein, prevents dimer 
formation (Pryor and Wright, 1993). Exact constraints on the C-terminal portion of 
the protein with respect to dimerization have yet to be defined. 
In all experimental systems, dimerization is a critical step in NS1 maturation. In 
30 
common with many other glycoproteins, mutations which prevent assembly into 
dimers also disrupt transport to the cell surface and secretion. In contrast. Hall etal 
(1999) reported that a cDNA clone of Kunjin virus with a single amino acid 
substitution (prolineaso to leucine) in NS1, ablated dimerization but still allowed 
replication to occur and for NS1 to be secreted in the monomer form. However this 
obsen/ation could be explained by the dimeric form of NS1 being highly unstable 
with this mutation and therefore difficult to detect by SDS-PAGE analysis. Virus 
replication was also shown to be slower, with reduced virulence in mice (Hall etal, 
1999). 
Dimerization of NS1 occurs in the ER prior to transport to the Golgi where 
processing of some of the N-linked glycans occurs (Winkler et al, 1989, Despres et 
al, 1991) (Figure 1.2A). The conversion of monomers to dimers has been related to 
the membrane-association of NS1. It appears that the NS1 protein exists 
temporarily in a hydrophilic form before becoming associated with the membrane. 
In pulse-chase experiments, the dengue-2 NS1 dimer appeared after 20 - 40 
minutes, suggesting that this transformation to the more hydrophobic membrane 
associated form was possibly due to dimerization and represented the functional 
form of the protein (Winkler et al, 1988; 1989). Winkler et al suggested that 
dimerization could expose hydrophobic domains on the surface of the molecule or 
that the process of dimerization was connected to post translational modification 
(eg. fatty acid acylation, carbohydrate interaction, or the attachment of a 
phosphatidylinositol anchor which could explain the membrane association) (Sefton 
and Buss, 1987). Flaviviruses within the JE serocomplex, which includes JE, MVE, 
Kunjin and West Nile viruses, express an additional form of NS1, designated NS1' 
due to a carboxy terminal extension of the polypeptide backbone (Mason, 1989). 
Other flaviviruses such as dengue-2, YF and Kokobera viruses however do not 
appear to produce NS1'. 
The kinetics of secretion are different for different flaviviruses. TBE virus NS1 is 
secreted in 45 minutes (Lee etal, 1989) compared to two hours for JE virus NS1 
(Mason, 1989) and YF virus (Despres etal, 1991). In contrast, NS1 secretion has 
not been observed for either JE virus-infected or dengue virus-infected C6/36 cells 
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(Mason, 1989). The inability of insect cells to further process complex sugars may 
account for this observation (Heish and Robbins, 1984). Secretion from infected 
mammalian cells is not however inhibited by tunicamycin or mutated glycosylation 
sites (Pryor and Wright, 1994; Winkler etal, 1989; Despres etal, 1991). 
(b) Glycosylation of NS1 
Multiple forms of NS1 have been identified for different flaviviruses which have 
been shown to be generated by variable glycosylation and / or differences in the 
cleavage of the polypeptide backbone (Mason et al, 1987; Winkler et al, 1988). 
Different viral strains as well as different host cells have also been shown to 
contribute to this heterogeneity. As a consequence, the molecular weight of NS1 
varies from 45 - 53 kDa. In dengue virus infected mammalian cells, two forms of 
NS1 are detected: a membrane bound (mNSI) (Cardiff and Lund, 1976) and an 
extracellular form (sNSI) (Russell etal, 1970). Both species of NS1 have two N-
linked glycosylation sites on each molecule (Smith and Wright, 1985) and each 
have the same polypeptide backbone as revealed by endoglycosidase digestion 
(Mason et al, 1987; Winkler et al, 1988; Young, 1990). However, the molecular 
weight of sNSI is some 3-5kDa larger that that of mSNI. In addition, sNSI 
migrates on SDS-PAGE as a diffuse band between 53 - 57kDa while mNSI runs as 
a sharp band of 49 kDa. The difference in molecular weight profiles between sNSI 
and mNSI derives from the fact that the secreted form of NS1 has one of its high 
mannose linkages trimmed and processed into a complex carbohydrate moiety 
(Winkler et al, 1998; Mason, 1989; Jacobs etal, 1992; Young, 1990) inferring 
transit through the Golgi apparatus (Lee et al, 1989). Winkler et al (1989) 
suggested that this indicates a precursor-product relationship between the two 
species however Mason (1989) demonstrated in pulse-chase radiolabelling 
experiments that mNSI accumulated within infected cells suggesting that while 
mNSI is the first species expressed, both the high-mannose and complex 
carbohydrate forms are potentially functional end-products. The exact nature of the 
cell-surface associated NS1 species has yet to be conclusively identified. 
The glycosylation of NS1 is noteworthy as it is unusual for an RNA virus to possess 
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a glycosylated non structural protein. There is some degree of heterogeneity 
between glycosylation of NS1 amongst the flaviviruses. NS1 of all four dengue 
serotypes, together with the NS1 of JE and YF viruses, have two conserved 
glycosylation sites at ^^°Asn and ^°^Asn (Rice etal, 1985; Mackow etal, 1987; Hahn 
etal, 1988; Irie etal, 1989). NS1 derived from WN, KUN, MVE and SLE viruses 
possess a third glycosylation site at '^'^ Asn (Coia et al, 1988; Trent et al, 1987; 
Castle etal, 1986; Dalgarno etal, 1986, Blitvich etal, 1999). Mandl ef a/(1989) 
have shown for TBE virus that NS1 possesses three glycosylation sites however 
only ^°^Asn is conserved with the mosquito borne flaviviruses. 
There is evidence that glycosylation is important for the biological activity of NS1 as 
well as its structural integrity. Mutagenesis of the glycosylation sites in infectious 
clones can alter neurovirulence (Pletnev et al, 1993; Muylaert et al, 1996) and 
ablation of the first glycosylation site reduced the rate of viral RNA accumulation, 
providing evidence of a role for NS1 in RNA replication (Muylaert et al, 1996). 
Removal of glycosylation sites on the dengue virus NS1 via mutagenesis was also 
shown to reduce the stability of the native dimeric form of the protein (Pryor and 
Wright, 1994). 
(c) Role of NS1 in infection and immunity 
In addition to the envelope (E) protein and prM, NS1 has been associated with 
antibody-mediated protective immunity. As noted above, NS1 exists in cell 
associated (Westaway, 1987), cell surface (Schlesinger et al, 1985) and 
extracellular forms (non-virion associated) (Mason, 1989; Smith and Wright, 1985; 
Winkler ef a/, 1988) and does not form part of the virion. Consequently, antibodies 
raised against NS1 have no neutralizing or haemagglutination inhibition activity, 
although some are able to fix complement (Schlesinger et al, 1985; Smith and 
Wright, 1985; Gibson etal, 1988; Falconar and Young, 1991). 
Schlesinger et al (1985) demonstrated that anti-NSI MAbs afforded passive 
protection to adult mice against lethal intra-cerebral (IC) challenge with the YF 17D-
204 vaccine . Of the five anti-NSI MAbs tested, two were able to confer protection. 
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Significantly these protective MAbs had high complement-fixing activities whereas 
the three non-protective MAbs had little or no detectable complement fixing activity. 
This observation suggests that protection was most likely mediated by antibody 
binding to cell surface expressed NS1 and complement mediated lysis of infected 
cells. It was also shown that active immunization with NS1 led to solid protection 
against lethal IC challenge with YF 17D-204 virus (Schlesinger etal, 1985). NS1 
immunization was also demonstrated to protect rhesus monkeys (the natural host 
of YF) from challenge. 
NS1 related protective immunity has also been investigated for dengue-2 virus. 
Active immunization of mice with dengue-2 NS1 conferred protection against 
challenge with the homologous dengue-2 virus but not heterologous challenge with 
dengue-1 virus (Schlesinger, 1987), despite the fact that common antigenic 
determinants exist on the NS1 protein (Russell etal, 1970). Synergistic effects of 
non-protective and partially protective antibodies were investigated by Henchal etal 
(1988). Although prolonged survival or reduced mortality occurred with most MAb 
combinations, increased morbidity was observed with the administration of two anti-
NSI MAbs. It was thought that this could be due to mutual competition on 
overlapping binding sites (Henchal et al, 1987) and / or unknown dynamic changes 
in antigen conformation. In light of more recent findings (Falconar, 1997) it is 
possible that these MAbs may have had direct deleterious effects on vascular 
integrity 
During human dengue virus infection, NS1 is a well established target of humoral 
immune responses. The protective capacity of anti-NSI antibody and the presence 
of substantial amounts of similar antibody in convalescent sera from dengue fever 
and dengue haemorrhagic fever patients (Falker et al, 1973) suggest a role for 
complement fixing, anti-NSI antibodies in the protective immune response to 
dengue virus infection. Other workers have found no apparent correlation between 
the complement fixing ability of individual MAbs and protective capacity (Henchal et 
al, 1988; Young and Falconar, 1990), suggesting other immune mechanisms for 
example, ADCC (antibody-dependent cell-mediated cytotoxity), may also be 
involved in recognizing NS1 on the surface of infected cells. 
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(d) NS1 function 
Although the precise function of NS1 is still unclear, a role for NS1 in virion 
assembly, transport and/or release was initially postulated because of its 
glycosylated nature and the fact that it was secreted with kinetics that mirrored that 
of the structural glycoproteins prM and E (Rice etal, 1986; Lee etal, 1989; Mason, 
1989). More recent reports from Mackenzie ef a/(1996), and genetic analyses by 
Muylaert et al (1996; 1997) and Lindenbach and Rice (1997; 1999) however 
suggested a role for NS1 in viral RNA replication despite its extracytoplasmic 
localization. A function for YF NS1 in early replication was demonstrated with a 
temperature sensitive mutant produced by a single mutation in NS1. RNA 
accumulation occurred at the nonpermissive temperature only after establishment 
of infection at a permissive temperature (Muylaert et al, 1997). Viral RNA 
accumulation, growth in culture and in vivo neurovirulence have all been shown to 
be impaired for viruses containing mutations of either or both N-linked glycosylation 
sites of yellow fever NS1 (Muylaert et al, 1998) indicating that NS1 requires 
translocation into the ER and subsequent carbohydrate linkage for function. Not 
surprisingly, a version of NS1 lacking its signal sequence also did not function in 
trans complementation (Moorman et al, unpublished data from Lindenbach and 
Rice, 1999). 
NS1 appears to function in a flavivirus-specific manner as dengue-2 virus NS1 did 
not productively interact with YF virus replication machinery (Lindenbach and Rice, 
1999). Complementation with the heterologous dengue-2 NS1 gene was not 
successful except following a mutation in NS4A with a change at residue 42 of an 
asparagine to tyrosine (Lindenbach and Rice, 1999) demonstrating for the first time 
a genetic interaction between NS1 and NS4A. It was further proposed that this 
translated to a direct interaction between the lumenal NS1 and the transmembrane 
NS4A that was pivotal to the function and/or stability of the replication complex 
(Figure 1.2C). These results are supported by previous cryo-EM studies showing 
that both NS1 and NS4A are localized to vesicle packets (Mackenzie etal, 1996; 
Mackenzie etal, 1998; Westaway etal, 1997b) (Figure 1.2B). 
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Figure 1.2 Maturation pathway of the dengue virus protein, NS1. A, NS1 is first expressed 
in the endoplasmic reticulum (ER) as a hydrophilic monomeric species that is 
rapidly glycosylated at two sites (1). Dimerization occurs within 10-20 minutes 
and is associated with the acquisition of hydrophobicity and membrane-
association (2). Dimeric NS1 traffics through the secretory pathway to the Golgi 
(3) where, for a portion of NS1, the carbohydrate moiety at ^^ °Asn is trimmed 
and processed to a complex form, generating sNSI (4). mNS1 associates with 
(or is involved in the formation of) vesicle packets derived from virally modified 
trans Golgi and functions to assist in viral RNA replication (5). sNS1 is 
transported to the cell-surface (6) and/or secreted (7). B (i), thin-section electron 
microscopy of dengue virus induced vesicle packets (VP) in Vero cells, (ii), 
cryo-immuno electron microscopy of vescicle packets immuno-gold labeled 
with anti-NSI MAbs (Mackenzie et al, 1996). C, Schematic of a hypothetical 
model showing the composition and architecture of the flavivirus replication 
complex in association with the VP membrane (Khromykh etal, 1999b). 
Further evidence was provided in biochemical assays using a recombinant NS4A 
fused to glutathione-S-transferase. When bound to glutathione beads, the fusion 
protein was found to retain several virus-specific proteins including NS1, NS2A, 
NS3, NS3-4A and NS5 (Mackenzie et al, 1998). Although it is unusual for a 
nonstructural glycoprotein to localize within vesicles and to be required for RNA 
replication, it has been hypothesized that NS1 may play a structural role in 
assembling the components of the viral replicase through its relationship with 
cellular membranes. It may also use protein-protein interactions directly to 
assemble replicase components although the involvement of other replicase 
36 
components cannot be excluded with current evidence. 
An unknown enzymatic function for NS1 and the regulation of another viral or host 
component by NS1, have all been postulated by Lindenbach and Rice (1997). 
Further work is required to clarify these issues, as the precise role that NS1 plays in 
RNA replication remains to be fully characterized. 
1.7 SCOPE OF THIS THESIS 
The aim of this thesis was to more clearly define the antigenic structure of dengue 
virus NS1. Although many studies have been undertaken on the E glycoprotein 
antigenicity and structure, detailed equivalent information for NS1 is currently 
unavailable. The fact that NS1 does not form part of the virion and is unable to 
contribute to the phenomenon of ADE, together with the fact that it is able to induce 
a protective immune response in both humans and animals makes it a potential 
component of dengue vaccine studies. To this end, the identification of antigenic 
regions of the protein were a priority. Where possible, attempts have been made to 
relate antigenic regions to that of a speculative tertiary model of NS1. The human 
immune response to NS1 during dengue virus infection was also investigated using 
immunoassays. This study was aimed primarily at determining specific anti-NSI 
antibody responses and NS1 levels in the serum of infected patients and to assess 
if there was any correlation with disease severity and these parameters. As the 
function of NS1 is still unknown, crystallography studies were undertaken to obtain 
a clearer understanding of function based on structural homology with other 
proteins. A purification regime was developed for recombinant NS1 expressed in 
the baculovirus system, to allow the production of high concentrations of protein. 
This recombinant protein was rigorously tested prior to crystallography trials to 
ensure that it maintained the native conformation of the protein in regard to 
oligomerization, glycosylation and antigenicity. Preliminary crystals generated in this 
study have formed the basis of ongoing studies. Taken together, this thesis 
undertakes to increase our knowledge on the antigenicity, structure and human 
immune response to dengue virus NS1. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 TISSUE CULTURE 
(a) Maintenance of cell lines 
Vero cells were split with 1% trypsin / versene at a ratio of 1:10 in M199 medium 
(Life Technologies) with 5% foetal calf serum (Life Technologies) and 
supplemented with sodium hydrogen bicarbonate (0.176% final concentration), 100 
U / mL penicillin and streptomycin (Life Technologies) and incubated at 37°C in an 
atmosphere of 5% CO2. For maintenance, Vero cells were incubated in the same 
media with a decrease in foetal calf serum to 2%. 
06/36 cells {Aedes albopictus) were obtained from the American Type Culture 
Collection (ATCC) and maintained in RPMI medium (Life Technologies) with 5% 
foetal calf serum and supplemented with antibiotics at a final concentration of 100 
U / mL penicillin and streptomycin and 1% glutamax (Life Technologies). C6/36 
cells were incubated at 28°C and were split at a ratio of 1:10 twice weekly. 
Spodoptera frugiperda (S/9) cells were purchased from Invitrogen and maintained 
primarily in TCI 00 medium (Life Technologies) supplemented with 10% foetal calf 
serum (Life Technologies) with the addition of 0.1 mg / mL kanamycin and 100 U / 
mL penicillin and streptomycin. For serum free conditions SF900 II medium (Life 
Technologies) was used and supplemented with 0.1 mg / mL kanamycin (Life 
Technologies) and 100 U / mL penicillin and streptomycin (Life Technologies). 
Serum free adapted Sf9 cells were a gift from Dr. Steve Reid from the Chemical 
Engineering Department, University of Queensland. S/9 cells were incubated at 
28°C either on a shaking platform at 120 rpm or in magnetic spinner bottles 
(Techne). 
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Serum free adapted S/9 cells were maintained with a strict splitting regime. The 
suspension cultures were adjusted to a concentration of 4 X 10^ cells / mL at each 
split and were never allowed to reach a density of greater than 4X10^ cells / mL. 
Cultures were infected at an m.o.i. of 1 -10 at a cell density of 2 X 10^ cells / mL. 
All cell lines used were routinely screened for the presence of Mycoplasma sp. 
using the Gen-Probe Rapid Detection System (BioMediQ) or an in-house PCR 
assay. 
(b) Propagation of Dengue Virus 
Dengue type 2 virus (PR159 or New Guinea-C strain) was grown either in Vero 
cells at 37°C or C6/36 cells at 28°C. Cell monolayers were infected at an m.o.i. of 
0.01 -1 in serum free media. The monolayers were incubated for one hour at their 
respective temperatures to allow virus adsorption after which the final concentration 
of foetal calf serum was adjusted to 2%. The tissue culture supernatants were 
harvested and clarified at approximately four days post infection or when cytopathic 
effect (CPE) was evident. Virus stocks were titred by plaque assay, aliquotted and 
stored at -70°C. 
(c) Dengue virus plaque assay 
Vero cell monolayers were grown in 24 well plates (Nunc). When the cells were 
90% confluent, 200 i^L of serially diluted virus was added in serum free Ml99 
media and incubated for one hour at 37°C in an atmosphere of 5% CO2. The 
inoculum was removed by aspiration and Ml99 media containing 1.5% (final 
concentration) carboxymethyl cellulose (CMC) (BDH) was overlaid on to the cells. 
The plates were incubated undisturbed for a minimum of seven days. 1.0 mL of 
20% formalin was added to each CMC containing well and incubated for 30 
minutes. The formalin was removed, the plate washed and then 0.2% crystal violet 
dissolved in PBS was added to each well and left for 30 minutes. The plates were 
then washed well under running water, air dried and the plaques counted. 
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(d) Preparation of polyethylene glycol (PEG) pellets 
At four days p.i., tissue culture supernatants were clarified at 4 000 rpm for 15 
minutes. The pellet was discarded and the supernatant was adjusted to a final 
concentration of 0.4 M NaCI and 7% PEG 6 000 (BDH) and mixed overnight at 4°C. 
The mixture was centrifuged at 13 000 rpm for 30 minutes and the pellet 
resuspended in 1.0 mL PBS. Samples were stored at -20°C. 
(e) Baculovirus plaque assay / plaque purification 
Monolayers of S/9 cells in 35 X 10 mm dishes (Nunc) were prepared, the tissue 
culture supernatant removed and serial dilutions of virus diluted in TCI 00 was 
added (250 |iL / dish). The virus was allowed to adsorb for one hour before being 
removed. Two mLs of a 1:1 mixture of 3% low gelling temperature (LGT) agar and 
AcNPV-PBS (150 mM NaCI, 25 mM KCI, 5 mM Na2HP04, 1 mM KH2PO4) was 
gently overlaid onto the cells and allowed to set. 1.0 mL of TCI 00 + 10% FCS was 
then added to the surface of the agar and the cells were subsequently incubated at 
28°C in a humid environment for a minimum of four days. A 1.0 mL solution of 
0.03% neutral red (Life Technologies) diluted in AcNPV-PBS was added to each 
dish and incubated for one hour at 28°C. The solution was then removed, the outer 
edges of the dishes sealed in parafilm, inverted and incubated for 24 hours. 
Plaques were either counted (for plaque assay) or individually picked using a 
pasteur pipette and added to 200 |xL of serum free TCI 00. The plaque picks were 
then stored at 4°C overnight to allow elution of the virus and 100 iiL was 
subsequently added to S/9 cells in 24 well dishes (Nunc) to amplify the virus. All 
recombinant baculoviruses were plaque purified three times. At each stage culture 
supernatants and cell extracts were screened by an immuno-dot blot assay for 
protein production using NS1-specific monoclonal antibodies. Those showing 
maximal secretion were chosen for further plaque purification. 
(f) Immunofluorescence 
The tissue culture supernatant of infected cell monolayers in individual wells of 24 
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well plates was removed, the cells were washed and then resuspended in PBS. 
Aliquots (30 |j,L) were dispensed onto immunofluorescence slides and allowed to air 
dry thoroughly. Alternatively, infected cells monolayers were grown on glass 
coverslips in 24 well plates, with the coverslips being taken through subsequent 
immuno-staining. If required, the cells were fixed in ice cold acetone for 15 minutes. 
Polyclonal serum or MAb was added to each spot in a 100 [xL volume of 0.01% 
Evans Blue and incubated in a humid chamber at 37°C for 30 minutes. The cells 
were subsequently washed by immersion in a stirring bath of PBS for five minutes. 
This was repeated three times. The secondary probe was added at a 1:200 dilution 
in PBS and incubated at 37°C for 30 minutes in a humid chamber. Cells were 
washed as previously described and mounted with glycerol saline (9:1 glycerol : 
PBS pH 8.6 containing 2.5% 1,4-diazabicyclo(2.2.2)octane) under a glass coverslip. 
Fixed and stained coverslips were inverted into glycerol saline on a glass 
microscope slide. The edges were sealed with Depex (BDH) and the slides were 
viewed under an immunofluorescence microscope. 
2.2 ANTIBODIES 
(a) Polyclonal rabbit anti-NSI 
Polyclonal rabbit anti-NSI was prepared by subcutaneous injection of rabbits with 
dengue-2 virus NS1 protein immuno-affinity purified from infected Vero 
supernatants. Fifty |ig of NS1 was mixed with an equal volume of complete 
Freund's adjuvant and injected at multiple subcutaneous sites. Two injections were 
given two weeks apart with a third injection (in incomplete Freund's) four weeks 
later. Blood was collected four weeks after the third injection, allowed to clot and 
serum was stored in aliquots at -70°C, or at -20°C, mixed 1:1 with sterile glycerol. 
(b) Monoclonal antibodies 
The anti-NSI monoclonal antibodies (MAbs) used in this study were selected from 
an extensive panel produced and described by Falconar and Young (1991). Their 
characteristics are described in Table 2.1. 
41 
BALB/c mice were hyperimmunized with immunoaffinity purified dimeric sNSI from 
dengue-2 virus (PR159) and splenocytes were fused with the SP2/0 Ag14 
plasmacytoma cell line. After cloning twice by limiting dilution, high titre stocks were 
obtained by ascitic fluid production in syngeneic mice. 
TABLE 2.1 : Characteristics of anti-NS1 monoclonal antibodies used in this study 
Monoclonal 
antibodies 
1C6.3 
1A12.3 
4H3.4 
3D1.4 
3A5.4 
5H10.3d 
1G5.4d 
1H7.4 
5H4.4 
2C9.4 
4D4.4 
5B9.3 
5C7.4 
5H5.4 
1G5.3 
5H4.3 
5F10.3 
1E2.3 
5H6.3 
5B6.3 
2A5.1 
5B5.3 
linear epitope^ 
"^YSWKTWGKA^^^ 
^"LRYSWKTWG"^ 
^'^YSWKTWGKA'^' 
"YRYSWKTWG^^^ 
-
^VHTWTEQYK^^ 
^VHTWTEQYK^^ 
-
. 
-
-
^°^TTASGKLIT^°^ 
'''RTTTASGKL'°' 
-
-
-
-
-
-
NS1 Antibody Specificity 
Flavivirus cross-reactive 
Flavivirus cross-reactive 
Flavivirus cross-reactive 
Flavivirus cross-reactive 
Flavivirus cross-reactive 
D2 specific 
D2 specific 
D2 specific 
D2 specific 
D2 specific 
D2 specific 
Flavivirus cross-reactive 
D2 specific 
D2/D4 specific 
Flavivirus cross-reactive* 
Flavivirus cross-reactive* 
Flavivirus cross-reactive* 
D2/D4 specific 
D2/D4 specific 
D2/D4 specific 
D2/D4 specific 
D2/D3/D4 specific 
Passive 
protection^ (%) 
14 
50 
13 
30 
30 
13 
50 
<6 
10 
10 
10 
<6 
20 
20 
<6 
33 
17 
50 
38 
17 
60 
38 
1. Linear epitope specifity was described in Falconar et al (1994). 
2. Passive protection data as reported in Young et al (1990). 
* Recognizes dengue-2 and dengue-4 and encephalitic flaviviruses (Young et al, 1990) 
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2.3 MOLECULAR CLONING 
(a) NS1 gene constructs 
Total cytoplasmic RNA was extracted 24 hours post-infection from dengue-2 virus 
infected C6/36 cells (m.o.i. of 10). The NS1 and NS2A genes were copied as cDNA 
using reverse transcriptase and primers located 3' of NS2A and was subsequently 
amplified by PCR using specific primers outlined in Table 5.1. The amplified 
products were cloned into the BamHI site of plasmid Bluescript II SK {+/-) 
(Stratagene). Nucleotide sequences at the 5' and 3' end of the inserts were verified 
by dideoxynucleotide sequencing (Sanger etal, 1977) using Sequenase (USB). 
(b) Construction of recombinant baculoviruses 
The NS1 inserts were removed from plasmid Bluescript SK by BamHI digestion 
and ligated to a BamHI, dephosphorylated derivative of the transfer vector pAcYMI 
(Matsuura et al, 1987). The derived recombinant transfer vectors were 
characterised by restriction enzyme digest analyses. Spodoptera frugiperda cells 
were transfected with a mixture of recombinant transfer vector DNA (1 i^g) and 
AcRP23-LacZ baculovirus linearized DNA (50 ng) using Lipofectin (Boehringer) 
(Kitts et al, 1990). Recombinant viruses were originally identified on the basis of 
their white plaque phenotype after staining with X-Gal (5-bromo-4-chloro-3-indolyl-
P-D-galactopyranoside). To confirm that NS1 protein was being expressed from the 
different constructs, infected cell extracts were analysed by immunoblotting with an 
NS1 specific MAb. Recombinant viruses were plaque purified three times before 
amplification of the virus stocks. Primary, secondary and tertiary virus stocks were 
grown, titred and stored at -70°C for long term storage or at 4°C (for working 
stocks). 
2.4 ENZYME LINKED IMMUNOSORBENT ASSAYS (ELISA) 
(a) NS1 capture ELISA 
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Immulon 4 ELISA plates (Dynatech) were coated with 50 fiL of a 1:1500 dilution of 
rabbit anti-NSI polyclonal sera in coating buffer (0.15 M Na2C03, 0.35 M NaHCOa, 
pH 9.6) overnight at 4°C. This antibody was removed and the plates were blocked 
with PBS containing 1% gelatin (type A from porcine skin. Bloom 60) (Sigma) and 
incubated at room temperature for one hour. The sample to be quantitated for NS1 
(either purified preparations, controls or patient serum samples) were serially 
diluted in PBS.0.25% gelatin and incubated at 37°C for one hour. Plates were then 
washed with PBS containing 0.5% Tween (PBS.T) and an anti-NSI MAb was 
added at a 1:1000 dilution in PBS.0.25% gelatin. After a one hour incubation at 
37°C the plates were washed as before and a 1:1000 dilution of peroxidase-
conjugated goat anti-mouse IgG (Jackson Immunochemicals) was added and 
incubated as previously described. The plates were then washed and developed 
using standard o-phenylene diamine (OPD) substrate methodology. The reaction 
was halted by the addition of 25 |iL of 2 M H2SO4 and the optical densities were 
read at a wavelength of 492 nm (MR5000, Dynatech). This method is shown 
diagrammatically in Figure 3.1. 
(b) ELISA detection of NS1-specific antibodies in patient serum 
samples 
Immulon 4 microtitre plates were coated with 50 fxL per well of a 1 |ig / mL stock of 
immunoaffinity purified secreted NS1 (sNSI) and incubated overnight at 4°C. After 
washing the plate four times with PBS.T, 150 |xL per well of PBS.1% gelatin 
(Sigma) was added and incubated at room temperature for one hour. 
Serum samples were diluted in PBS.T.0.25% gelatin (usually 1:5, 1:10 and 1:50) 
and incubated at 37°C for one hour. Following four washes with PBS.T a 1:1000 
dilution of peroxidase conjugated goat anti-human IgG was added and incubated at 
37°C for one hour. After washing with PBS.T the plates were developed using 
standard OPD methodology as above. 
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(c) Competition ELISA 
The competition assays were based on a method described by Lopez ef a/(1986) 
with slight modification. Each competition experiment was done in quadruplicate 
and 50 |iL was used per well, unless specified othenwise. Immulon 4 microtitre 
plates (Pacific Diagnostics) were coated with 10 [ig of Protein A (Pharmacia) in 
coating buffer overnight at 4°C. After washing the plates with PBS.T, 150 |iL of 
blocking solution (PBS containing 1% gelatin) was added to each well and left at 
room temperature for one hour. The plates were washed with PBS.T and then 18 
|ig of rabbit anti mouse IgG (H & L) in PBS.T / 0.25% gelatin was allowed to bind to 
the Protein A for one hour at 37°C. Following four washes with PBS.T, the primary 
MAb (diluted 1 /100 in PBS.T / 0.25% gelatin) was added and incubated at 37°C 
for one hour. Plates were washed as before and immunoaffinity purified ^^S-
methionine / cysteine-labelled NS1 (2 000 cpm / well) was combined with a 1/10 
dilution of the secondary MAb in PBS.T / 0.25% gelatin, and immediately added to 
the plate and incubated at 37°C for one hour. The plate was then washed four 
times with PBS.T followed by the addition of lysis buffer (2% SDS, 1% 2-
mercaptoethanol in SDS - PAGE sample buffer) to each well. After ten minutes 
incubation at room temperature the lysis buffer was removed individually from each 
well, added to 1.0 mL of scintillation fluid (Optiphase HiSafe II, Wallac) and counted 
in a p-scintillation counter (LKB). A set of positive controls were run with each set of 
experiments and binding was expressed as a percentage of NS1 binding in the 
absence of competing antibody ie. 
average cpm in the presence of competing antibody 
X 100 = % binding 
average cpm in the absence of competing antibody 
Between 0 - 30% binding was defined as strong competition, 31 - 75% was defined 
as partial competition, 76 - 150% as no competition and greater than 150% as 
indicating enhanced binding. 
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2.5 PROTEIN ANALYSIS 
(a) Immunoaffinity purification of NS1 
([) Preparation of the immunoaffinity column 
A protein A column was washed sequentially with 50 mLs of 40 mM diethylamine 
(DEA) in PBS, 0.1 M citric acid pH 2.5, 2 M urea pH 8 and high salt binding buffer 
(1.5 M glycine / 3 M NaCI pH 8.63). The latter was used because the monoclonal 
antibody (5B9.3) employed to generate the column was of the IgGI subclass. 
Ascites (20 mLs) was clarified at 10 000 rpm for 60 minutes and filtered through a 
0.45 |im filter. NaCI was added to give a final concentration of 3 M and glycine to 
1.5 M. The pH was adjusted to 9.0. The protein A was then added to the ascites 
solution and mixed overnight at 4°C on a rotating mixer before being poured into a 
column and washed with 50 mLs of high salt binding buffer. Antibody was eluted 
with 0.1 M citric acid pH 3 and twenty 0.5 mL fractions were collected. Protein 
assays were performed (with a BCA kit (Pierce)) and the six peak fractions were 
collected. 
A 20 mg / mL sodium periodate solution was added to the peak antibody fractions 
at a 1:10 dilution and mixed at room temperature for sixty minutes. The oxidizer 
was removed using an Econo-Pac 10DG desalting column and six peak fractions 
(0.5 mL each) were collected. After washing to remove isopropanol, affi-gel Hz (Bio-
Rad) was added to the peak fractions and mixed on a rotary shaker overnight at 
room temperature. The gel slurry was poured into a chromatography column and 
washed with PBS and subsequently stored in PBS containing 0.02% sodium azide. 
(ii) Protein production 
Vero cells were infected at an m.o.i. of 0.5 and incubated for four days prior to 
immunoaffinity purification. C6/36 cells were infected with the same regime for two 
days and S/9 cells were infected with recombinant baculovirus at an m.o.i. of 1 for 
24 hours. For ^^S - labelled NS1, cells were then labelled overnight with 50 |iCi / mL 
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of frans^^S-methionine/cysteine (ICN) in minimal essential media (MEM) deficient 
in methionine and cysteine (ICN) for Vero and C6/36, and methionine and cysteine 
free SF900II for Sf9 cells. Both cell monolayers and media were harvested 
separately and membrane-associated (mNSI) and secreted forms of NS1 (sNS1) 
were immunoaffinity purified according to the method of Falconar and Young 
(1990). In summary, infected cell culture supernatants were clarified by 
centrifugation and adjusted to contain 5 mM EDTA, 0.02% NaNs, 1 mM PMSF and 
1 mM benzamidine HCI. 
Cell monolayers were washed with ice cold PBS (pH 7.4) and scraped into ice-cold 
non-denaturing harvest buffer (HB; 0.005 M EDTA pH 8,0.01 M Tris pH 7.4,0.15 M 
NaCI, with protease inhibitors). TX-100 was added to give a final concentration of 
2% (v/v) and the cells were solubilized with slow mixing on a magnetic stirrer 
overnight at 4°C. The detergent insoluble fraction was removed by centrifugation at 
13 000 rpm at 4°C. The TX-100 concentration in the cell lysates was reduced to 
0.5% by the addition of ice-cold HB. All subsequent steps were performed at 4°C. 
The immunoaffinity column was prepared for use by equilibration of the column with 
HB containing 0.5% TX-100 and the cell lysate and culture media fractions were 
passed through the column separately. The column was then washed with HB 
containing 0.1% TX-100 and the bound NS1 was eluted by reverse flow using 20 
mM DEA (diethylamine) in HB with 0.1% TX-100. Half mL fractions of the NS1 
containing eluate were collected and neutralized with 40 |iL of 1 M Tris-HCI pH 6.0. 
For secreted NS1 the immunoaffinity purification was the same as that stated 
above, except for the omission of detergent from the procedure. 
Eluted protein was analyzed for purity by western blotting and silver staining. 
Protein concentration was determined using a Lowry modified BCA (bicinchoninic 
acid) reagent (Pierce) with BSA protein standards. 
(b) Centricon purification of NS1 
Routinely, centricon-30 (Amicon) and microcon-100 concentrators (Amicon) were 
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used to concentrate protein solutions according to the manufacturer's instructions. 
Briefly, protein solution (2 mL maximum volume) was added to the sample 
reservoir. The centricon concentrator was placed in an SS34 rotor and centrifuged 
at 5000g at 4°C in 15 minutes intervals, until the desired concentration was 
achieved as determined by the amount of filtrate generated. The concentrator 
assembly was then disassembled and the filtrate retained for analysis (if required). 
A retentate cup was then placed over the sample reservoir and the assembly was 
inverted and centrifuged at lOOOg for 2 minutes at 4°C to collect the retentate. 
(c) Cross-linking 
A protein solution for cross-linking was diluted in 0.2 M NaCI / 50 mM Hopes with a 
range of BS^ {Bis (Sulfosuccinimidyl) Suberate) (Pierce) concentrations (usually 0 -
20 mM) and incubated at room temperature for two hours. The samples were then 
boiled in sample buffer containing DTT (5 mM) and run on pre-cast 4-20% SDS -
PAGE gradient gels (Bio-Rad) at 4°C prior to silver staining or western blotting. 
(d) Enzymatic Digestions 
(i) Trypsin and Staphylococcus aureus V8 protease 
Routinely, 0.2 |ig of immunoaffinity purified sNSI in 5 |xL, was digested with 100 i^g 
/ mL trypsin or Staphylococcus aureus V8 protease in SDS - PAGE sample buffer 
for two hours at 37°C. Preparations were either boiled in the presence of 0.12% 
SDS or left untreated prior to digestion. Digests were solubilized with disruption 
buffer containing SDS, without a reducing agent, (unless othenwise stated) and 
boiled (unless othenwise stated) before separation on a 10% SDS - PAGE gel. 
(ii) Endoglycosidase digestions 
Protein to be analysed was adjusted to 0.4% SDS and boiled for five minutes 
unless othenwise specified. An equal volume of 2X reaction buffer was added to the 
supernatant: for endoglycosidase H (Roche Molecular Biochemicals) the buffer 
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consisted of 0.2 M sodium citrate pH 5.5 and for endoglycosidase F (Roche 
Molecular Biochemicals) the buffer contained 0.1 M sodium phosphate pH 6.8,0.1 
M EDTA, 1 % triton X-100. For endoglycosidase F and H, 0.05 units and 0.001 units 
were used respectively for 10|j.L reactions. Samples were digested at 37°C for three 
hours. An appropriate volume of 5X SDS sample buffer was then added and the 
digested samples were analysed by SDS - PAGE and western blotting. 
(e) Immunoblotting 
All protein preparations were electrophoresed through 10% discontinuous SDS -
PAGE gels (0.375 M Tris-HCI pH 8.8, 0.1% SDS) with a 3.5% stacking gel (0.125 M 
HCI pH 6.8, 0.1 % SDS) (Laemmli, 1970) using a disruption buffer containing SDS, 
without a reducing agent, unless othenwise stated. Proteins were transferred to 0.2 
micron nitrocellulose membranes (Schleicher & Schuell) in transfer buffer (0.5 M 
Tris, 0.4 M glycine pH 8.4, 20% methanol) at 160 mA per gel for 20 minutes on a 
semidry western blotter (Satroblot II, Sartorius). Blots were probed with various 
MAbs (Table 2.1) as previously described (Young, 1989). The membrane was 
dried prior to blocking for two hours in PBS.T containing 3% skim milk powder 
(Carnation or Diploma) (PBS.T.MP). Blots were probed with an appropriate 
antibody diluted in PBS.T.MP and incubated for a minimum of one hour at room 
temperature. The membrane was then given three 10 minute washes in PBS.T 
followed by the addition of the secondary antibody (usually peroxidase-conjugated 
goat anti-mouse IgG (H & L) (Jackson Immunochemicals)) diluted in PBS.T.MP and 
incubated at room temperature for one hour. 
(i) Enzyme substrate detection 
Following the same washing procedure the proteins were visualized by the addition 
of 30 mg of chloronaphthol (Sigma) and 10 mg of DAB (BDH) each dissolved in 5 
mL of methanol, added to 40 mL of PBS and 10 ^ iL of hydrogen peroxide (Young, 
1989). 
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(ii) Chemiluminescence detection 
Alternatively, proteins were detected by chemiluminescence (ECL PLUS, 
Amersham Pharmacia Biotech) after the final wash in PBS.T following the 
manufacturer's instructions. Briefly, the primary antibody was diluted 1:5000 in 
PBS.T and added to the membrane, sealed in a plastic bag and incubated for one 
hour at room temperature. The membrane was washed three times, for five minutes 
each and the secondary antibody was diluted 1:10 000 in PBS.T and incubated for 
one hour at room temperature. The membrane was washed as before and given a 
final rinse in PBS. Supplied solutions A and B were allowed to come to room 
temperature and combined in a 40:1 ratio in a sufficient volume to allow 100 |iL / 
cm^ of membrane (generally 2.5 mL total volume for a mini-gel blot). Excess PBS 
was drained from the membrane and placed protein side up on a sheet of plastic. 
The mixed detection reagents were added to the membrane and incubated for 5 
minutes in the dark at room temperature. Excess detection reagent was drained 
from the membrane and placed protein side down, on to a piece of plastic, folded to 
seal the edges and air bubbles smoothed out. The blot was exposed to X-ray film in 
an X-ray cassette and exposed initially for 15 seconds and subsequently for up to 
two minutes depending on the intensity of the signal after developing the first 
exposure. 
(iii) N-terminal amino acid sequencing 
Protease digested NS1 was separated on a preparative 10% SDS - PAGE gel, 
transferred to 0.2 |im PVDF membrane (Bio-Rad) in a 10 mM CAPS blotting buffer 
(pH 11) containing 10% methanol, and stained with 0.1 % amido black. Appropriate 
bands were excised with a scalpel and submitted to an external facility for N-
terminal sequencing. 
(f) Triton X-114 (TX-114) phase separation of proteins 
The method followed was that of Bordier (1981). Briefly a sucrose cushion (10 mM 
Tris-HCI pH 7.4, 150 mM NaCI, 0.06% TX-114 (Sigma), 6% sucrose, 0.003% 
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bromophenol blue) was added to a 0.5 mL microcentrifuge tube and 200 |iL (ie. 150 
|iL NS1 and VA volume of 4X TX-114 buffer (40 mM Tris-HCI pH 7.4, 600 mM NaCI, 
4% TX-114)) of the test sample was slowly layered on top of the cushion. The tube 
was then incubated at 30°C for three minutes before being centrifuged at 2000 rpm 
for three minutes at room temperature. The aqueous phase (upper layer) was 
removed to a fresh microcentifuge tube containing 1 |LIL of TX-114 on ice and 
subsequently loaded back onto the same sucrose cushion. The tube was 
reincubated at 30°C for three minutes and centrifuged at 2000 rpm for three 
minutes at room temperature. The supernantant was collected in a fresh 
microcentrifuge tube on ice containing 4 i^L of TX-114 and incubated at 30°C and 
recentrifuged. This supernatant was collected as the aqueous phase. The detergent 
phase was collected from underneath the sucrose layer. Volumes and TX-114 
concentrations were adjusted to give concentrations of salt and surfactant content. 
Samples were analysed by western blotting. 
(g) Two dimensional gel electrophoresis 
Isoelectric focusing was performed using a Mini-PROTEAN II 2D cell (Bio-Rad) 
following the manufacturer's instructions. Proteins were subsequently visualized by 
silver staining. 
(i) Tube gel preparation 
Briefly, capillary gel tubes were set up in a vertical position in a casting tube which 
was sealed at the base with parafilm. Monomer solution was prepared (See 
Appendix 2.1) and each tube was filled to % of the length of the tube. After 
polymerization of the solution the blue striped end of the tubes were attached to the 
sample reservoirs with tubing connectors and the bottom of each tube was washed 
with lower buffer. A gel tube was inserted into each of the 16 positions in the tube 
adaptor. Each sample resen/oir was filled with upper chamber buffer (Appendix 2.1) 
and lower chamber buffer (Appendix 2.1) was added to the base. With a magnetic 
stirring bar in the base and with the apparatus sitting on a magnetic stirrer, the 
capillary tubes were pre-electrophoresed successively at 200V for 10 minutes, 
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300V for 15 minutes and 400V for 15 minutes. The buffers were then discarded and 
fresh buffers added to the sample reservoirs. 
(ii) Sample preparation, loading and isoelectric focusing 
An equal volume of first dimension sample buffer (Appendix 2.1) was added to the 
sample and incubated at room temperature for 15 minutes. With a hamilton syringe, 
the sample was underlaid at the base of the sample reservoir. The sample was 
then overlaid with 20 - 40 |iL of sample overlay buffer (Appendix 2.1). Gels were run 
at 500V for 10 minutes followed by 750V for 3.5 hours. 
(iii) The Second Dimension 
To remove the tube gels from the capillary tubes a 1.0 mL syringe was added to the 
white end of a tube gel ejector. This was then attached to the end of a capillary tube 
and the gel gently extruded on to a piece of parafilm. The gel tube was then 
positioned lengthwise on to the top of a mini-protean gel (prepared as described 
previously) prepared with a two-dimensional gel comb. Two dimensional gel 
markers (Bio-Rad) were run concomitantly. The resulting gels were then silver 
stained. 
(h) Staining of SDS-PAGE gels 
(i) Silver staining 
Gels were run as previously described and fixed in a solution of 30% ethanol and 
10% acetic acid for one hour. The silver stain procedure is a modification of that of 
Blum et al (1987). Gels were rinsed three times with 30% ethanol for 20 minutes 
each followed by two rinses of 15 minutes in distilled water. The gel was then 
sensitized by the addition of a 0.25 g / L sodium dithionite solution for one minute, 
followed by two one minute washes in distilled water. The gel was then stained with 
a solution of 0.2% silver nitrate and 1 mM formaldehyde for 30 minutes and washed 
for one minute in distilled water. Protein bands were then visualised with the 
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addition of a developing solution (6% sodium carbonate, 6 mM formaldehyde, 20 
|iM sodium thiosulphate) for five to ten minutes. Finally the reaction was stopped 
with the addition of 3.5% acetic acid and the gel washed in distilled water. For 
storage the gels were dried on to 3MM filter paper (Whatman) using a gel dryer 
(Bio-Rad). 
(ii) Coomassie blue staining 
Gels were fixed for one hour in 30% methanol, 10% acetic acid and then stained 
with 0.006% Coomassie Brilliant Blue G-250 (Bio-Rad), 10% acetic acid for two 
hours. Destaining was performed in 10% acetic acid for approximately two hours 
and fresh destain solution was added as required. 
(i) Pulse-chase experiments 
Prior to labelling 3 X 1 0 ^ S/9 cells were added to 35 x 10 mm dishes (Nunc), 
allowed to attach and form a monolayer and infected with a recombinant 
baculovirus at an m.o.i. of either 1 or 10. At 24 hours post infection (p.i.) the cell 
monolayers were washed twice with methionine / cysteine deficient SF900 II 
(Gibco) and then starved in the same media for 30 minutes. The cells were then 
pulse labelled for one hour with 50 |j.Ci / mL of trans ^ ^S methionine / cysteine (ICN 
Biomedicals). After the pulse period, the monolayers were washed and chased in 
"cold" media with an excess (10 mM) of methionine and cysteine for various 
periods. 
0) Analysis of baculovirus expressed protein by radio-immuno 
precipitations (RIP) 
Tissue culture fluids were harvested in the presence of protease inhibitors (10 mM 
pefabloc (Boehringer), 10 |ig / mL aprotinin (Bayer), 2 | ig / mL leupeptin (Sigma), 2 
\ig I mL benzaminidine (Sigma) and 10 |ig / mL Na-p-tosyl-L-lysine chloro-methyl 
ketone (TLCK) (Sigma)). Subsequent to the addition of protease inhibitors the 
samples were clarified by centrifugation at 2 OOOg for 15 minutes at 4°C and the 
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supernatant was used for further analysis. Cell monolayers were rinsed with ice 
cold AcNPV phosphate buffered saline (AcNPV-PBS: 140 mM NaCI, 27 mM KCI, 8 
mM Na2HP04, 1.47 mM KH2PO4, pH 7.4), and incubated on ice for 20 minutes in 
500 |iL RIPA buffer (10 mM HCI, pH 7.5, 150 mM NaCI, 5 mM EDTA, 1% sodium 
deoxycholate, 1% triton X-100, 0.1% SDS) containing protease inhibitors. The S/9 
monolayers were then scraped from the dish into the RIPA buffer and clarified by 
centrifugation for 20 minutes at 13 000 g at 4°C. An appropriate volume of 4X RIPA 
buffer with protease inhibitors was added to the tissue culture supernatant so that 
the buffer conditions would mirror that of the cell extract. 
Equal volumes (200 jxL) of the cell extract and cell culture supernatant were added 
to 300 (iL of RIPA buffer and precleared with 25 ^L of 30% Protein A sepharose 
(Pharmacia) hydrated in RIPA buffer, and mixed for one hour at 4°C. The samples 
were then centrifuged at 10 OOOg for five minutes and the pellet was discarded 
before adding 3 \xL of an anti-NSI monoclonal antibody and mixing the samples 
overnight at 4°C. A 25 |LIL aliquot of a 30% suspension of protein A sepharose was 
added to the samples and incubated at 4°C for one hour. The sepharose was then 
pelleted by centrifugation, rinsed twice with RIPA buffer containing 0.5 M NaCI and 
finally with RIPA buffer. Bound protein was released by boiling the sepharose in 50 
|iL of dissociation buffer (0.05 M Tris-HCI, pH 6.8,10% glycerol, 2% SDS, 0.001% 
bromophenol blue) and resolved on a 10% SDS - PAGE gel. Gels were fixed (30% 
ethanol, 10% acetic acid) for one hour, soaked in Amplify (Amersham) for 15 
minutes, dried and autoradiographed. 
(k) Factorial screen for crystallography trials 
(i) Hanging drop vapour diffusion method 
Twenty-four well plates were set up with 1.0 mL of each Hampton factorial solution 
in the base. The composition of each solution is listed in Appendix 5.1. The rim of 
each well was greased with vaseline and glass coverslips were prepared with one 
microlitre of the concentrated protein solution together with one microlitre of the 
factorial solution. The coverslip was then inverted over the well and gently pressed 
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to ensure that the well was completely sealed. Duplicate plates were set up and 
incubated at 4°C and 20°C respectively. 
Plates were observed using an inverted microscope, on completion of the set up 
procedure and weekly thereafter. 
(I) Electron Microscopy 
Proteins were diluted in PBS to concentrations of the order of 0.01 - 0.001 mg / mL. 
Where cross-linking was performed, prior to dilution 10% gluteraldehyde (Fluka) 
was added to the PBS to achieve a final concentration of 1% gluteraldehyde. 
Droplets of approximately 3 |iL of this solution were applied to thin carbon film on 
400-mesh copper grids that had been glow-discharged in nitrogen for 30 seconds. 
After one minute the excess protein was drawn off, followed by washing in 5 )iL of 
PBS, then 2 - 3 droplets of negative stain (2% uranyl acetate or 2% uranyl formate) 
was added. Uranyl acetate was obtained from Agar; uranyl formate was prepared 
according to the method of Russell and Hyder (1976). The grids were air-dried and 
then examined at 80 kV in a JEOL 100B transmission electron microscope at a 
magnification of 100 OOOX, or in a JEOL 2000FX transmission electron microscope 
at 120 kV and a magnification of 67 OOOX. Electron micrographs were recorded on 
Kodak SO-163 film and developed in undiluted Kodak D19 developer. The electron-
optical magnification was calibrated for both microscopes by comparison with the 
width of Tobacco Mosaic Virus (180A) imaged under these conditions. This work 
was performed by Dr. Lynne Lawrence, BRI, Melbourne. 
55 
APPENDIX 2.1 
TWO DIMENSIONAL GEL BUFFERS 
SOLUTIONS FOR THE FIRST DIMENSION 
First Dimension Acrylamide stock 
Acrylamide / bis 28.38 g 
30% T / 5.4% C 1.62 g 
The above chemicals were made to 100 mL with water, filtered and stored at 4°C in 
the dark. 
10% Triton X-100 stock (w/v) solution 
10 mL TX-100 was added to 90 mL distilled water and deionized overnight with 5g 
of AG 501-X8 ion exchange resin (BioRad) 
First Dimension Sample Buffer 
9.5 M Urea 5.7 g 
2.0% triton X-100 2 mL of 10% stock 
5% p-mercaptoethanol 0.5 mL 
1.6% 5 / 7 Ampholyte 400 |iL 
0.4% 3 /10 Ampholyte 100 i^L 
The above components were diluted to a final volume of 10 mL and warmed in a 
water bath to dissolve urea. Aliquots were stored at -70°C. 
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First Dimension sample overlay buffer 
9 M urea 5.41 g 
0.8% 5 / 7 Ampholyte 200 |iL 
0.2% 3 /10 Ampholyte 100 |iL 
0.05% Bromophenol Blue 500 |iL 
The above components were diluted to 10 mL with distilled water and warmed in a 
water bath (maximum of 45°C) to dissolve urea. Aliquots were stored at -70°C. 
Upper Chamber Buffer 
degassed 100 mM NaOH 
Lower Chamber Buffer 
degassed 10 mM H3PO4 
First Dimension gel monomer solution 
9.2 M urea 5.5 g 
4% acrylamide 1.33 mL first dimension acrylamide stock 
20% triton X-100 2.0 mL 10% triton X-100 solution 
1.6% 5 / 7 Ampholyte 400 |iL 
0.4% 3 /10 Ampholyte 100 |xL 
0.01% ammonium persulfate 10 |iL of 10% solution 
0.1% TEMED 10|LiL 
This solution was made fresh (without the polymerization reagents) and warmed to 
dissolve the urea. The solution was then degassed for a minimum of 15 minutes 
before adding the TEMED and APS. 
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SOLUTIONS FOR THE SECOND DIMENSION 
SDS Sample Equilibration buffer 
0.0625 M Tris-HCI, pH 6.8 12.5 mL of 0.5 M Tris-HCI pH 6.8 stock 
2.3% (w/v) SDS 23 mL 10% SDS solution (w/v) 
5.0% (v/v) p - mercaptoethanol 5 mL 
10% glycerol (w/v) 8 mL 
0.05% Bromophenol Blue 2.5 mL 
Distilled Water 49 mL 
58 
CHAPTER 3 
NS1 IN HUMAN SERA 
Publications arising from this Chapter: 
Young PR, Hilditch PA, Bletchly C and Halloran W (2000) An antigen capture 
enzyme-linked immunosorbent assay reveals high levels of the dengue virus protein 
NS1 in the sera of infected patients. Journal of Clinical Microbiology 38 (3) 1053 -
1057. 
3.1 INTRODUCTION 
NS1 was first described in the early 1970s as a soluble complement fixing (SCF) 
antigen in infected cell cultures (Brandt etal, 1970; Cardiff et al, 1971) and was 
recognized as an important immunogen in infections of humans (Russell et al, 
1980), and experimentally infected mice (Brandt etal, 1970). As NS1 does not from 
part of the virion, antibodies directed against it have no neutralizing or 
haemagglutination-inhibiting activity (Gibson etal, 1988). Protection by antibodies 
to NS1 is thought to involve immune recognition of NS1 on the surface of infected 
cells, leading to complement-mediated lysis and/or antibody dependent cell 
cytotoxicity or ADCC (Schlesinger et al, 1987). It should also be noted that the 
onset of hypovolemic shock in DHF patients is preceded by extensive activation of 
the serum complement system (Russell etal, 1969; Memoranda, 1973). 
Despite the fact that the dengue virus non-structural protein NS1 has been found to 
be able to induce a partially protective immune response in experimental animal 
models (Schlesinger etal, 1985; Henchal et al, 1988), and for anti-NSI MAbs to 
confer passive protection, few studies have examined in detail, the human immune 
response to NS1 in dengue virus infection (Falker et al, 1973; Kuno et al, 1990; 
Churdboonchart etal, 1991; Alcon etal, 2002). In contrast, the antigenic regions of 
the flavivirus E protein have been comprehensively studied (Henchal etal, 1985; 
Mandl etal, 1989; Guirakhoo etal, 1989; Hall etal, 1990; Tsekhanovskaya etal, 
1993; Self et al, 1995; Roehrig et al, 1998; Seraf in and Aaskov, 2001; Beasley and 
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Aaskov, 2001) and serotype specific and cross-reactive determinants have been 
reported (Henchal etal, 1982; Megret etal, 1992; lacono-Connors et al, 1996; 
Roehrig etal, 1998). There is also extensive information available in the literature 
regarding the human immune response to the E protein in flavivirus infections 
(Shyu etal, 1997; AbuBakar etal, 1997; Valdes etal, 2000; Roehrig etal, 2001; 
Wang e/a/, 2001). 
The most prominent feature of DHF is plasma leakage (Kurane and Ennis, 1994). 
Microscopic studies at autopsy show swelling of capillary endothelial cells and 
capillary edema in soft tissues. Surprisingly though, the tissue damage observed in 
pathological studies is not very severe compared to the severity of illness 
(Bhamarapravati, 1989). Dengue virus antigens are not detected in vascular 
endothelial cells and patients with DHF recover quickly by replacement of lost 
plasma with electrolyte solutions (Nimmannitya, 1987). It has been suggested that 
this plasma leakage is due to an increase in vascular permeability arising through a 
malfunction in vascular integrity, rather than direct viral mediated destruction of 
endothelial cells (Kurane et al, 1991b; Kurane and Ennis, 1992). Henchal etal 
(1987) speculated that NS1 may stimulate an anamnestic response during human 
secondary dengue infections and that high levels of anti-NSI may contribute to the 
pathogenesis of DSS through the formation of immune complexes. 
If the proposal that NS1 be included as part of a sub unit vaccine to prevent dengue 
virus infections is to be considered, more information is required in relation to NS1 
in naturally acquired human dengue virus infection. Limited information is currently 
available regarding the human dengue NS1-specific antibody responses and a 
better understanding of the immune response to NS1 and its role in protective 
immunity and / or pathogenesis of DHF / DSS is required (Shu et al, 2000). This 
section of the study therefore was designed to establish an assay that was able to 
quantitatively assess the level of NS1 in the serum of infected individuals and to 
relate these findings to disease severity. Previous studies in this area have been 
inconclusive due to the difficulties inherent in comparing results obtained using 
different methodologies, different flaviviruses, different viral proteins and different 
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stages of flavivirus infections. We aimed therefore to establish a sensitive capture 
ELISA using an existing panel of MAbs (Falconar and Young, 1991), and to screen 
a relatively large series of patient sera that included acute and convalescent sera, 
primary and secondary sera and samples from patients suffering different clinically 
defined grades of dengue virus infection. Furthermore, the induced antibody 
response to NS1 was also investigated in order to examine the postulated role of 
antibody to NS1 in pathogenesis originally suggested by Falker e/a/(1973). 
3.2 RESULTS 
(a) NS1 Capture ELISA 
An NS1 antigen capture ELISA was developed to detect and quantitate NS1. This 
assay was in the form of a double sandwich ELISA in which the NS1 protein was 
captured by a polyclonal antibody immobilized on a microtitre plate. This polyclonal 
rabbit anti-NSI is able to bind all four serotypes of NS1, with a subsequent specific 
MAb used as a selective probe for individual serotypes (Figure 3.1). Various 
capture and detection parameters were investigated. Patient serum samples were 
tested for the presence of circulating NS1 using the optimized ELISA. A preliminary 
screen was performed at a dilution of 1/10 to detect positive samples followed by 
titration and quantification. 
(b) Development of the assay 
(I) Selection and optimization of capture and detection antibodies 
In order to establish a sensitive capture ELISA for the dengue virus NS1 
glycoprotein, a cross-reactive rabbit polyclonal antisera raised against 
immunoaffinity purified sNSI was generated and used to capture NS1 from all four 
dengue virus serotypes. A panel of MAbs listed in Table 3.1 including both cross-
reactive and type-specific epitopes were also trialled as capture probes. Using any 
of the MAbs either in combination or alone as capture antibodies resulted in a 
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decreased signal and so the rabbit polyclonal antibody was chosen for all 
subsequent studies. Previous chequerboard analyses of a dilution series of the 
rabbit antisera against the full panel of MAbs and using a standard concentration of 
immunoaffinity purified NS1, established an optimum dilution of 1:1500 for the 
polyclonal antibody. 
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Figure 3.1 Schematic diagram of NS1 capture ELISA. Polyclonal rabbit anti-NS1 was 
used to coat the wells of an ELISA plate. Diluted patient serum samples 
were then added and allowed to bind. Non-specific serum components 
were removed by washing and an NS1 specific monoclonal antibody 
(MAb) probe was then added. The MAb was detected with a goat anti-
mouse IgG-peroxidase probe. 
Figure 3.2 shows the results of using these MAbs as detection probes in the 
analysis of a range of dilutions of the immunoaffinity purified secreted form of NS1. 
The graph clearly indicates that the dengue-2 specific MAbs (5H4.4, 1H7.4, and 
2C9.4) clustered as a group and showed the highest binding profile. Peptide 
binding studies (Falconar et al, 1994) and the competition analyses described in the 
subsequent chapter (Chapter 4) have mapped these MAbs to the same epitope 
(^VHTWTEQYK^^). The cross - reactive MAbs (3D1.4, 3A5.4 and 4H3.4) also 
clustered together reflecting their common epitope specificity 
( "YRYSWKTWGKA^^^ ) (Falconar et al, 1994). Although these MAbs are less 
efficient as detection probes for dengue-2 NS1, they should be able to be utilized 
for the analysis of NS1 produced by each of the other dengue virus serotypes. 
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Table 3.1 NS1 specific monoclonal antibodies used as detection probes in the 
NS1 capture ELISA 
Monoclonal 
antibod/ 
1H7.4 
2C9.4 
5H4.4 
5H6.3 
5B5.3 
4H3.4 
3D1.4 
3A5.4 
ELISA 
titre' 
6.0 
5.4 
5.4 
4.6 
3.5 
5.3 
5.2 
5.7 
Linear epitope'^  
+ 
+ 
+ 
-
-
+ 
+ 
+ 
Cross-reactivity with other dengue serotypes'^  
DEN1 
-
-
. 
-
+++ 
+++ 
+++ 
DEN2 
+++ 
++ 
+++ 
+++ 
++ 
+++ 
+++ 
+++ 
DEN3 
-
-
-
+++ 
+++ 
+++ 
+++ 
DEN4 
-
-
+ 
+ 
+++ 
+++ 
+++ 
a All monoclonal antibodies used in this study are of the IgG 1 isotype and are described in detail in Falconar and Young (1991). 
b Titres are expressed as log,o 50% end-points as measured against purified NS1 coated ELISA plates. 
c Reactivity of the MAbs with linear epitopes was determined by dot blot analysis against reduced and carboxy-methylated, 
purified NS1. PEPSCAN analysis has identified the location of these epitopes and is reported in Falconar etal, 1994. See text 
for details, 
d Cross-reactivities were determined by immunoblot analysis of SDS-PAGE separated SDS lysates of Vero cells infected with 
the dengue virus serotype prototypes, DEN1 (Hawaii), DEN2 (NGC), DEN3 (H87) and DEN4 (H241). 
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Figure 3.2 Reactivity of a panel of monoclonal antibodies against serial dilutions of 
Immunoaffinity purified NS1 in the capture ELISA. NS1 was captured 
with a 1:1500 dilution of rabbit anti-NSI polyclonal antisera coated onto 
ELISA plates and subsequently probed with the monoclonal antibodies 
at a dilution of 1:1000. 
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Due to the identification of synergistic interactions between specific MAbs in the 
competition analyses (described in Chapter 4), the effect of various combinations of 
MAbs on the detection sensitivity of the assay was examined. No improvement in 
detection was observed with these mixtures of MAbs when compared with the MAb 
1 H7.4 alone, therefore this MAb was selected for further assessment. 
(ifl Sensitivity and reproducibility of the assay 
To determine the sensitivity of the NS1 capture assay, replicates of serially diluted 
NS1 of known concentration were probed with MAb 1 H7.4 (Figure 3.3). Both PBS 
and pooled normal human sera were used as diluents in order to determine the 
effect that the presence of serum may have on detection sensitivity. Figure 3.3 
shows that the effect of normal human serum components on the capture and 
detection of NS1 was minimal at a dilution of 1 in 5 and negligible at 1 in 10. As the 
subsequent analysis of patient sera was carried out at dilutions equal to, or greater 
than 1 in 10, it was assumed that serum at these dilutions had little effect on 
detection sensitivity. 
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Figure 3.3 
NS1 (ng/ml) 
Effect of human serum components on the detection of NS1 in the 
capture ELISA. Purified secreted NS1 was serially diluted in the 
absence (•) or presence of normal human serum at a dilution of 1 in 5 
(A) and 1 in 10 (O). Data points represent the mean ± SD for four 
replicates. The dashed line is the mean for the negative control 
samples (OD490 0.122 ± 0.012). 
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The assay was considered positive if a sample gave an OD reading that was 3 
standard deviations (0.036 OD492 units) above the mean OD value for negative 
control samples (0.122 ± 0.012). The limit of detection of NS1 using these criteria 
was approximately 4 ng / mL when the MAb 1H7.4 was used, however this was 
reduced to 15 ng / mL when the cross - reactive probe 3D1.4 was utilized. 
The reproducibility of the assay was examined with multiple replicates assessed 
within the same test and by repeated testing over a two month period. Not 
surprisingly, the coefficient of variation (CV) results varied considerably depending 
on the level of NS1 present in the samples. In subsequent analyses of patient test 
sera, samples were titrated and estimates of NS1 levels were determined by 
comparison of absorbance readings of appropriately diluted fractions with a 
standard curve derived from a titration series of purified NS1, within the range 20 to 
200 ng / mL. At a concentration of 100 ng / mL, the coefficient of variation for 12 
replicates tested in the same assay was 4% and the test-to-test coefficient of 
variation, using 16 replicates was 12%. 
(iii) Comparison of type-specific and group-reactive monoclonal 
antibodies in the detection of secreted NS1 of all four dengue 
virus serotypes 
In order to examine the reactivity in the ELISA capture assay of NS1 derived from 
each of the four dengue virus serotypes, clarified tissue culture supernatants 
harvested from infected cell monolayers at peak CPE were tested (ranging from five 
to nine days depending on the serotype). The supernatant fractions were tested in 
the capture assay using either the type-specific (1 H7.4), or group-reactive (3D1.4) 
monoclonal antibodies as detection probes (Figure 3.4). The specificity of the 1 H7.4 
probe for dengue 2 virus NS1 is clearly demonstrated in Figure 3.4A, as is the 
increased detection sensitivity of the MAb (approximately four fold) compared with 
MAb 3D1.4 (Figure 3.4B). Comparison with a standard curve performed in parallel 
and prepared with serial dilutions of purified dengue 2 virus NS1 of known 
concentration indicated that between 5 - 7 jxg /10^ cells of NS1 is secreted from 
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dengue-2 virus infected Vero cells under these conditions. A time course analysis of 
NS1 secretion from infected cells, paralleled virus titres as determined by plaque 
assay (PR Young, personal communication) suggesting that it may be possible to 
use secreted NS1 as a surrogate marker for viral infection. 
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Figure 3.4 Capture ELISA detection of NS1 secreted from Vero cells infected 
with each of the four dengue virus serotypes. A, type-specific (1 H7.4) 
and B, group-reactive (3D1.4) monoclonal antibodies were used as the 
detection probes for tissue culture supernatants from Deni 
(Hawaii^), Den2 (NG-C«), DenS (H81H) and Den4 (H241 ^ ) infected 
cells. 
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It is not known whether 3D1.4 recognizes the NS1 species derived from each 
serotype with equal avidity, however it is interesting to note that the reactivity profile 
demonstrated in Figure 3.2 reflects the antigenic pairings of the two known serotype 
subgroups, dengue 2/4 and dengue 1/3. It is also likely that the different levels of 
detection are in part due to the binding characteristics of the rabbit polyclonal 
capture antibody which was prepared by immunization with purified dengue-2 virus 
NS1 (refer to Chapter 2.2a). Differences in growth kinetics in Vero cells between 
the four dengue serotypes will also contribute to the varying levels of antigen 
detected in this assay. Currently, the assay employing 3D1.4 as the detection probe 
can only provide estimates of NS1 derived from all four serotypes. Purified 
preparations of each serotype will need to be generated to establish appropriate 
standard curves. 
(iv) Detection of NS1 in patient sera 
In order to test the suitability of the assay for quantifying NS1 in clinical samples, a 
panel of sera from dengue virus infected patients was examined. Serum samples 
were serially diluted and processed in the ELISA capture assay (using 1 H7.4 as the 
detecting antibody) in parallel with a titration of immunoaffinity purified sNSI as a 
standard. Absorbance readings of those dilutions that fell within the straight-line 
portion of the standard curve (10 -100 ng / mL) were used to calculate the serum 
NS1 concentration. 
(c) EVALUATION OF SERUM SAMPLES 
A total of 589 serum samples from 304 different patients were obtained from 
colleagues at AFRIMS, Bangkok and were assayed for the presence of NS1 using 
the NS1 antigen capture ELISA. A large proportion of the serum samples were 
paired sera. Appendix 3.1 gives information on each serum sample according to the 
patient's age, sex, infecting serotype (by HAI) and grade of disease and is arranged 
in numerical order. A clinical diagnosis of DHF was assigned following the World 
Health Organization clinical definition based on the presence of plasma leakage 
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and thrombocytopenia (WHO, 1986; Table 1.1). Control serum samples from both 
outpatients and inpatients were supplied with the serum panel. Not all assays were 
performed on all serum samples due to the limitation of the volumes available. 
Several tables presenting identical information will be included in this results section 
that are derived from the original table (Appendix 3.1) but are sorted according to 
relevant characteristics for clearer interpretation of the results. 
(i) Analysis of serum samples from dengue infected patients 
Most notably, NS1 was not detected in the serum of the 30 patients with primary 
dengue infection (Table 3.2) indicating that NS1 is either absent, or is present in 
concentrations below the level of detection of the assay. Given that NS1 is secreted 
from all infected mammalian cells the latter is the most likely possibility. Three 
primary infected patients did however have detectable levels of antibody to NS1 in 
both SI and S2 sera suggesting that NS1 may be complexed to antibody and is 
therefore undetectable by the anti-NSI probe. In patients with the more severe form 
of the disease (secondary infections with DHF grades III and IV) (Refer Table 1.1 
and Table 3.3) the results show detectable levels of NS1 in a high proportion of the 
SI sera, along with detectable anti-NSI antibody. In the convalescent (S2) sera 
NS1 was rarely detectable while antibody to NS1 was usually at higher levels than 
for SI sera. As the S2 sera were usually collected during convalescence some two 
weeks after the first bleed, viraemia and NS1 production would have long ceased. 
Indeed the detection of NS1 in any of the S2 sera is of interest as it may indicate 
either prolonged infection or continuing NS1 circulation. 
Interestingly, Appendix 4.1 also shows that two negative control inpatients, who had 
been admitted for reasons other than flavivirus infection showed detectable levels 
of NS1 in their SI serum samples of 5.1 and 1.3 |ig / mL. These NS1 
concentrations are low compared to some of the other values determined but may 
indicate that these patients had a low level dengue infection at the time of 
admission that went undiagnosed. 
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Table 3.2 Data for patients with primary infections (n=30) 
SERUM # S1 SEROTYPE DHF GRADE NS1 ug/mL NS1 [Ab] ' S2 NS1 ug/mL NS1 [Ab] * r / 2° 
41 
1 
2 
3 
4 
5 
6 
11 
12 
15 
175 
183 
187 
209 
213 
13 
48 
181 
190 
193 
176 
43 
42 
10 
17 
18 
19 
20 
177 
178 
M3132 
M0519 
M0582 
M0736 
Ml 580 
M2822 
M2994 
M6848 
M7172 
M4837 
M l 0996 
M7878 
M4215 
M4183 
M3165 
M0926 
M6829 
M5631 
M l 1327 
M5196 
M l 795 
M3010 
M0022 
M6795 
M0138 
M0379 
Ml 673 
Ml 739 
M0177 
M0723 
2 
2 
3 
2 
1 
3 
2 
2 
3 
1 
1 
1 
1 
3 
3 
1 
1 
1 
1 
1 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
3 
3 
3 
3 
3 
4 
DF 
DF 
DF 
DF 
DF 
DF 
DF 
DF 
DF 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
NT = 
2.36 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
2.32 
2.40 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
Not Tested 
M3158 
M0577 
M0638 
M0802 
Ml 594 
M2870 
M3019 
M7120 
M7200 
M4866 
Ml 1057 
M7890 
M4246 
M4212 
M3166 
M0960 
M7061 
M5665 
Ml 1428 
M5254 
M1811 
M3055 
M0090 
M7114 
M0162 
M0380 
M l 709 
M l 755 
M0201 
M0749 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
2.52 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
2.47 
2.58 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
* reciprocal logio end point titrations 
As described earlier, the capture assay used the type-specific MAb 1 H7.4 and as 
such, only detected dengue 2 virus NS1. The data shown in Table 3.3 highlights 
this serotype-specificity with detectable levels of NS1 only being found in patients 
with HAI confirmed dengue 2 virus infections. Interestingly, there was a single 
exception to this, with NS1 being detected at quite high levels in a patient 
diagnosed by HAI to be infected with dengue 3 virus (Table 3.3, SI #M9210). Either 
the patient was dually infected or the HAI data provided an incorrect diagnosis. The 
possibility of dual infection with more than one serotype has been documented 
previously using RT-PCR (Laille etal, 1991). Intriguingly, this patient also had the 
highest level of detected NS1 in their convalescent sera (Table 3.3, S2#M9273) 
which may indicate an ongoing persistent infection. 
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Table 3.3 
SERUM # 
45 
44 
21 
22 
23 
24 
182 
180 
174 
49 
51 
50 
25 
28 
71 
184 
27 
26 
52 
53 
16 
30 
31 
32 
47 
185 
210 
214 
57 
58 
56 
29 
55 
54 
60 
33 
35 
43 
207 
61 
62 
63 
66 
37 
38 
39 
40 
70 
192 
194 
64 
65 
36 
67 
Data for patients with secondary dengue 
SI 
M0650 
M0634 
M0651 
M0787 
M l 909 
M2059 
M7203 
M7161 
M4462 
M0155 
Ml 647 
M0290 
M0136 
M0516 
M5803 
M7946 
M9244 
M0204 
M9210 
M0140 
Ml 664 
M2826 
M6768 
M0626 
M0683 
Ml 648 
M4286 
Ml 839 
M4401 
M3672 
M0570 
M0581 
M0481 
M0021 
M0270 
M0032 
Ml 690 
M0309 
M2859 
M2583 
M3804 
Ml 803 
M2041 
M3041 
M1820 
Ml 654 
Ml 689 
M l 752 
M1801 
M5743 
M2465 
Ml 0390 
M0880 
M1671 
M3315 
M2206 
SEROTYPE 
2 
2 
2 
2 
2 
2 
3 
2 
2 
2 
2 
2 
2 
2 
3 
3 
3 
2 
3 
2 
2 
2 
3 
2 
2 
2 
3 
3 
3 
3 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
3 
3 
3 
2 
2 
2 
2 
DHF GRADE 
1 
1 
1 
1 
1 
t 
1 
1 
1 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
4 
4 
4 
4 
4 
4 
4 
4 
DF 
DF 
DF 
DF 
DF 
DF 
DF 
DF 
DF 
DF 
DF 
DF 
NS1 ug/mL 
0 
0 
0 
0 
0 
0 
0 
11.5 
46.5 
0 
0 
0 
0 
0 
0 
0 
0 
20 
44 
61 
10 
4.6 
0 
0 
0 
0 
0 
0 
0 
0 
15 
37.5 
48.5 
54 
23 
43.5 
0 
0 
0 
0 
0 
4 
14 
42 
0 
0 
0 
P 
0 
0 
0 
0 
3 
3 
26 
46 
infections 
NS1 [Ab] * 
3.91 
5.03 
NT 
NT 
NT 
NT 
NT 
3.17 
2.87 
2.32 
4.09 
4.64 
NT 
NT 
NT 
NT 
NT 
2.91 
1.95 
2.26 
2.81 
3.24 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
3.28 
3.11 
3.32 
2.09 
3.57 
3.29 
4.4 
NT 
NT 
NT 
NT 
4.13 
2.60 
2.87 
2.93 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
2.17 
2.58 
2.05 
2.32 
S2 
M0668 
M0646 
M0725 
M0810 
M2017 
M2018 
M7229 
M7199 
M4686 
M0173 
Ml 678 
M0291 
M0160 
M0517 
M6427 
M8035 
M9368 
M0238 
M9273 
M0164 
Ml 665 
M2897 
M6808 
M0662 
M0747 
Ml 679 
M4306 
Ml 942 
M4659 
M3778 
M0790 
M0627 
M0491 
M0497 
M0297 
M0091 
M l 722 
M0310 
M2899 
M2616 
M3891 
M l 847 
M2053 
M3180 
M l 853 
Ml 662 
M1711 
M l 807 
M l 846 
M5769 
M2555 
M l 0745 
M0909 
Ml 707 
M3655 
M2470 
NS1 ug/mL 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
39 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
4.5 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0.9 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
NS1 [Ab] * 
4.32 
5.04 
NT 
NT 
NT 
NT 
NT 
4.87 
4.92 
4.4 
5.79 
5.79 
NT 
NT 
NT 
NT 
NT 
4.25 
2.06 
4.88 
5.80 
5.80 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
5.43 
4.23 
3.95 
3.15 
5.12 
5.83 
5.47 
NT 
NT 
NT 
NT 
5.75 
3.87 
5.48 
3.63 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
3.49 
3.95 
3.42 
2.91 
VIZ" 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
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Table 3.4 Data for patients with dengue serotype 2 infections only (n=49) 
SERUM« 
43 
42 
66 
37 
38 
39 
40 
64 
65 
36 
67 
41 
45 
44 
21 
22 
23 
24 
180 
174 
15 
49 
51 
50 
25 
28 
27 
26 
52 
53 
190 
30 
31 
32 
57 
58 
56 
29 
55 
54 
60 
33 
35 
43 
207 
61 
62 
63 
81 
M3010 
M0022 
Ml 820 
Ml 654 
Ml 689 
Ml 752 
M1801 
M0880 
Ml 671 
M3315 
M2206 
M3132 
M0650 
M0634 
M0651 
M0787 
M l 909 
M2059 
M7161 
M4462 
M4837 
M0155 
Ml 647 
M0290 
M0136 
M0516 
M0204 
M0140 
Ml 664 
M2826 
Ml 1327 
M0626 
M0683 
Ml 648 
M0570 
M0581 
M0481 
M0021 
M0270 
M0032 
Ml 690 
M0309 
M2859 
M2583 
M3804 
M0474 
M l 803 
M2041 
M3041 
SEROTYPE 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
DHF GRADE 
DF 
DF 
DF 
DF 
DF 
DF 
DF 
DF 
DF 
DF 
DF 
1 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
4 
4 
4 
4 
4 
4 
4 
4 
4 
NS1 ug/mL 
0 
0 
0 
0 
0 
0 
0 
3 
3 
26 
46 
0 
0 
0 
0 
0 
0 
0 
11.5 
46.5 
0 
0 
0 
0 
0 
0 
20 
61 
10 
4.6 
0 
0 
0 
0 
15 
37.5 
48.5 
54 
23 
43.5 
0 
0 
0 
0 
0 
0 
4 
14 
42 
NS1 [Ab] 
2.32 
2.40 
2.93 
NT 
NT 
NT 
NT 
2.17 
2.58 
2.05 
2.32 
2.36 
3.91 
5.03 
NT 
NT 
NT 
NT 
3.17 
2.87 
NT 
2.32 
4.09 
4.64 
NT 
NT 
2.91 
2.26 
2.81 
3.24 
NT 
NT 
NT 
NT 
3.28 
3.11 
3.32 
2.09 
3.57 
3.29 
4.4 
NT 
NT 
NT 
NT 
4.31 
4.13 
2.60 
2.87 
82 
M3055 
M0090 
M l 853 
M l 662 
M1711 
M l 807 
M l 846 
M0909 
Ml 707 
M3655 
M2470 
M3158 
M0668 
M0646 
M0725 
M0810 
M2017 
M2018 
M7199 
M4686 
M4866 
M0173 
M l 678 
M0291 
M0160 
M0517 
M0238 
M0164 
Ml 665 
M2897 
M l 1428 
M0662 
M0747 
M l 679 
M0790 
M0627 
M0491 
M0497 
M0297 
M0091 
Ml 722 
M0310 
M2899 
M2616 
M3891 
M0575 
M l 847 
M2053 
M3180 
NS1 ug/mL 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
4.5 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0.9 
0 
N81 [Ab] 
2.47 
2.58 
3.63 
NT 
NT 
NT 
NT 
3.49 
3.95 
3.42 
2.91 
2.52 
4.32 
5.04 
NT 
NT 
NT 
NT 
4.87 
4.92 
NT 
4.4 
5.79 
5.79 
NT 
NT 
4.25 
4.88 
5.80 
5.80 
NT 
NT 
NT 
NT 
5.43 
4.23 
3.95 
3.15 
5.12 
5.83 
5.47 
NT 
NT 
NT 
NT 
5.15 
5.75 
3.87 
5.48 
1°/2° 
1 
1 
2 
2 
2 
2 
2 
2 
2 
2 
2 
1 
2 
2 
2 
2 
2 
2 
2 
2 
1 
2 
2 
2 
2 
2 
2 
2 
2 
2 
1 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
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Data from patients infected with dengue-2 only are shown in Table 3.4 and all 
subsequent analyses refer to only this data set. Nine patients (n=19) with grade III 
and IV DHF dengue-2 virus infections showed detectable NS1 in their SI sera, 
however the S2 sera (n=19) showed only two samples with detectable NS1 levels 
of 4.5 |ig / mL and 0.9 |ig / mL. Figure 3.5B shows that levels of NS1 antibody 
generally increase more markedly between SI and S2 sera for DHF than for DF 
patients. Figure 3.5A conversely shows that the levels of NS1 antigen detected 
decreases in the S2 sera for all grades of DHF and DF. Taken together these 
results most likely reflect the fact that the levels of NS1 present at the time the SI 
sera were taken correlate with active infection and induce the specific antibody 
response that is subsequently detected in the S2 sera. The high levels of NS1, 
coupled with a rapid anamnestic rise in anti-NSI, also suggests the likely 
generation of immune complexes during this phase of the illness. 
In order to test for NS1 that was associated with immune complexes, a number of 
techniques such as microwave and acid treatment that have been previously 
reported to successfully dissociate immune complexes (Kestens etal, 1991; Miles 
etal, 1993) were analysed for subsequent detection of bound NS1. Each protocol 
appeared to lead to significant loss of NS1 antigenicity (data not shown). Although 
immune complex detection was considered an important component of these 
studies, the available serum samples had been freeze-thawed on numerous 
occasions, a procedure which is known to generate non-specific aggregates that 
are potential sources of error in these assays (Lambert etal, 1978), and so these 
studies were discontinued. Alternative procedures are currently under investigation 
in collaboration with our colleagues at AFRIMS, Thailand and the University of 
Massachusetts, USA. 
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Figure 3.5 Plots of A, NS1 levels and B, anti-NSI antibody levels in patient sera 
correlated with clinically defined grades of dengue disease. Acute and 
convalescent sera are designated SI (•) and S2 (O) respectively. Capture 
assay detection limit is shown in A. Mean of negative control sera titres in the 
antibody ELISA is shown with a horizontal dashed bar in B. 
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Figure 3.6 shows the correlation between DHF grade and both NS1 and anti-
NSI antibody concentration in patient serum. Although the sample size is 
relatively small, the graph shows that serum taken at convalescence has higher 
anti-NSI antibody concentrations with NS1 being undetectable either because 
levels have waned by this time or because the protein is bound within immune 
complexes. For serum taken from patients during the acute phase of infection 
there appears to be a correlation between disease severity and the presence of 
both detectable NS1 and antibody to NS1. 
S) 
o 
<Ii 
c 
(0 
6 
5 
4 
3 
2 
1 
I 
I . 
i: 
• • 
• Grade 3 acute 
• Grade 4 acute 
Grade 1 acute 
• Grade 2 acute 
• Dengue fever 
• Grade 1 convalescent 
+ Grade 2 Convalescent 
• Grade 3 convalescent 
• Grade 4 convalescent 
10 20 30 40 50 60 
Figure 3.6 
[NS1] Mg/mL 
Correlation between clinically defined dengue disease with NS1 
concentration and anti-NS1 antibody levels. 
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Figure 3.7 Graphic plot comparing NS1 concentration in sera taken from patients in 
the acute phase of the disease (S1 sera) with anti-NS1 antibody levels in 
sera during convalescence (S2 sera) for patients with different grades of 
disease. 
74 
Vaughn et al (2000) have shown in a study of patients in Thailand that those with 
dengue-2 infection were more likely to present with DHF (66%) than those infected 
by other virus serotypes. Therefore, taking patients with dengue 2 infections only 
(as the assay is most sensitive in detecting this serotype), those with the most 
severe form of the disease (grades III and IV) tended to have high levels of 
antibody to NS1 in the S2 sera with the concomitant "disappearance" of NS1 (Table 
3.4). 
A number of reports have suggested that levels of anti-NSI in patient sera may 
correlate with disease severity (Chan et al, reported in Brandt, 1988; Shu et al, 
2000). In an attempt to find a correlation between either NS1 levels and/or anti-NSI 
and disease severity these parameters were plotted in a number of ways. An 
analysis of dengue patient sera where acute NS1 concentration is plotted against 
convalescent anti-NSI antibody titre (Figure 3.7) reveals that there is a trend for 
those patients with the more severe forms of dengue infection (grades III and IV) to 
have high levels of both NS1 and antibody to NS1. Those patients however, with 
DF infections have lower levels of antigen (in SI sera) and antibody (in S2 sera) 
overall. Patients with grade II and III infections have higher levels of anti-NSI (in S2 
sera) and lower levels of NS1 (in SI sera). It should be pointed out that the graph 
clearly shows that there are significant outliers to this trend. The limitation of 
numbers of serum samples from seriously ill patients makes a more thorough 
analysis difficult. Nevertheless, these results suggest that high levels of both NS1 
antigen and antibody to NS1 may be significant markers for patients who progress 
to the more serious complications of dengue infection. More detailed studies 
involving the kinetics of appearance of NS1 in patient serum samples taken daily 
during the course of the acute phase of the disease would be required to provide a 
clearer picture of any disease association. 
(ii) Data from a North Queensland dengue outbreak 
Patient serum samples were also obtained from the former State Health 
Laboratories in Brisbane, from a dengue outbreak in 1995 in North Queensland. 
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Being from an area where dengue is not endemic, the majority of samples were 
primary cases. As NS1 was not detected in the serum samples taken from primary 
patients in Thailand this series was examined for comparison. 
The results from the north Queensland outbreak are shown in Table 3.5. Due to the 
low concentrations of NS1 detected, the accuracy of the quantitation is difficult to 
verify because the OD values didn't fall within the "straight line" region of the 
standard curve. Nevertheless the results show that NS1 was able to be detected in 
some primary infected patients (14/34) at low levels, in contrast to the results 
obtained from the serum samples from Bangkok. The inability to detect NS1 in 
these samples is most likely the result of handling issues and sample stability, 
possibility due to several freeze/thawing cycles which the serum endured or 
because they were collected late in illness. As can be seen from Table 3.5, NS1 
was undetectable in all convalescent serum samples as would be expected when 
active infection wanes. 
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Table 3.5 NS1 quantitation results form dengue patients in a North Queensland outbreak 
Identiflying Code 
27854 
29207 
20448 
21842 
26910 
29532 
26910 
26732 
25449 
22662 
25795 
26680 
27119 
27865 
15231 
17885 
19804 
20362 
20412 
22710 
24106 
24190 
25426 
27119 
27840 
28664 
30112 
31823 
32157 
32351 
33090 
37832 
39780 
41369 
21010 
27836 
28115 
28672 
29516 
32022 
32349 
33984 
35374 
1/5 NHS 
Primary/Acute 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
Secondary By HAI D2 Isolated 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
N/A 
NS1 ug/mL 
0.05 
0.05 
0.07 
0.14 
0.84 
1.46 
1.64 
1.88 
1.92 
>S. 
»2 
>2 
>2 
>2 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
Convalescent 
29540 
33437 
30121 
27514 
31637 
30106 
28808 
30112 
33979 
NSI ug/mL 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
N/A 
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3.3 DISCUSSION 
A capture ELISA for the detection of dengue virus NSI has been developed and 
described. Screening of a panel of MAbs as detection probes and utilizing rabbit 
polyclonal anti-NSI hyperimmune sera as capture antibody, led to the optimization 
of both type-specific and serotype cross-reactive assays. Despite the availability of 
an extensive number of MAbs specific for linear and conformational determinants 
(Falconar and Young, 1991), the majority were ineffective as detection probes. 
Significantly, only those MAbs specific for linear determinants, one type specific and 
the other cross-reactive among the dengue viruses, were efficient as detection 
probes. These linear epitopes have been identified previously through binding of 
MAbs to a set of overlapping peptides (Falconar etal, 1994). Although the amino 
acid sequence of the peptide defined by the dengue-2 virus specific MAbs 
(^^VHYWYEQYK^^) is shared by the other three virus serotypes, the type-specificity 
of their binding was clearly demonstrated in this study (Figure 3.3). This finding 
supports the earlier demonstration that amino acids flanking this linear epitope 
appear to contribute conformational constraints that lead to the epitope specificity 
seen in the native protein (Falconar et al, 1994). The sensitivity of the dengue-2 
virus type-specific assay was estimated using the immnoaffinity purified secreted 
form of NSI. Using this preparation as a reference standard, the assay was able to 
detect levels of NSI down to 4 ng / mL. In the second part of this study, levels of 
NSI in a panel of patient sera were examined with the aim of assessing the 
potential of the capture assay to measure NSI as a surrogate marker of infection. 
The detection of NSI in patient sera demonstrated that it is produced in dengue 
virus infected individuals and is secreted to circulate in the bloodstream. The 
significance of the detection of NSI in the acute phase of secondary but not 
primary infections in one series of dengue patients, may indicate that in the primary 
infection, NSI concentrations may be below the level of detection of the assay or 
that it is absent altogether. The former appears to be the case given a recent study 
by Alcon ef a/(2002) which reported detectable NSI levels in dengue-1 infected 
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primary patients albeit at low levels (in the range of 0.04 - 2 fig / mL). This study 
correlates well with our findings on serum taken from patients with primary infection 
in a North Queensland outbreak in which low levels of NSI were detected. 
The significance of the presence of secreted NSI for disease outcome is unclear 
although it has been postulated to contribute to dengue virus pathogenesis (Young 
et al, 2000; Alcon et al, 2002; Libraty et al, 2002). Early reports in the literature 
recognized anti-NSI responses in various flavivirus infections by western blot 
detection, including Japanese encephalitis virus (Lee et al, 1995) and TBE in 
human sera and spinal fluid (Matveeva etal, 1995). Antibody appeared no earlier 
than eight days post infection and no difference was detected between the immune 
responses of males and females (Matveeva etal, 1995). Although the immunoblot 
procedure does not provide quantitative data, reports using this procedure have 
noted that anti-NSI responses were found exclusively in secondary infections 
(Falker et al, 1973; Kuno etal, 1990; Churdboonchart etal, 1991; Valdes et al, 
2000). Anti-NSI antibody has also been detected more frequently in severe, rather 
than milder grades of DHF (Chan etal, reported in Brandt, 1988). This study has 
been able to confirm this finding with data showing that the highest overall levels of 
NS1 antibody was detected in DHF grade III and IV patients (Table 3.4). It has 
been proposed that antibodies generated during the acute phase of disease may 
contribute to the pathogenesis of DHF (Shu etal, 2000). One possible pathogenic 
mechanism was postulated by Falconar (1997) who demonstrated that anti-NSI 
MAbs produced haemorrhage in mice. The cross-reactivity of these antibodies with 
fibrinogen, thrombocytes and endothelial cells suggested that antigenic mimicry 
may contribute to DHF pathogenesis. Further work is required to determine if this 
phenomenon occurs in naturally acquired dengue infections. 
A more obvious candidate for a role in pathogenesis are immune complexes. 
Immune complexes, formed when antibodies combine non-covalently with their 
corresponding antigens, may be formed after interaction of antibodies with tissue-
fixed antigens or with antigens free in serum (Lambert et al, 1978). Immune 
complexes have been implicated in the pathogenesis of diseases such as chronic 
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hepatitis, measles, malaria and DHF (Ruangirachuporn etal, 1979) and have been 
reported in the sera of DHF patients with secondary infections (Petchhclai and 
Saelim, 1978; Theofilopoulos etal, 1976; Ruangjirachuporn etal, 1979). The level 
of immune complexes and complement consumption has been shown to correlate 
well with the clinical severity of dengue disease in several studies 
(Ruangjirachuporn et al, 1979; Sobel et al, 1975; Theofilopoulos et al, 1976) 
pointing to a clear role for immune complexes in the pathogenesis of DHF and DSS 
(Bokish etal, 1973; Malasit, 1987; Rothman and Ennis, 1999). Immune complexes 
have been reported in 80% of DHF patients (n = 80) from day 2 after fever, and up 
to 3 days prior to shock (Ruangjirachuporn etal, 1979). These immune complexes 
have also been found in biopsy tissues (Boonpucknavig et al, 1976a; 
Boonpucknavig et al, 1976b). Under appropriate conditions, circulating immune 
complexes may be deposited in tissues resulting in complement activation and 
polymorphonuclear cell-mediated tissue injury (Cochrane and Dixon, 1976), and 
may also interact with receptors on cells resulting in release of biologically active 
mediators. For example, complement can cause the lysis of dengue infected 
mononuclear phagocytes via complement mediated cytolysis, resulting in the 
release of potent biological mediators which could affect vascular permeability 
(Bhadki and Kazatchkine, 1990). Additionally, these biological mediators could be 
released by natural killer (NK) cell activity (Hill et al, 1993) and/or antibody 
dependent cell mediated cytotoxicity (ADCC) (Kurane and Ennis, 1992) that has 
been demonstrated against dengue virus infected cells in vitro (Kurane etal, 1984). 
Immune complexes were originally postulated by Russel (1971) as the initiating 
factor in the immunopathological mechanism of shock in DHF although the specific 
antigen(s) involved was not identified. Several investigators have reported that both 
the amount of dengue virus antigen circulating as immune complexes and the level 
of complement consumed, (providing an indication of antigen-antibody complexing) 
by the classic pathway varies in direct proportion with disease severity 
(Ruangjirachuporn etal, 1989; Malasit, 1987; Suvatte, 1987; Bokisch etal, 1973). 
C3 split products were demonstrated to be present in the sera of DHF grade III and 
IV patients, and split product appearance correlated with shock (Churdboonchart et 
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al, 1983). There is evidence that activation occurs via both classical and alternate 
complement pathways, with classical pathway involvement via antigen-antibody 
complexes possibly the more prominent (Cornain etal, 1987). 
Huang efa/(1999) reported that anti-NSI antibody in patients with primary dengue 
infection reacted with a peptide corresponding to the first 15 amino acids of NSI. 
This report is interesting in that it presents an opportunity to examine serum from 
dengue patients and to study the human immune response to various NSI 
epitopes. It would be valuable to be able to utilize a similar competition assay to 
that described in Chapter 4 of this thesis, to examine which NSI epitopes are 
recognized by human anti-NSI antibody as a basis for vaccine studies. 
This study has now identified the secreted form of dengue virus NSI as a potential 
candidate for a viral antigen that may form immune complexes (Young etal, 2000). 
The antigen capture ELISA has detected relatively high levels of NSI in the sera of 
dengue virus infected patients. It is likely that either free or immune complexed NSI 
may become bound by cell populations such as platelets, monocytes and / or 
endothelial cells. Dengue-specific immune complexes have been identified on the 
surface of platelets from infected patients (Boonpucknavig etal, 1979). It follows 
that these cells would then become targets of complement mediated lysis leading to 
the induction of the pronounced thrombocytopenia observed in DHF / DSS 
(Funuharaefa/, 1987). 
Although this study was unable to generate conclusive data confirming an 
association of NSI and anti-NSI antibody with disease severity it has provided the 
basis for additional studies. The preliminary data suggested that the serum of 
patients with severe forms of dengue infection contained both high levels of NSI 
antigen in acute sera and high levels of specific antibody in convalescent sera. 
Subsequent studies in the Young laboratory in collaboration with colleagues in 
Bangkok and access to samples from a prospective study on DHF patients, found 
that NSI levels detected in dengue patient serum correlated with viremia levels and 
were higher in DHF patients compared to DF. An elevated plasma level of NSI 
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(>600 ng / mL) within 72 hours of illness onset identified patients at risk of 
developing DHF (Libraty etal, 2002). 
The potential role of NSI (previously known as the soluble complement fixing 
antigen, SCF) in immunopathogenesis was first proposed in 1973 (Falker et al, 
1973) due to the presence of anti-SCF antibodies in sera from patients undergoing 
secondary infections. This study confirms and considerably extends these and 
subsequent observations. It has also been suggested that anti-NSI antibody bound 
to cell-surface NSI in a multimeric form may activate complement more efficiently 
than the monomer, as the affinity of complement binding increases proportionately 
with immune complex size (Cooper, 1985). This proposal warrants further 
investigation especially in the light of evidence that native secreted NSI is a 
hexameric multimer (Flamand etal, 1999; Chapter 5 of this thesis). NSI may prove 
to be a candidate antigen that may be pivotal to the formation of immune 
complexes in secondary infections and is present in sufficient quantities to explain 
the complement activation seen in DHF / DSS. More primary sera are needed 
however to examine this issue more clearly as well as kinetic data to look for trends 
in antigen / antibody production. 
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CHAPTER 4 
EPITOPE MAPPING OF THE NS1 GLYCOPROTEIN 
OF DENGUE-2 VIRUS 
4.1 INTRODUCTION 
The development of effective dengue virus subunit vaccines would clearly be 
aided by a more comprehensive knowledge of the location and structure(s) of 
those epitopes on dengue virus proteins that elicit a protective immune 
response. Epitopes present on dengue viral structural proteins have been 
extensively studied and reported widely in the literature (Roehrig et al, 1983 
Henchal etal, 1985; Guirakhoo etal, 1989; Aaskov etal, 1989; Innis etal, 1989 
Mandl etal, 1989a; Megret etal, 1992; Jianmin etal, 1995; Roehrig etal, 1998 
1990; Grill and Roehrig, 2001). However, both in vitro and in vivo evidence 
suggests that antibodies raised against structural proteins of one serotype may 
enhance replication of heterologous dengue virus serotypes in Fc receptor 
bearing cells (Kliks et al, 1989; Morens et al, 1987). Consequently, there has 
been a long-standing interest in the study of the non-structural glycoprotein NSI 
as a candidate immunogen for inclusion in vaccine strategies. This interest is 
based on its demonstrated antigenicity (Russell et al, 1980) and the ability of 
anti-NSI antibodies to passively protect experimental animals against live virus 
challenge (Schlesinger et al, 1985; Gould et al, 1986; Henchal et al, 1988; 
Schlesinger et al, 1986,1987; Young and Falconar, 1990); or by active 
immunization with purified native or recombinant NSI (Falgout et al, 1990; 
Putnak and Schlesinger, 1990; Falconar and Young, 1991; Qu et al, 1993). A 
sub-unit vaccine based on NSI has the potential of inducing a protective 
immune response in the absence of infection-enhancing virion reactive 
antibodies. 
The relationship of epitopes to both the primary and tertiary structure of NSI is 
poorly understood (Henchal et al, 1987; Chambers et al, 1990; Burke and 
Monath, 2001). Only limited studies defining epitope specificity on the flavivirus 
87 
NSI protein have been published and these have reported variable findings. 
Using monoclonal antibodies prepared against yellow fever (YF) virus, Gould et 
al (1986) demonstrated that epitopes on NSI were mainly type specific (ie. YF 
specific) although Schlesinger et al (1985) published results indicating that 
flavivirus group-reactive determinants were also present. Hall et al {^ 990; 1995) 
reported that for MVE NSI, the majority of epitopes recognized by monoclonal 
antibodies were specific to MVE and not flavivirus-group reactive consistent with 
previous findings (Schlesinger et al, 1983; Gould et al, 1985; Henchal et al, 
1987). The production of a large panel of monoclonal antibodies to the dengue-2 
virus NSI by Falconar and Young (1991) revealed MAbs defining a number of 
dengue virus subgroup, dengue virus complex and flavivirus cross-reactive 
epitopes on the NSI protein. One group of MAbs recognized a dengue-2 and 
dengue-4 virus subgroup epitope and another quite significant group was shown 
to cross-react with linear and conformational epitopes common to the NSI of all 
four dengue virus serotypes and some members of the antigenic group III 
flaviviruses. A number of dimer-specific NSI monoclonal antibodies were also 
identified consistent with a report of a dimer specific anti-NSI MAb specific for 
MVE NSI {HaW etal, 1990). 
Work in our laboratory examined the reaction of 34 mouse monoclonal 
antibodies (Falconar and Young, 1991) to 174 overlapping nonameric peptides, 
representing the complete sequence of dengue-2 virus NS1 (PR159S1) in a 
PEPSCAN analysis (Falconar et al, 1994). This analysis revealed the precise 
binding sites of eight MAbs from this panel. A potentially significant finding was 
the identification of a flavivirus cross-reactive, linear epitope involved in 
protection (Young and Falconar, 1990). A summary of these findings is shown in 
Table 2.1. Passive protection data in mice had also been obtained previously 
(Young and Falconar, 1990) (Table 2.1), which showed that some of these anti-
NSI MAbs were able to confer up to 60% passive protection against challenge. 
With this background of information, the aim of this section of the work was to 
build a more detailed epitope map for the remaining MAbs on the native dimer 
form of NSI and therefore to identify epitopes which may be important in 
conferring protection. In addition, it was expected that a detailed picture of the 
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antigenic structure of NSI may provide insights into the tertiary structure of this 
protein. 
4.2 RESULTS 
(a) Monoclonal antibody epitope competition assay 
The methodology used to examine monoclonal antibody binding sites has 
previously been described (Lopez et al, 1986). As this protocol does not require 
any chemical modification of the antibodies and uses immunoaffinity purified 
NSI in its native dimer form (as shown by silver stained SDS-PAGE gels and 
western blot analysis), interactions occurring between antigen and antibody 
should not be affected by steric hindrance artefacts. Plates were initially coated 
with protein A which binds to the Fc portion of rabbit anti-mouse IgG which in turn 
captured the primary anti-NSI MAb. Fifty microlitres of protein A (0.01 mg / ml) 
was added per well of a microtitre plate, according to the published method 
(Lopez et al, 1986). Excess competing antibody was then added in the presence 
of purified labelled pS]methionine / cysteine NSI. A total of 2000 counts per 
minute (cpm) of p S ] - NSI in 50 pL was added per reaction. 
To establish optimal conditions for this assay, the effect of different dilutions of 
the rabbit anti-mouse capture antibody and both primary and competing 
monoclonal antibodies was first evaluated. The binding of radiolabelled NSI to 
four different anti-NSI monoclonal antibodies captured by varying dilutions of 
rabbit anti-mouse antibody is shown in Figure 4.1. Replicates were performed in 
quadruplicate and then averaged. Dilutions of 1/100 and greater, led to a 
marginal decrease in the amount of radiolabelled NSI that was bound to the 
captured MAb, so a 1/50 dilution of the rabbit anti-mouse IgG was chosen for the 
assay. 
Figure 4.2 shows the level of NSI binding by two different dilutions (1/100 and 
1/500) of primary MAb under conditions of competition and non-competition. 
Bound radioactivity is given as a percentage of the value obtained in the 
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Figure 4.1 Titration of rabbit anti-mouse IgG antibody against various anti-NS1 
MAbs in the presence of 2000 cpm of ^^S-methionine/cysteine labeled 
NS1. 
absence of competitor antibody. 
The MAbs 3D1.4 and 1H7.4 were used in these trial experiments in pair-wise 
crosses as they had previously been shown to bind to topologically distinct linear 
epitopes (Falconar et al, 1994). At a 1/500 dilution (Figure 4.2B), little difference 
was observed between self and cross-competition (particularly for 3D1.4), while 
at a 1/100 dilution of primary antibody (Figure 4.2A), 1H7.4 competed strongly 
with itself for NSI binding but did not compete with primary binding by 3D1.4. A 
dilution of 1/100 was therefore chosen for primary MAb binding. Although 
significant competition for binding by 1 H7.4 with itself was seen out to dilutions of 
1/810 of secondary antibody, 3D1.4 was not as effective at competitive binding 
with itself above dilutions of 1/10. Subsequent analyses demonstrated that MAbs 
binding to the epitope recognized by 1H7.4 exhibited higher binding avidities 
(see Fig 3.1 and data not shown) than most of the other antibodies in the panel, 
all of which were required in high concentrations to effectively compete as 
secondary antibodies. A 1/10 dilution was therefore chosen for all secondary 
anti-NSI MAb competition. 
90 
140 
O 120 
c 
o 
o 
1 — 
o 
^ 
E 
a 
a 
•D 
C 
3 
O 
OQ 
100 
80 
60 
40 
?n 
B 
140 
i^ 
o 
^ 4-1 
r 
o 
o 
«^  
o 
^ 
E 
a 
o 
TJ 
c 3 
o 
CQ 
i?n 
100 
80 
60 
40 
20 
1H7.4/ 1H7.4 
•3D1.4/3D1.4 
•1H7.4/3D1.4 
0 10 30 90 270 810 2430 7290 
Reciprocal secondary MAb dilution 
•3D1.4/3D1.4 
•3D1.4/1H7.4 
• 1H7.4/1H7.4 
0 10 30 90 270 810 2430 7290 
Reciprocal secondary MAb dilution 
Figure 4.2 Homologous and cross-competition binding of ^^S-NS1 between 
anti-NSI MAbs 1H7.4 and 3D1.4 at either 1:100 dilution (A) or 
1:500 dilution (B) of the primary MAb. Bound cpm was calculated 
as a percentage of a control containing no 2° competing MAb. 
Graph legends refer to 172° MAbs. 
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(b) Identification of antigenic domains 
A chequerboard competition map of 22 MAbs reacted against metabolically 
labelled sNSI immunoaffinity purified from infected Vero cell tissue culture 
supernatants is shown in Figure 4.3. The original antibody panel chosen 
comprised 34 MAbs in total, however due to poor primary binding in this assay, 
twelve MAbs were eliminated from the study in the preliminary screen. With few 
exceptions, all MAbs showed efficient self-competition (top left to bottom right 
diagonal in Figure 4.3) thus providing an inbuilt control for the effectiveness of 
the assay. 
(i) Antigenic map for sNS1 derived from Vero cells 
The competition map shown in Figure 4.3 reveals five major antigenic domains 
(labelled A, B, C, D and E) for sNSI derived from Vero cells, with domains C and 
D comprising a cluster of overlapping epitopes. Domain B and E define unique 
sites recognized only by the MAbs 5H10.3d and 5B5.3 respectively. The 
presence within the A, C and D domains of antibodies that were previously 
shown to react with defined linear determinants (Falconar et al, 1994) enabled 
the placement of this epitope map in the context of the primary sequence (Figure 
4.4A). The topology of epitope distribution on NSI is shown schematically in 
Figure 4.4b. Interestingly, the primary binding of several MAbs (5H 10.3d, 5B9.3, 
5H4.3 and 5F10.3) were found to dramatically enhance the binding of secondary 
MAbs, particularly in the A domain. The dimer specific MAb 5H10.3d also 
promotes stronger binding of MAbs recognizing the D3, D4 and D5 epitopes. 
Enhanced binding of A determinant specific MAbs suggested that this epitope 
may be further exposed through conformational changes induced by antibody 
binding to selected epitopes in the non-overlapping domain D. Alternatively, this 
synergistic binding may simply be due to the stabilization of the native structure 
of NSI. Of particular note is the binding profile of 5B9.3. As a secondary 
antibody it successfully competes with all MAbs within the C and D domains. 
Given that a subset of the C domain antibodies have been shown to react with 
an epitope in the N-terminal half of NSI (CI , amino acids 23-33; Falconar et al, 
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1994) while D domain antibodies reacted with epitopes in the C-terminal half 
(D1, amino acids 249-257 and D2, amino acids 299-307; Falconar et al, 1994) 
this cross-competition indicated that the large overlapping cluster may define a 
structural domain that comprised the two ends of the same NSI molecule in 
close proximity (schematically represented in Figure 4.4B). 
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Figure 4.3 Competition map of captured anti-NSI MAb binding of S-sNSI from 
Vero cells in the presence of secondary competitor MAb. Primary MAbs 
(1°) are listed horizontally and secondary MAbs (2°) vertically. 
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Figure4.4 Location of antigenic epitopes on NSI. A, Schematic of the 
location of linear determinant specific epitopes on the primary 
sequence of dengue-2 virus NSI; B, topology of overlapping 
epitopes defined by the competition map; and C, overlapping 
epitopes with shaded regions signifying epitopes that bound 
MAbs that were able to provide >30% passive protection in a 
mouse model (Young and Falconar, 1990). N and C represent the 
N- and C-terminal halves of the NSI molecule respectively. 
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(ii) Analysis of intramolecular versus intermolecular competition 
The competition map shown in Figure 4.3 was determined using native sNSI in 
its oligomeric, most likely hexameric form. Therefore, it is possible that the 
competition observed between epitopes that are spatially distant in the primary 
sequence (the C1/C2 and D1/D2 epitope clusters) may be the result of either 
inter- or intra-molecular interactions (see Figure 4.5A). In the former, a head-to-
tail orientation of NSI subunits could give rise to the competition seen between 
the C and D domains. 
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Figure 4.5 Intra- versus inter-competition between MAbs reacting with 
the C and D epitopes. A, schematic representing two possible 
molecular arrangements for NSI sub-units leading to 
competition between these two epitopes. N and C indicate the 
N- and C-terminal halves of the NSI molecule. Competition 
maps of B, monomeric sNSI and C, monomeric mNSI. Solid 
squares represent > 70% competition, shaded boxes 50-70% 
competition. 
In order to determine which of these structural forms leads to the observed 
competition, epitope mapping was carried out for monomeric sNSI. The 
formation of dimeric NSI involves non-covalent interactions that may be 
dissociated by either heat or low pH treatment (Winkler and Winkler, 1989; 
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Falconar and Young, 1990). Both of these procedures could also lead to 
denaturation of NSI and a loss in structural integrity. Therefore, primary binding 
by the panel of MAbs to heat treated and monomeric NSI was initially assessed 
for retention of epitope reactivity. Figure 4.6 shows a histogram of the 
percentage reduction in primary binding of selected MAbs to immunoaffinity 
purified, ^^S - methionine / cysteine labelled monomeric sNSI and mNSI 
(monomerization was confirmed by western blot analysis). 
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Figure 4.6. Reduction in binding of monomeric ^^S-NS1 to representative MAbs 
of each of the epitope domains. Percentage reduction determined by 
comparison with binding to dimeric ^°S-NS1 run in parallel. Both 
mNSI and sNSI forms were examined. Data represents an average 
of four replicates. 
All MAbs showed a reduction in primary binding although a greater reduction 
overall was seen in MAb binding to monomeric sNSI. This overall reduction in 
binding was not unexpected given that binding is measured in terms of total 
bound ^^S - methionine / cysteine label and that dimeric NSI had been 
converted to monomeric NSI. Consequently only half as much radioactivity (or 
one sixth, if the majority of NSI is in hexameric form) should be expected to bind 
to the same quantity of MAb. The significant reduction in binding of A 
determinant specific MAbs (1A12.3 and 4H3.4) however suggested that this 
epitope may not be exposed in the monomeric form. Regardless of these 
qualitative differences, the majority of MAbs (with the exception of A domain 
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specific MAbs) reacted with NSI in its monomeric form. Given this finding, partial 
competition maps were generated for monomeric sNSI and mNSI to address 
the question of overlapping epitopes in the N- and C-terminal domains (Figure 
4.5B and C). Both maps showed that 5B9.3 (D1) still effectively competed as a 
secondary MAb with 1H7.4 (CI) indicating that the N- and C-terminal regions of 
one NSI molecule may be in close spatial proximity and that the observed 
competition is occurring intramolecularly. It should be noted however, that the 
cross-competition between C2 and D2 MAbs seen for the dimeric form of NSI 
(Figure 4.3) is lost in the monomeric NSI form (Figure 4.5B and C). 
(iii) Epitope specificity 
The strain specific and cross-reactive binding pattern of each MAb in the panel 
had previously been determined (see Table 2.1; Falconar and Young, 1991). 
MAbs that shared a similar specificity clustered predominantly into the same 
epitope groups defined by the competition map (Table 4.1). Epitope A comprised 
MAbs that recognized NSI from all four dengue virus serotypes plus members of 
the encephalitic flaviviruses (eg. JEV, MVE and KUN). CI and C2 consisted of 
MAbs that were dengue-2 virus specific and recognized both linear (1H7.4, 
5H5.4) and conformational (2C9.4, 4D4.4 and 1G5.4d) determinants. D1, D2 and 
D3 MAbs primarily recognized epitopes defining dengue-2 and dengue-4 
subgroup specificity as well as recognizing NSI of the encephalitic flaviviruses. 
D4 and D5 MAbs recognized NSI only from dengue-2 and dengue-4 virus. The 
sole MAb recognizing the unique E epitope (5B5.3) reacted with NSI from \ 
dengue-2, dengue-3 and dengue-4 viruses. In summary, this panel of MAbs 
identified five separate flavivirus reactivity patterns that closely parallelled 
epitope clusters (Table 4.1; A, C1/C2, D1/D2/D3, D4/D5 and E) that define 
topologically distinct domains on the NSI protein. 
The protective efficacy of passive administration of these MAbs in a mouse 
model has been previously determined (Young and Falconar, 1990). The MAbs 
that provided significant passive protection (>30%) belong to the epitopes 
shaded in Figure 4.4C and includes one of the D3 epitope MAbs, 5H4.3. As with 
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Flavivirus cross-reactivity, these MAbs also involve topologically distinct 
domains. 
Table 4.1 Flavivirus cross-reactivity of domain specific MAbs 
DOMAIN 
A 
01 ,02 
D1,D2, D3 
D4, D5 
E 
FLAVIVIRUS CROSS-REACTIVITY 
Flavivirus cross-reactive 
Dengue-2 specific 
Dengue-2 and 4 specific and encephalitic flaviviruses 
Dengue-2 and Dengue-4 
Dengue-2, Dengue-3, Dengue-4 
(iv) Antigenic map for mNSI derived from Vero cells 
The epitope profile of immunoaffinity purified NSI from infected cell lysates (the 
membrane-associated form, mNSI) was also examined by competition mapping 
(Figure 4.7). The map showed the same basic pattern of epitope groupings with 
two major differences. The first was an apparent disruption in the integrity of D 
domain competition and the second was a failure of any of the A domain specific 
MAbs to bind to this form of NSI. Intriguingly, it was these MAbs which failed to 
bind efficiently to the monomeric form of sNSI (Figure 4.6). The absence of 
detectable binding of the A specific MAbs to mNSI occurred despite the fact that 
these antibodies recognized a linear sequence present in both forms of NSI and 
had readily reacted with mNSI bound to ELISA plates or immunoblots following 
SDS-PAGE separation. Presumably, these procedures lead to structural 
modifications that exposed the epitope that is othenwise sequestered in the 
native solubilized form of mNSI used in the competition assay. MAbs specific for 
the A determinant have been shown to provide significant passive protection to 
mice in lethal virus challenge experiments (shown schematically in Figure 4.4C). 
It is relevant to note therefore that mice immunized with sNSI were afforded 
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much higher levels of protection than those immunized with mNSI (Young and 
Falconar, 1990). 
m 
z 
< 
o 
Q 
C1 
C2 
D1 
D2 
D3 
D4 
D5 
E 
^ \ 1° 
20 \ . 
1C6.3 
1A12.3 
4H3.4 
3D1.4 
3A5.4 
5H10.3d 
1G5.4d 
1H7.4 
5H4.4 
2C9.4 
4D4.4 
5B9.3 
5C7.4 
5H5.4 
1G5.3 
5H4.3 
5F10.3 
1E2.3 
5H6.3 
5B6.3 
2A5.1 
5B5.3 
10
6.
3 
1A
12
.3
 
4H
3.
4 
3D
1.
4 
3A
5.
4 
5H
10
.3
d 
1G
5.
4d
 
1H
7.
4 
5H
4.
4 
20
9.
4 
4D
4.
4 
5B
9.
3 
50
7.
4 
5H
5.
4 
1G
5.
3 
5H
4.
3 
5F
10
.3
 
1E
2.
3 
5H
6.
3 
5B
6.
3 
2A
5.
1 
5B
5.
3 
• • 
• n n 
E 
E 
E E 
• 
E E 
E E 
•^ ; 
E 
-
•_J u 
• • 
Figure 4.7 35e Competition map of captured anti-NSI MAb binding of S-mNSI from 
Vero cells in the presence of secondary competitor MAb. Primary MAbs 
(1°) are listed horizontally and secondary MAbs (2°) vertically. 
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The loss in integrity of the epitope map across the D domain may be a 
consequence of reduced overall binding of the MAbs to mNSI as a result of 
detergent solubilization of this membrane-associated species and the continued 
presence of detergent in the assay. It should be noted that sNSI was purified 
and prepared in the absence of detergent (for details refer to 2.5a (iii)). Under 
these conditions MAbs with higher avidities might effectively block competition 
by other MAbs recognizing the same epitope. For example, primary binding of 
the MAbs 5B9.3, 5F10.3 and 1E2.3 all effectively prevented competition by most 
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secondary binding antibodies while as secondary antibodies, they efficiently 
competed with most D domain specific MAbs. Alternatively, disruption in the D 
domain competition may indicate induced conformational changes to a region 
directly affected by detergent solubilization and membrane dissociation. An 
additional feature of the mNSI map that should be noted is the loss of the cross-
competition between MAbs of the C2 and D2 domains that was seen for sNSI 
(Figure 4.3). Again, this observation may be a direct consequence of alterations 
in MAb reactivity resulting from detergent solubilization of NSI. 
(v) Effect of glycosylation on antigenic maps 
The differential availability of the A epitope for MAb binding in the two different 
forms of NSI was unexpected. Apart from their localization (cell-associated for 
mNSI and extracellular for sNSI) the only other major difference between these 
two species is their glycosylation profile. Both are glycosylated at two sites, 
^^°Asn and ^°''Asn. However for mNSI, both of the linked glycans are of the high-
mannose type while sNSI contains one high-mannose and one complex glycan. 
It has been shown previously that the processing of only one glycosylation site 
for sNSI is likely the result of dimerization prior to passage through the Golgi 
(Young and Falconar, 1990). This assumption is based on the observation that 
one of the carbohydrate sites is resistant to cleavage by endoglycosidases when 
NSI is in its native dimeric form (Young and Falconar, 1990) ^^°Asn was 
subsequently identified as the complex glycan linkage site (Young et al, 1993; 
Pryor and Wright, 1994) with ^^''Asn being the high mannose site which is 
sequestered following dimerization. As ^^°Asn is in close proximity to the primary 
sequence of the A epitope (A specific MAbs have been shown to bind to 
peptides comprising amino acids 111-121; Figure 4.4A) (Falconar and Young, 
1994) it was hypothesized that the differential antibody binding may be the result 
of conformational constraints or changes in this region induced by two different 
carbohydrate moieties. In a preliminary analysis, an epitope map was generated 
for immunoaffinity purified membrane-associated NSI derived from dengue virus 
infected C6/36 mosquito cells. Insect cells are not able to add complex terminal 
sugars to carbohydrate moieties on glycoproteins and as such it was expected 
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that this species would generate an epitope map that was similar to that of 
mammalian cell derived mNSI. Figure 4.8 shows the epitope map of a selected 
subset of MAbs for C6/36 derived NSI (Figure 4.8B) in comparison with the 
epitope map for Vero mNSI (Figure 4.8C) and sNSI (Figure 4.8A). 
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Figure 4.8 Partial epitope competition maps of A, Vero (mammalian) cell 
derived sNSI; B, C6/36 (insect) cell derived mNSI; C, Vero cell 
derived mNSI. 
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While the same loss in integrity of the D domain was found with the insect cell 
derived mNSI, all A specific MAbs were found to readily bind to this species. 
This result suggested that the presence or absence of complex sugars on this 
carbohydrate moiety was not sufficient to explain the differential antibody 
binding. It should be pointed out however that glycoproteins expressed in insect 
cells do undergo some additional modifications during traffic through the Golgi 
(Butters et al, 1981; Naim and Koblet, 1992) and it may be these modifications 
that lead to conformational changes in NSI that resulted in exposure of the A 
epitope. 
To examine the possibility that the lack of recognition of the A epitope in Vero 
cell derived mNSI was simply a consequence of steric hindrance by the 
carbohydrate, ^ S - methionine / cysteine labelled immunoaffinity purified NSI 
was treated with endoglycosidase F before examining primary binding by the A 
epitope specific MAb 1A12.3. The MAb 1H7.4 (CI epitope) which binds 
efficiently to mNSI, was also examined as a positive control. Prior to the binding 
analysis, the removal of carbohydrates was confirmed by autoradiography of the 
digested samples (Figure 4.9). 
mNSI sNSI ^ 
EF 
z 
V) 
Figure 4.9 35c Autoradiograph of endoglycosidase F (EF) treated S-sNSI and ^"S-
mNSI. Untreated preparations of immunoaffinity purified ^S-met/cys 
labeled mNSI (open arrowhead) and sNSI (solid arrowhead) are shown 
in the last two lanes. Mock digested and endo F digested samples of 
both mNSI and sNSI are shown in the first four lanes. 
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It should be noted that carbohydrate removal was not completely efficient. As 
dimeric NSI was digested, the carbohydrate linked to ^°''Asn is likely to remain 
intact. Figure 4.10 shows histograms of untreated, mock digested and 
endoglycosidase F digested radiolabelled mNSI and sNSI bound to 1A12.3 
(Figure 4.10B) and 1H7.4 (Figure 4.1 OA). 
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Figure 4.10 Histograms showing the amount of metabolically labeled and 
35e immunoaffinity purified "* S-mNSI and "'"S-sNSI captured by A, MAb 
1H7.4 (CI epitope) or B, MAb 1A12.3 (A epitope) following mock 
digestion or endoglycosidase F (EF) digestion. Error bars represent 
1 standard deviation (SD) around the mean of four replicates. 
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Mock digestion of the NSI samples reduced overall binding (particularly to 
sNSI) but removal of the carbohydrate moiety did not modify the binding 
efficiency of either MAb to mNSI or sNSI. Collectively these results would 
suggest that the differential glycosylation of the two forms of NSI generated in 
mammalian cells may not be responsible for the differences in A epitope 
recognition. 
(c) Partial Enzyme Digestions 
The previous identification of antibody-reactive linear determinants spanning the 
NSI sequence ^^ •^''^ ^A, 25-33Q^ 249-257p., ^^^ 291-307^ 2 (Figure 4.4A) (Falconar et 
al, 1994) provided the opportunity to use MAbs specific for these regions as 
"site-specific" probes or markers, in the competition maps. As the preceding 
section showed, competition within specific epitope clusters that included these 
MAbs helped to identify the binding domains of conformation specific MAbs. In 
order to provide further insights into the location of these epitope clusters, partial 
enzyme digestion of purified NSI was performed with the objective of reliably 
producing overlapping cleavage fragments that spanned the entire length of the 
molecule. It was hypothesized that the identification of these fragments by N-
terminal sequencing followed by analysis of MAb binding on immunoblots would 
provide further information on binding sites in the context of the primary 
sequence. 
Several proteases were examined for their ability to generate NSI fragments by 
partial digestion that were suitable for SDS-PAGE and immunoblot analysis. 
These included chymotrypsin, S. aureus V8 protease, trypsin and 
hydroxylamine. Preliminary experimental digestions with each of these 
proteases individually on immunoaffinity purified sNSI indicated that of all these 
reagents, trypsin and S. aureus V8 protease (V8) generated the most 
reproducible cleavage fragments. Both native dimeric NSI and heat denatured 
monomeric NSI were used as substrates. The most reproducible cleavage 
fragments generated were from trypsin treatment of native dimeric NSI, and V8 
digestion of heat-denatured (monomeric) NSI (data not shown). The kinetics of 
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digestion were also examined in order to define optimal reaction conditions. 
Immunoblots of SDS-PAGE separated cleavage fragments from sNSI treated 
with 1 pg / mL of trypsin at 37°C over incubation periods ranging from 0 to 60 
minutes were prepared (Figure 4.11) and were probed with representative MAbs 
from different epitope groups; A, 1G5.3 (D2); B, 5B9.3 (D1); C, 1H7.4 (CI) and 
D, 3D1.4 (A). Two significant observations were the generation of a 25 kDa 
fragment which was recognized by the D domain specific MAbs 1G5.3 (D2) and 
5B9.3 (D1) and the total loss of reactivity by 3D1.4 (A) to any species. Extended 
cleavage experiments (not shown) demonstrated that the 25 kDa species was 
relatively stable to further digestion. The differential recognition of this species by 
the D domain specific MAbs suggested that it was a C-terminal fragment and 
most likely corresponded to the gp24 trypsin fragment reported by Cauchi et al 
(1991). The loss of 3D1.4 binding is probably the consequence of trypsin 
cleavage within the exposed epitope as two lysines and one arginine were 
present in the linear A determinant, ^^^RYSWKTWGK^^° (Falconar etal, 1994). 
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Trypsin digestion time (minutes) 
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Figure 4.11 Western blots of immunoaffinity purified NSI 
digested with trypsin for various time periods and 
probed with the anti-NSI MAbs A, 1G5.3 (D2 
epitope); B, 5B9.3 (D1 epitope); C, 1H7.4 (CI 
epitope) and D, 3D1.4 (A epitope). 
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(i) Identification of high mannose and complex glycosylation sites 
The cleavage fragments generated by trypsin digestion of NSI were further 
examined by endoglycosidase treatment (Figure 4.12). Both heat denatured and 
native dimeric NSI were subjected to either mock (Figure 4.12A and B, lanes 1 
and 2 respectively) or trypsin digestion (Figure 4.12A and B, lanes 3-8) . 
EF EH 
Trypsin 
Heat + 
+ + + + + + 
1 2 3 4 5 6 7 8 
Figure 4.12 Western blots of immunoaffinity purified sNSI either heated or left 
unheated prior to mock digestion or trypsin digestion. A and B, 
selected samples were further digested with or without the 
endoglycosidases F (EF) and H (EH). All samples were then boiled 
prior to SDS-PAGE separation. Blots were probed with the anti-NSI 
MAbs 3D1.4 (A) and 1G5.3 (B). C, Western blot probed with 1G5.3 of 
unheated mNSI digested with or without trypsin. Samples were then 
either left unheated or heated prior to SDS-PAGE analysis as 
indicated. Dimer and monomer forms are shown (open and solid 
arrowheads respectively). 
The products of trypsin digestion were then treated with either endoglycosidase 
F (Figure 4.12A and B, lanes 5 and 6) or endoglycosidase H (Figure 4.12A and 
B, lanes 7 and 8) prior to SDS-PAGE separation and immunoblotting with MAbs 
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3D1.4 (Figure 4.12A) or 1G5.3 (Figure 4.12B). As identified previously, the gp25 
fragment was only generated efficiently when native dimeric NSI was digested 
(compare Figure 4.12B and lanes 3 and 4). By contrast, reactivity to 3D1.4 
(Figure 4.12A, lane 4) was completely lost following digestion of dimeric NSI. 
Heat denatured monomeric NSI as well as a number of cleavage fragments 
were however recognized by this antibody (Figure 4.12A, lane 3). This result is 
entirely consistent with the previous finding (see Figure 4.6) that monomeric 
sNSI failed to react efficiently with A epitope specific MAbs indicating that this 
epitope is poorly exposed in the monomer form and is therefore unlikely to be 
available for trypsin digestion. Both endoglycosidase F and H digestion were 
found to remove approximately 3 kDa from the gp25 trypsin cleavage fragment 
(Figure 4.12, lanes 6 and 8 respectively) indicating that this species had one 
high mannose carbohydrate linkage. Combined with the observation that this 
species is recognized by MAbs reactive to epitopes in the C-terminal half of NSI, 
the finding that this species contains only the second carbohydrate linkage site, 
^°^Asn (known to be the linkage site for the high mannose glycan) indicates that 
this C-terminal fragment is generated by cleavage between the two glycan sites, 
^^°Asn and ^ '^^ Asn. A somewhat unexpected finding was the removal from what 
appeared to be full-length NSI (arrowed in Figure 4.12B lane 4) of 6 - 8 kDa by 
both endoglycosidase F (lane 6) and endoglycosidase H (lane 8). This molecular 
weight difference would represent two carbohydrate moieties, both of the high 
mannose type due to complete cleavage by endoglycosidase H. However this 
digestion was of sNSI which contains one of its glycans as the complex type 
which should be resistant to endoglycosidase H treatment. On closer inspection, 
the species indicated in Figure 4.12, lane 4 (open arrowhead) is slightly higher in 
molecular weight than full length NSI (compare with lanes 1 - 3). As traces of 
dimeric NSI can be seen in the undigested tracks (Figure 4.12A and B lanes 1 
and 2) it may be inferred that the species migrating at 50 kDa in lane 4 is not full-
length NSI but a dimer of the gp25 fragment. This dimer would contain two high 
mannose glycans and explain the endoglycosidase digestion result. 
To confirm this hypothesis, trypsin digested native dimeric sNSI was either 
boiled or left unboiled prior to SDS-PAGE separation and immunoblot analysis 
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(Figure 4.12C). While the 50 kDa species was seen in the unheated sample, no 
gp25 was detected (Figure 4.12C, lane 3). Prior heat treatment however resulted 
in conversion of the 50 kDa species (gp50) into gp25 (Figure 4.12C, lane 4) 
confirming that gp50 is likely to be a dimer of gp25. Cauchi et al (1991) had 
previously shown that the gp24 trypsin fragment they had identified also existed 
as a dimer. The identification of this fragment as being derived from the C-
terminal half of NSI confirms previously published evidence that the dimerization 
domain is in this part of the molecule (Pryor and Wright, 1993; Gruenberg and 
Wright, 1992; Pryor etal, 1998; Hall etal, 1999). 
Similar kinetic experiments were performed for V8 digestion of heat denatured 
monomeric NSI (data not shown) in order to establish optimal reaction 
conditions. As for trypsin, representative MAbs from four different epitope groups 
were used to probe immunoblots of partial V8 digestions separated by SDS-
PAGE (Figure 4.13). Four differentially recognized cleavage fragments were 
identified for further analysis (indicated by arrowheads in Figure 4.13); two 
glycoproteins gp31 and gp20 and two smaller polypeptides with no linked 
glycans, p i3 and plO. Analysis following reduction with 2-mercaptoethanol 
confirmed that they were single polypeptide fragments (data not shown). 
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Figure 4.13 Western blot analysis of V8 protease digested mNSI probed with 
the anti-NSI MAbs (A) 5B9.3, (B) 1H7.4, (C) 3D1.4 and (D) 1G5.3. 
Cleavage fragments chosen for analysis are arrowed. M refers to 
protein marker standards. 
109 
The glycosylation status of these species was determined by a series of 
endoglycosidase H and F digestions (data not shown). Gp31 contains both high 
mannose and complex carbohydrate moieties and gp20 only glycans of the 
complex type indicating that gp31 covers the region comprising both 
glycosylation sites ^^°Asn and ^°''Asn while gp20 contains only the first 
glycosylation site, ^^°Asn. A 22-25 kDa species was also recognized by MAbs 
5B9.3 and 1G5.3 in the mock digested sample (Figure 4.13, lanes 2 and 8 
respectively). This fragment has a similar reactivity profile to the gp25 cleavage 
fragment generated by trypsin digestion, and was often seen in purified 
preparations of NSI that had not been frozen immediately following purification 
or that had been subjected to incubation conditions at room temperature and 
above. The spontaneous generation of this species has been noted previously 
for the NSI protein of dengue virus (Henchal et al, 1987) and probably reflects 
cleavage by contaminating trace amounts of trypsin-like activity in preparations 
not treated with protease inhibitors. 
(ii) N-terminal sequence analysis of proteolytic fragments 
In order to precisely define the identity of the five cleavage fragments chosen for 
analysis, preparative SDS-PAGE gels were run, blotted and then stained as 
described in section 2.5e (iii). The region of the blot corresponding to the 
appropriate fragment was cut and the PVDF strips were submitted (to the Protein 
Facility, QIMR) for N-terminal sequence analysis. Figure 4.14 shows strip blots 
of trypsin and V8 protease digested NSI probed with representative MAbs from 
the major epitope groups. The five cleavage fragments investigated are indicated 
by arrows. The five panels at the top right of Figure 4.14 show the N-terminal 
amino acids identified for these fragments. The N-terminus of gp31 and gp20 is 
the authentic N-terminus of NSI while p i3 and plO have ^^^Ser as their N-
terminal amino acid. The trypsin fragment gp25 has '^'^ Glu as its N-terminus, 
confirming that this is a C-terminal fragment of NSI. Schematics of the various 
cleavage fragments generated are shown in the bottom panel. The presence of 
either complex or high mannose carbohydrate moieties linked to ^^°Asn on gp31 
and gp20 depended on whether NSI had been derived from the secreted or 
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membrane-associated form respectively (schematically represented in Figure 
4.14B). 
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Figure 4.14 Location of proteolytic cleavage fragments in the context of the 
primary NSI sequence. A, left panel; immunoblot strips of SDS-
PAGE separated cleavage fragments probed with representative 
MAbs from epitope groups A (3D1.4), CI (1H7.4), D1 (5B9.3), D2 
(1G5.3), and D4 (1E2.3) showing the different patterns of reactivity 
observed. A, right panel; N-terminal sequence analysis of the five 
cleavage fragments identified in the left panel. The primary amino 
acid sequence of NSI is shown on top, with amino acids icJentified 
by N-terminal sequencing in bold below. B, schematic 
representation of sNSI and mNSI. C, schematic representation of 
cleavage fragments in relation to the full sequence. The positions of 
linear epitopes are identified by lettered boxes and glycosylation 
sites by square paddle-pops. Open and filled boxes represent high 
mannose and complex CHO moieties respectively. 
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While the exact C-terminus cannot be defined for any of these fragments from 
the analyses presented, their molecular weights, location of cysteine residues 
involved in disulfide bridges, carbohydrate moieties and cleavage site specificity 
has limited the options and assisted in defining their locations. The C-terminus of 
gp31 most likely ends at either ^^% ^^^D or ^^ ^D while that of gp20 ends at ^^ "^ E, 
156^  or ^^' 'D. Both gp25 and pi 3 have molecular weights that would suggest they 
possess the true C-terminus while plO must be truncated at the C-terminus, 
most likely back to ^^E. The reactivity of MAbs known to bind to linear 
determinants within the primary sequence of NSI (boxes labelled A, C I , D1 and 
D3 in the schematics) is entirely consistent with the identity of the fragments 
represented in Figure 4.14. 
Having identified an overlapping set of cleavage fragments, the entire panel of 
MAbs, including those that are conformation specific, were reacted with strips cut 
from blots of SDS-PAGE preparative gels of cleavage fragments generated by 
digestion with either V8 protease or trypsin. Reactivity with specific fragments 
placed MAb binding within the context of the primary sequence (Table 4.2). In 
confirmation of the competition maps, epitopes A, CI and C2 were located in the 
N-terminal half of the NSI molecule. Epitopes comprising both the D domain and 
E epitope spanned the C-terminal third. All D domain specific MAbs and the 
single representative of the E epitope, 5B5.3 recognized the pi 3 cleavage 
fragment generated by V8 digestion. Based on molecular weight, this fragment 
comprises C-terminal residues from ^^ ®S to presumably the true C-terminus, 
^^ ^A. Significantly, MAbs belonging to the D4 and D5 epitopes did not recognize 
plO which had the same N-terminus as pi 3 but was missing approximately the 
C-terminal 17 amino acids. The separation of MAbs recognizing these epitopes 
from the other D domain reactive MAbs is consistent with the competition profile 
(Figure 4.3), Flavivirus cross-reactivity (Table 4.1) and ability to confer passive 
protection in a mouse model (Figure 4.4C). The absence of reactivity with plO 
could be the result of either the location of the D4 and D5 epitopes in the C-
terminal 17 amino acids or alternatively, a conformational change induced in the 
region ^^^S to ^^E through the loss of this C-terminal fragment that alters the 
availability of these epitopes for MAb binding. 
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Reactivity of individual MAbs with immunoblots of V8 protease and trypsin 
digested NS1 cleavage fragments. 
Reactivity of MAbs belonging to epitopes D1, D2 and D3 with the plO fragment 
localizes them to the region spanning ^^^S to ^^E. 
The reactivity of 5B9.3 (epitope D1) with both gp31 and gp25 confirmed that 
these were overlapping fragments. Furthermore, the reactivity of the 
conformational epitope specific MAb 4D4.4 (C2) with gp31 and not gp25, located 
this MAb to the N-terminal half of the molecule. This finding lends further support 
to the suggestion that the cross-competition identified in the epitope map 
between these two MAbs (see Figure 4.3) as well as the MAbs from the CI and 
D2 epitopes, was not simply the result of distant conformational effects but true 
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overlapping competition representing spatially adjacent sites on the same 
molecule. 
(d) Triton X-114 (TX-114) phase extractions of NSI 
Having identified the location of the cleavage fragments in the primary sequence, 
it was thought that they may be used to provide further insight into the region of 
NSI responsible for membrane association. TX-114 phase separation 
experiments have previously shown that flavivirus NSI is first expressed as a 
monomeric hydrophilic species (Winkler et al, 1989). This was consistent with a 
sequence that suggested a predominantly hydrophilic protein with few 
hydrophobic regions (Figure 4.15). 
...GVMVQA DSGCVV, LVNSLVTA GHGQI. 
Figure4.15 Relative hydrophobicity plot of dengue virus NSI. Schematic of the 
dengue virus genome is shown above. The boxed panel below 
highlights the region of the genome encoding NSI (numbers refer to 
nucleotides from the 5' end of the genome) and a hydrophobicity 
plot of the translated sequence. The amino acid sequence of the 
cleavage site between E/NS1 and NS1/NS2A are indicated below. 
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Oligomerization occurs within 20 minutes in the ER (Winkler et al, 1989) with an 
associated transition to hydrophobic character (Winkler et al, 1989; Mason, 
1989; Despres et al, 1991; Flamand et al, 1992; Leblois and Young, 1995). 
Although the nature of this induced hydrophobicity has been extensively 
investigated, no clear picture has emerged (Lindenbach and Rice, 2001). Our 
laboratory has identified cell-surface associated NSI that is linked to a GPI 
anchor (Jacobs et al, 2000) however these studies showed only a small 
percentage of membrane - associated NSI was anchored in this way. It is 
assumed that for the majority of mNSI, oligomerization induces a conformational 
change that exposes hydrophobic residues capable of interacting stably with 
membranes. This possibility is supported by the results presented earlier in this 
chapter which provide clear evidence for a change in the conformation of NSI 
between its secreted and membrane-associated forms in the differential 
exposure of the A determinant and the disruption of D domain integrity. 
In order to investigate the hydrophobic character of NSI, immunoaffinity 
purified preparations of both sNSI and mNSI were examined by TX-114 phase 
separation (Figure 4.16). Both native oligomeric NSI (sNSI, lanes 2 and 3; 
mNSI, lanes 6 and 7) and heat treated monomeric NSI (sNSI, lanes 4 and 5; 
mNSI, lanes 8 and 9) were examined. 
In agreement with results previously reported (Fan and Mason, 1990; Mason, 
1989; Winkler, 1989) the dimeric form of NSI partitions into both the aqueous 
and detergent phases (sNSI, lanes 2 and 3; mNSI, lanes 6 and 7) indicating a 
"partial" hydrophobic character. Monomeric NSI in contrast, partitions almost 
exclusively into the aqueous phase confirming the suggestion that 
hydrophobicity was induced only following oligomerization (sNSI, lanes 4 and 5; 
mNSI, lanes 8 and 9). The fraction of NSI for both forms that remained dimeric 
despite heat treatment, partitioned into both phases, thereby providing an 
internal control. It was noted that a trace amount of monomeric mNSI was 
variably found in the detergent phase in repeated experiments, while monomeric 
sNSI was never found in this fraction. As a subset of NSI has previously been 
115 
shown to be GPI-anchored (Jacobs et al, 2000) it is possible that this small 
fraction of mNSI may represent this post-translationally modified form. 
sNSI mNS1 
A D A 
Boil 
dimer 
< monomer 
1 4 8 
Figure 4.16 Immunoblot analysis of TX-114 detergent phase separation of 
dimeric and monomeric sNSI and mNSI. Immunoaffinity purified 
sNSI and mNSI were either boiled or left untreated prior to TX-114 
phase separation. Aqueous (A) and detergent (D) phases were then 
separated by SDS-PAGE, the gel was blotted and then probed with 
the MAb 3D1.4. Dimer and monomer forms are arrowed. Protein 
standard markers (M) are as indicated. 
To attempt to identify the region of NSI responsible for imparting this 
hydrophobic character, the products of both V8 protease and trypsin digestion 
were subjected to TX-114 phase separation. Immunoblots of SDS-PAGE 
separated digests were probed with the A epitope MAb, 3D1.4 (Figure 4.17A, V8 
digest) and the D3 epitope MAb, 1G5.3 (Figure 4.17B, trypsin digest). 
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Figure 4.17 Immunoblot analysis of TX-114 detergent phase separation of A, 
trypsin digested dimeric mNSI and B, V8 protease digested 
monomeric mNSI. Samples were either subjected to TX-114 
phase separation resulting in aqueous (labeled A) and detergent 
(labeled D) phase fractions or left as an untreated control (labeled 
C). Samples were separated by SDS-PAGE, the gel was blotted 
and then probed with the MAbs 1G5.3 (A) or 3D1.4 (B). Cleavage 
fragments are indicated by arrows to the right of the figures. 
Molecular weights of protein standard markers (M) are as 
indicated to the left. 
The gp25 trypsin fragment (Figure 4.17A) and the gp31 V8 protease fragment 
(Fig 4.17B) were clearly seen. The partitioning of gp31 predominantly into the 
detergent phase for mNSI (Figure 4.17B) and gp25 into the aqueous phase 
(Figure 4.17A) indicated that the hydrophobic character acquired by NSI would 
appear to reside in the N-terminal half of the molecule (amino acids 1-172). 
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4.3 DISCUSSION 
(i) Antigenic structure and epitope organization of dengue virus NSI 
Five antigenic domains and up to ten distinct epitopes on the dengue virus NSI 
glycoprotein have been identified in competition assays using a panel of dengue 
virus cross-reactive, dengue-2 virus specific and flavivirus cross-reactive MAbs. 
Antigenic maps for three different species of immunoaffinity purified dengue-2 
NSI were generated; secreted and membrane-associated NSI (sNSI and 
mNSI respectively) derived from dengue virus infected mammalian (Vero) cells 
and mNSI from insect (C6/36) cells. A similar antigenic profile was observed for 
all three species (Figure 4.8) with some important differences being noted. The 
most significant difference was the lack of recognition by A determinant specific 
MAbs of Vero cell derived mNSI. This linear epitope, localized to amino acids 
112-120 in the primary sequence (Falconar et al, 1994) is known to react with 
flavivirus cross-reactive MAbs, many of which have also been shown to confer 
passive protection in a mouse model (Young etal, 1994). The differential display 
of this epitope on different NS1 species might explain the finding reported earlier 
(Young and Falconar, 1990) that greater protection from lethal dengue challenge 
was observed for mice immunized with sNSI than for those immunized with 
mNSI. The second major difference between the antigenic maps is the 
breakdown in the integrity of competition in the D domain cluster of epitopes for 
mNSI derived from either mammalian or insect cells by comparison with the 
sNSI D domain (see Figure 4.8). 
MAb reactivity with proteolytic digests (Figure 4.14) as well as PEPSCAN 
analyses (Falconar et al, 1994) have shown the D domain epitope cluster to be 
localized to the C-terminal half of the molecule while the A and C epitopes are 
located in the N-terminal half (see Figure 4.4). The observation that a number of 
C domain specific MAbs (CI and C2) competed with those reactive for the D 
domain (D1 and D2) suggests that these epitopes may be in close proximity in 
the native folded structure. The possibility that the obsen/ed competition was a 
result of inter-molecular interactions rather than intra-molecular association was 
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investigated by comparing competition maps of both dimeric and monomeric 
forms. Although competition between C2 (4D4.4) and D2 (5H4.4) MAbs was lost 
in the monomeric form of sNSI, the one-way competition between D1 (5B9.3) 
and CI (1H7.4) was retained for both mNSI and sNSI. It is difficult to interpret 
the significance of the loss of the C2-D2 competition under these conditions 
particularly in light of the absence of competition between these two epitopes in 
dimeric mNSI (Figure 4.7), and the significantly reduced primary binding of the 
C2 specific MAb, 4D4.4 following monomerization (Figure 4.6). It is possible that 
the treatments employed to generate monomers (heating) and mNSI (detergent 
solubilization) may be responsible for this altered reactivity and that only native 
oligomeric sNSI is providing an accurate picture of MAb competition. The one-
way competition seen by 5B9.3 as a secondary MAb may be a consequence of 
(a) displacement of the bound antibody by a more avid species recognizing the 
same epitope, (b) positional effects where antibody binding blocks reactivity to 
an adjacent site or (c) conformational changes induced by binding to a 
positionally distant epitope that affects binding sites elsewhere in the polypeptide 
(Henchal et al, 1987). The first explanation can be discounted given that these 
MAbs recognize different, sequence defined binding sites. However the latter 
two possibilities cannot be excluded for this MAb. Nevertheless, the two-way 
cross-competition between epitopes C2 and both D1 and D2 for dimeric sNSI, 
suggests that competition may indeed be a direct result of recognition of spatially 
adjacent sites. This finding has been incorporated into the structural model 
presented at the end of this Chapter (Figure 4.20). Final resolution of the spatial 
arrangement of these epitopes will only be revealed by the three-dimensional 
structural determination of NSI. 
Two previously defined characteristics of the panel of MAbs, flavivirus cross-
reactivity and the ability to confer passive protection were placed in the context 
of the epitope map (Table 4.1 and Figure 4.4C) (Falconar and Young, 1991; 
Young and Falconar, 1990). Not surprisingly, these MAb phenotypes clustered 
reasonably well with epitope groupings, suggesting that they were associated 
with defined, topologically distinct domains. Five flavivirus cross-reactivity 
patterns previously identified (Falconar and Young, 1991) (Table 4.1) clustered 
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into separate domains that comprise either single or groups of epitopes. The 
ability to confer passive protection in a mouse model also clustered into 
particular domains with MAbs from epitope groups A, D3, D4, D5 and E, 
providing protection from a lethal virus challenge when passively administrated 
to mice (Figure 4.4C and Young and Falconar, 1990). It is interesting to note that 
MAbs belonging to the large overlapping cluster of epitopes, C I , C2, D1 and D2 
do not provide passive protection in this model. Given that protection by NS1-
specific antibody is thought to be primarily mediated by antibody dependent cell 
cytotoxicity (ADCC) and/or complement mediated lysis of infected cells (Henchal 
etal, 1988) accessibility of antibody to NSI on the infected cell surface would be 
a pre-requisite for providing the protective effect. Although the MAbs comprising 
this epitope cluster were able to bind to cell-surface NSI in immunoflorescence 
studies (data not shown) it is still possible that binding orientation is not optimal 
for effective ADCC or complement mediated lysis. 
One of the most intriguing observations in this study was the considerable 
variation in the reactivity of A determinant specific MAbs to the multiple forms of 
NSI analysed. Under the same conditions, reactivity of the remaining panel of 
MAbs remained fairly consistent. These variable reactivity patterns included the 
loss of binding to mNSI purified from Vero cells (Figure 4.7) but not for insect 
cell derived mNSI (Figure 4.8B). A epitope specific MAbs also failed to react 
with NSI that had been monomerized by heat treatment (Figure 4.6). This 
differential exposure of the A epitope in native and monomer forms was further 
supported by their different susceptibility to trypsin digestion (Figure 4.12A). The 
presence of two lysines and one arginine residue within the linear sequence 
previously defined as being recognized by these MAbs (Falconar et al, 1994) 
ensured cleavage within the epitope and therefore loss of MAb reactivity only if 
the epitope was exposed. In addition, primary binding of several D domain 
specific MAbs to sNSI was shown to significantly enhance subsequent binding 
by A epitope reactive MAbs (Figure 4.3). This synergistic binding indicates a 
conformational dependency between the two halves of the molecule and 
provides further support for the spatial juxtaposition of N- and C-terminal regions 
of NSI suggested by the overlapping C and D epitopes (Figure 4.4B). In 
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summary, the variability in reactivity of A determinant specific MAbs suggests a 
degree of flexibility in the structure of the domain encompassing the A epitope, 
with altered orientation in each form of NSI determining how efficiently this 
epitope is presented for MAb binding. 
Digestion of proteolytic fragments with endoglycosidases H and F formally 
confirmed earlier findings (Young etal, 1993; Pryor and Wright, 1994) that in the 
secreted form of NSI, it is only the carbohydrate linkage site at ^^°Asn that 
undergoes trimming and complex processing in the Golgi. Presumably the 
presence of only high-mannose residues at ^°''Asn reflects the sequestration of 
this site in the oligomeric form of the protein and hence protection from 
subsequent modification during passage through the Golgi. Given that ^^°Asn is 
only ten amino acids C-terminal to the A epitope (^^^R-K^^°; Falconar etal, 1994) 
the possibility was investigated that the altered binding profiles of the A epitope 
specific MAbs for mNSI and sNSI were the result of differences in the 
glycosylation status of this site. However, endoglycosidase digestion of both 
mNSI and sNSI, failed to modify MAb binding thereby demonstrating that the 
differential reactivity was not a simple consequence of steric hindrance by the 
different carbohydrate moieties (Figure 4.10). Nevertheless, it is still possible that 
trimming and processing of carbohydrate residues at ^^°Asn may induce 
irreversible conformational changes that affect exposure of the A epitope. 
Binding profiles of NSI produced in cells treated with tunicamycin or from 
recombinant constructs with this carbohydrate site removed would need to be 
performed to conclusively address this possibility. 
The N-glycosylation site ^°''Asn is conserved in all mosquito-borne flaviviruses 
sequenced to date. The functional and structural significance of this finding 
remains to be fully elucidated, however the conservation of this site does 
suggest that glycosylation plays an important role in NSI function. Previous 
studies have provided data that supports this hypothesis (Pryor and Wright, 
1994; Pletnev et al, 1993). It has been shown that the stability of the native 
oligomeric form of NSI is largely dependent on the carbohydrate moiety 
attached to this site (Pryor and Wright, 1994) and that recombinant viruses 
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lacking this carbohydrate are significantly attenuated (Pletnev et al, 1993; Pryor 
et al, 1998). As noted above, removal of the carbohydrate residue at ^°''Asn 
substantially destabilizes the oligomeric integrity of NSI while removal of the 
carbohydrate at ^^°Asn does not (Pryor and Wright, 1994). However, if both 
carbohydrate residues are removed (recombinant G3 in Pryor and Wright, 1994) 
dimer integrity is significantly recovered suggesting that while the carbohydrate 
at ^°''Asn does indeed stabilize the oligomeric form, the carbohydrate at ^^°Asn 
may also play a role by providing a countering destabilizing effect. 
Apart from the glycosylation profile, the other defining characteristic that 
differentiates mNSI from sNSI is membrane-association. A simple explanation 
for the absence of the A epitope on mNSI may be that this epitope is buried in a 
region that is involved in membrane-association, whereas in the secreted form it 
is exposed. The finding that it is the N-terminal half of NSI that harbours 
hydrophobic properties (Figure 4.17) is consistent with this hypothesis. Indeed, 
the association of the A epitope with a region of hydrophobic character is 
supported by a number of other observations made in this study. Oligomeric 
sNSI is partially hydrophobic as determined by TX-114 phase separation 
experiments and is recognized by A determinant specific MAbs (Figure 4.16). 
Conversion to a monomeric species by heat treatment renders sNSI hydrophilic, 
implying that hydrophobic domains are buried in this form of the protein. This 
conversion is paralleled by a loss of reactivity by the A epitope MAbs (Figure 
4.6). It is interesting to note that although monomeric full-length NSI is 
hydrophilic, the monomeric N-terminal gp31 cleavage fragment does exhibit 
hydrophobic properties (Figure 4.17). Presumably the loss of the C-terminal 
fragment no longer allows this N-terminal hydrophobic domain to be buried. The 
association between C-terminal and N-terminal domains has been discussed 
previously in the context of the epitope map and this hydrophobic interaction 
may be reflecting the same association. The possibility that the C-D epitope 
interaction is hydrophobic in nature may also explain the dramatic loss in 
integrity of the D domain competition map for detergent solubilized mNSI 
(Figure 4.7). 
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Numerous studies have already been reported that have sought to define the 
antigenicity of flavivirus NSI at the epitope level. These have utilized synthetic 
peptides, recombinant deletion constructs, phage display and MAb epitope 
mapping (Henchal etal, 1987; Putnak etal, 1988, Mason etal, 1990; Yao etal, 
1995; Garcia etal, 1997; Huang etal, 1999; Wu etal, 2001; Bugrysheva et al, 
2001). The current study is the most comprehensive to date having identified the 
binding profile of 22 individual MAbs and generated a competition map that 
places the binding of these MAbs in the context of the primary amino acid 
sequence. 
The competition map presented by Henchal et al (1987) and derived from the 
reactivity of nine different MAbs with dengue-2 virus NSI has some striking 
similarities with the competition map described in this Chapter. Although eight of 
the competition MAbs used by Henchal et al (1987) were dengue-2 virus 
specific, two main overlapping epitope clusters were identified that are similar to 
the C and D domains recognized here. One of their MAbs, 47-10/10 is involved 
in one-way competition similar to our 5B9.3 and it is this MAb that unites the two 
major domains as overlapping clusters. The similarity between these two MAbs 
is strengthened by the fact that 47-10/10 was also shown to recognize a 
spontaneously generated 22 kDa fragment, suggesting that this MAb, like 5B9.3, 
recognizes an epitope in the C-terminal half of the molecule. This was also the 
only MAb that showed any cross-reactivity, in this case with JEV. It is significant 
to note that MAbs defining the epitopes D1, D2 and D3 in the current study also 
recognized JEV in addition to dengue-2, dengue-4 and other members of the 
encephalitic flaviviruses. 
Putnak et al (1988) cloned and expressed deletion constructs of NSI from the 
New Guinea C strain of dengue-2 virus in E. coll to study the antigenic domains 
of the protein. Both the N- and C-terminal regions of NSI were found to be 
antigenic when reacted with dengue-2 mouse polyclonal sera and dengue-2 
MAbs respectively. This correlates with our C and D domains. Conversely, a 
rabbit polyclonal antiserum against purified NSI reacted more strongly with 
carboxy-terminal than amino-terminal derived proteins. This was interpreted as 
123 
being due to differences in antigen presentation or it could be explained by 
differences in immunodominance in different species (Putnak etal, 1988). 
In contrast to the studies of Putnak et al (1988), subsequent findings by Mason 
et al (1990) with E. coli expressed dengue-1 virus NSI, found that monoclonal 
antibodies reacted with determinants clustered at the amino-terminus (amino 
acids 57 - 126). The reason for this discrepancy most likely lies in the methods 
used to generate and select monoclonal antibodies (Mason et al, 1990). The 
determinants described by Mason et al (1990) between amino acids 57 - 126 
correlate with our A determinant which specifically recognizes the region 
between amino acids 111 - 121 (See Table 2.1 (Falconar et al, 1994)). Due to 
the small number of anti-NSI MAbs used by Mason et al (five in total, only one 
of which cross reacted with dengue-2 NSI) it is likely that they too, are seeing a 
subset of the large range of epitopes recognized in the current study. 
The identification of epitope clusters along the full-length of the protein has also 
provided an opportunity to assess likely correlates in the characteristics of MAbs 
and epitopes previously reported by others. The current work primarily builds on 
the identification by PEPSCAN analysis (Falconar et al, 1994) of the binding 
sites of a limited set of MAbs that were originally recognized as reacting with 
linear determinants (Falconar and Young, 1991). Of the five epitopes reported in 
that original study, four were found to map topologically to their expected sites as 
suggested by the specific peptide sequence each had been show to recognize. 
However one epitope, recognized by the MAb 5H4.3, did not fall into the 
expected epitope grouping following competition analysis nor did it recognize the 
relevant peptide fragment that would correlate with the originally defined epitope 
(referred to as 24A, comprising amino acids ®^ T-K®^ ) (Falconar et al, 1994). The 
competition map placed this MAb into the D3 epitope group with reactivity to the 
plO cleavage fragment thereby identifying its binding site to be within the amino 
acids ^''^M-E^^. It can be inferred that the peptide originally identified in the 
PEPSCAN analysis was operating as a mimotope of the true, conformationally 
dependent binding site. This finding also helps to explain why in the earlier 
studies this MAb failed to show the sub-complex reaction profile with peptides 
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that was seen with native NSI when synthetic peptides derived from the amino 
acids 61-69 of all four serotypes were examined (Falconar etal, 1994). 
More recently, the focus of epitope investigations has been on the use of 
synthetic peptides and the application of phage display. Garcia et al (1997) 
generated a series of synthetic peptides based on the hydrophilic profile of NSI. 
The five peptides generated were derived from regions of predicted hydrophilicity 
and reacted with sera taken from dengue-4 virus infected patients. Four of the 
five reacted preferentially with infected patient sera when compared to controls. 
Interestingly, the one peptide that failed to react, corresponded exactly to the 
sequence recognized in dengue-2 virus by our MAb 5B9.3. Whether the lack of 
reactivity to this region by human sera is specific only to dengue 4 virus will 
require further study but it is relevant to note that 5B9.3 is known to cross-react 
with dengue-4 virus NSI. One of the reactive peptides consisted of a seventeen 
amino acid region derived from the C-terminus of NSI. This region corresponds 
to the site recognized by MAbs defining the D4 and D5 epitopes, indicating that 
human and murine immune responses target this region. Wu ef a/(2001) reports 
the identification of a B-cell epitope on dengue-1 virus NSI through the use of 
phage display and selection with MAb 15F3-1. Interestingly, the epitope region 
identified corresponds precisely with our A epitope although the authors do not 
refer to the prior identification of this epitope in an earlier paper from our 
laboratory (Falconar etal, 1994). The majority of sera taken from dengue-1 virus 
infected patients responded to a peptide corresponding to this region, thereby 
identifying the A determinant as a B cell epitope recognized in the human 
response to dengue virus infection. 
(ii) Structural Model of Dengue-2 NSI 
Figure 4.18 is a schematic representation of the primary structure of the NSI 
protein of dengue-2 virus summarizing the locations of antigenic determinants, 
known disulfide bridges, biophysical features and structural characteristics of this 
protein that have been determined in the current study and reported previously. 
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There are twelve cysteine residues in the NSI protein of flaviviruses and these 
are totally conserved amongst all members sequenced to date. These residues 
form intra-chain disulfide bonds and the level of conservation suggests a 
common structure throughout the flavivirus family. The positions of these 
residues are indicated in Figure 4.18 with the disulfide bonds indicated for those 
that have been biochemically identified to date for MVE NSI (Blitvich et al, 
2001). Earlier work by Pryor and Wright (1993) had employed site-directed 
mutagenesis of cysteine pairs to identify the location of disulfide bridges. They 
reasoned that the mutation of naturally paired cysteines would have a less 
disruptive effect on dimer formation than pairs of cysteines not normally involved 
in forming disulfide bridges. All painwise combinations were assessed with 
^^^Cysll, and it was found that only with the associated mutation of ^^^CyslO, 
were dimers formed. It is possible therefore that ^^^CyslO and ^^^Cysll also 
form a disulfide bridge although biochemical or structural data is required to 
confirm this hypothesis. 
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Figure4.18 Schematic of the primary structure of dengue 2 virus NSI. Relative 
positions of cysteine residues are indicated with open circles, and the 
known disulphide bridges are shown. Linear sequence epitopes are 
indicated by the open boxes with the binding domains of conformation 
specific epitopes identified by solid bars. Glycosylation sites are marked 
with square paddle-pops (high mannose, open box; complex, filled box) 
and the sites of V8 protease and trypsin cleavage are indicated with arrow 
heads. The regions identified to have hydrophobic properties and to be 
involved in dimerization are also shown. 
The partial proteolytic digestions performed in the current study are consistent 
with the disulfide bridges identified by Blitvich et al (2001). V8 protease and 
trypsin digestion between residues '^^ ^Cys4 and ^''^Cys5 and between ^^^Cys6 
and ^^°Cys7 without the formation of disulfide-linked species indicate that 
126 
cysteines "^Cysl to ^'^Cys4 are involved in disulfide bridges, as are cysteines 
^^ ®Cys5 and ^^^Cys6. Although the disulfide bridges formed by the remaining six 
cysteines await confirmation, a number of possibilities are suggested by existing 
data. As discussed above, cysteine residues ^^^CyslO and ^^^Cysl 1 are likely to 
be linked by disulfide bonds (Pryor and Wright, 1993) while disulfide bridges 
between ^^°Cys7 and ^^^Cys8, ^^^Cys9 and ^^^CyslO, and ^^^Cysl 1 and ^2^Cys12 
have been excluded by Blitvich et al (2001) based on peptide fragments 
identified by HPLC. These findings leave only the paired residues between 
^^°Cys7, ^^^Cys8, ^^^Cys9 and ^^^Cys12 to be defined. Figure 4.18 also shows 
the binding sites for the majority of epitopes examined in this study. D domain 
epitopes are seen to cluster in the C-terminal third of NSI with the binding 
location of the conformational epitopes D3, D4, D5 and E defined by their 
interaction with peptide fragments (summarized in Figure 4.14). The dimerization 
domain has been localized to the C-terminus of NSI through a number of 
independent studies. These include the expression of truncated recombinants 
(Parrish et al, 1991) and the disruption of dimerization following site-directed 
mutagenesis of cysteine residues and selected hydrophobic residues within this 
region (Pryor and Wright, 1993). The identification in the current study of a 
dimeric trypsin cleavage fragment representing the C-terminal half of the 
molecule is consistent with these observations. Finally, TX-114 phase separation 
experiments performed on selected protease cleavage fragments have localized 
the hydrophobic character of NSI to a site within the N-terminal half of the 
molecule. 
In order to provide further insights into the structural organization of the NSI 
protein, a secondary structure model was built for data generated by the 
structure prediction algorithm PHD (Rost and Sander, 1994a; 1994b; Rost, 
1996). This web based program uses multiple aligned protein sequences as 
input to estimate the probability of secondary-structure motifs and solvent 
accessibility. Figure 4.19 shows a consensus of the final secondary structure 
predictions generated, with helices (graphic spirals), p sheets (open arrows), and 
coils (straight lines) indicated above a subset of representative aligned 
sequences (of a total of 27) obtained from the protein database and used in the 
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analysis. The locations of the defined linear epitopes A, CI , D1 and D2 are 
shown, as are areas of high amino acid sequence conservation amongst the 
flaviviruses (open boxes). A particularly high level of sequence homology can be 
seen in the C-terminal fifty amino acids, perhaps reflecting the location in this 
region of the functionally important dimerization domain (Parrish et al, 1991; 
Pryor and Wright, 1993). 
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The prediction suggests a high level of helical content in the N-terminal third of 
NS1 with (3 sheets and coils comprising the remainder. The secondary structure 
predictions were incorporated into a tertiary structure model along with the 
known disulphide linkages, suspected overlapping epitopes and cleavage sites 
that were shown to generate stable sub-domains (Figure 4.20). The model 
suggests that disulfide linkages may be found between ^^°Cys7-^^^Cys12 and 
2^^Cys8-^ ^2Cys9 but linkages between 2^°Cys7-^^2Cys9 and 2^^Cys8-^2^Cys12 are 
equally possible. 
NH2 
^^S^S^ 
B 
Domain I 
Domain II 
Figure 4.20 Tertiary structure model of dengue virus NS1. A, Positions of cysteines 
and disulphide bridges are shown, as are linear sequence epitopes (open 
boxes). Epitopes C1, D1 and D2 are shown in close association based on 
competition mapping. Predicted secondary structure elements are 
schematically drawn as spirals (a-helices), arrows (P-sheets) and lines 
(coils) and glycosylation sites are indicated by paddle-pops. Sites of 
proteolytic digestion are shown with arrowheads (V8 protease, filled; 
trypsin, open). B, Two domains of NSI, based on the stability of cleavage 
fragments, are highlighted. 
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The cleavage of mature oligomeric mNSI and sNSI by trypsin at ^^ ^R to yield a 
stable C-terminal oligomeric fragment that is resistant to further digestion and 
maintains its dimeric configuration, suggests that NSI may comprise two distinct 
domains. These have been highlighted in Figure 4.20 and termed domains I and 
II. The presence of the carbohydrate moiety at ^°^Asn within this fragment is 
consistent with its protection in the dimeric form from further trimming and 
processing despite passage through the Golgi. 
The N-terminal third of the molecule was examined for regions that may 
contribute to the hydrophobicity of this part of the molecule (Figure 4.17). Three 
of the predicted helices in this region were found to be amphipathic in nature and 
in each case, the hydrophobic residues involved were highly conserved, 
suggesting an important functional role. One of the predicted helices forms a 
component of the A epitope. Given the failure of A determinant specific MAbs to 
recognize the membrane-associated form of NSI, it is tempting to speculate that 
membrane-association may be the consequence of the differential exposure of 
this epitope. It is also known that the hexameric form of secreted NSI is 
sensitive to detergent treatment (Flamand et al, 1999; own observations). In 
considering these two observations it is possible that dimerization and the 
acquisition of hydrophobic character for newly synthesised NSI commits each 
dimeric form to one of two pathways; either the hydrophobicity induces 
membrane-association or alternatively, an association with two other dimers via 
hydrophobic interactions. This implies that membrane-associated NSI, in its role 
as a component of the replication complex, is dimeric in its mature form. 
Maturation of the secreted form however involves the generation of hexameric 
NSI. Furthermore, the association of mNSI with membranes via a hydrophobic 
domain that is spatially near the glycosylation site at ^^°Asn may help to explain 
the lack of processing of this moiety despite traffic through the Golgi. This 
hypothesis is currently under investigation in the Young laboratory. 
131 
CHAPTER 5 
TOWARDS THE CRYSTALLIZATION OF NS1: 
BACULOVIRUS EXPRESSION OF DENGUE-2 VIRUS 
NS1 
5.1 INTRODUCTION 
Although the function of NSI is yet to be fully defined, several recent publications 
provide evidence that NSI is involved in RNA replication (Chu and Westaway, 
1992; Mackenzie etal, 1996; Muylaert etal, 1996; 1997; Lindenbach and Rice; 
1997; 1999). Earlier reports however, suggested that NSI played a role primarily in 
virus assembly and maturation due to its presence on the cell surface and its 
association with the E protein through the secretory transport pathway (Rice etal, 
1986b; Mason 1989). 
Since 1992 it has been known that NSI cosediments in sucrose gradients with 
heavy membrane fractions extracted from infected cells which have an associated 
RNA-dependent RNA polymerase activity (Chu and Westaway, 1992). However, 
the first report that suggested a direct role for NSI in RNA replication was shown by 
immunofluoresence and cryo-immuno electron microscopy (Mackenzie etal, 1996). 
This study demonstrated the co-localization of NSI and viral double-stranded RNA 
replicative intermediates with virus modified cellular vesicles. Genetic studies have 
provided further evidence implicating NSI in viral RNA replication (Muylaert etal, 
1996; 1997; Lindenbach and Rice, 1997; 1999). Although the precise role of NSI in 
RNA replication remains to be identified it has been postulated that NSI is 
structurally involved in the assembly of the components of the viral replicase 
(Mackenzie etal, 1996; Lindenbach and Rice, 1997). 
The elucidation of the correct three dimensional structure of dengue virus NSI 
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should provide further insights into the function of this glycosylated non-structural 
protein. As has been outlined in Chapter 4 of this thesis, and in the absence of a 
functional assay, a detailed antigenic structure of the dengue-2 virus NSI was 
obtained which will serve as a basis for interpretation of tertiary structural 
information. The aim of this section of the thesis was to express and purify 
sufficient NSI for preliminary crystallization studies. 
NSI from a range of sources is potentially suitable for crystallography. It is 
imperative that protein destined for crystallography is of high concentration and 
purity. Mammalian cells (for example, Vero cells), produce both a secreted (sNSI) 
and membrane-associated form of NSI (mNSI). The secreted form contains both a 
high-mannose and complex type glycan suggesting transport through the Golgi 
apparatus (Lee etal, 1989), whereas the membrane-associated form contains only 
high-mannose linkages on its two N-linked glycosylation sites (Lee etal, 1989). In 
agreement with findings by Mason (1989) we have found that insect cells (eg. 
C6/36 mosquito cells) produce only a relatively small amount of the secreted form 
of NSI however a membrane-associated form is produced in higher concentration 
than that seen in Vero cells. Of the various forms of NSI available, the membrane-
associated form derived from C6/36 cells is produced in the highest amounts. The 
use of the membrane-associated form could be problematic however in terms of 
extraction and purification of the protein from the infected cell. Furthermore the 
recent publication from our laboratory outlining evidence for the anchoring by 
glycosylphosphatidyl inositol (GPI) of a portion of NSI to cellular membranes 
(Jacobs etal, 2000) also suggests that membrane associated NSI would likely be 
comprised of a heterogeneous population of protein species. 
GPI anchored proteins are derived from nascent forms that contain two signal 
peptides, both of which are removed during processing in the ER. Removal of an 
amino terminal signal peptide occurs through the action of a signal peptidase 
(Blobel and Dobbestein, 1975; Lingappa et al, 1977) and the carboxy-terminal 
signal peptide targets the protein to a putative GPI transamidase in the ER. 
Covalent attachment of the GPI moiety to an internal residue (the co site) occurs 
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with the concomitant release of the carboxy terminal signal peptide. This mature 
(GPI linked) form of the protein is subsequently transported through the secretory 
pathway to the plasma membrane where it is anchored solely through the fatty 
acids that are components of the GPI anchor. The precise role of GPI anchoring 
has yet to be determined although it has been implicated in signal transduction 
(Robinson ef a/, 1989;Suefa/, 1991; Robinson, 1997) and confers on proteins the 
ability to transfer between the plasma membranes of different cells (llangumaran et 
al, 1996). It has been shown that GPI-anchored proteins that are transferred remain 
functional (Medof etal, 1985) and retain the capacity for signal transduction (van 
den Berg, 1995). 
NSI % 
glucosamine 
inositol 
ethanolamlne 
Cell 
membrane 
Figure 5.1 A schematic representation of the components of the glycosylphosphatidyl 
inositol (GPI) anchor showing oligomeric NS1 attached to a cellular membrane. 
It is envisaged that non-GPI anchored NSI would be a more appropriate protein for 
crystallography because of the lack of this complex and highly glycosylated species 
(See Figure 5.1). In natural dengue infections most of the NSI protein is retained 
within the infected cell, either in the ER or at the cell surface, with a proportion 
being secreted (Winkler etal, 1988; Mason, 1989; Post etal, 1991). Previous work 
by Post ef a/(1991) reported that 35 - 45% of YF NSI was secreted from infected 
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mammalian cells. Recombinant baculovirus expression of JE virus NSI reported 
recombinant protein levels corresponding to 6% of the total cell protein content 
(Flamand etal, 1995) with the majority of NSI being retained intracellularly. 
The aim of the work described in this chapter was to express non - GPI anchored 
dengue-2 virus NSI in the baculovirus expression system by using a range of 
constructs introducing mutations at or near the co site. Once expressed, 
recombinant protein would be purified and concentrated for use in crystallography 
trials. 
As with the E protein (Heinz etal, 1991), all twelve cysteines are conserved in the 
NSI protein of the flaviviruses. Thus a common structural organization of NSI can 
be assumed. A crystal structure of NSI should provide insights into the functional 
roles of this protein as well as providing an additional target for drug design. 
5.2 RESULTS 
(a) Design and generation of recombinant baculoviruses 
All mutants were based on a construct encoding an N - terminal signal sequence of 
28 amino acids derived from the carboxy terminus of E, which is sufficient for the 
translocation of the NSI protein into the ER (Falgout et al, 1989). This coding 
sequence was preceded by a consensus Kozak motif (ACC) and a methionine 
residue to provide an efficient translation initiation site (Kozak, 1984). Sequence 
analysis of this isolate of dengue-2 virus (PR159 strain) has been previously 
reported by Leblois and Young (1994). 
Four different constructs were made which are shown schematically in Figure 5.2. 
The first construct, Ac.NSI, contained the signal sequence and the entire 
nucleotide coding sequence of NSI. For the mutant constructs, the 3' - ends were 
modified. Ac.NSI A9 and Ac.NSI .F were designed with the intention of preventing 
GPI anchoring by removing or ablating the co site. Ac.NSI A9 construct had the last 
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nine amino acids removed from NSI whereas Ac.NSI.F had the terminal amino 
acid substituted to a phenylalanine residue which has been shown to be a non-
acceptor residue for GPI anchoring (Udenfriend and Kodukula, 1995; Eisenhaber et 
al, 1998). 
NH: prM NSI 2A 2B NS3 4A 4B NS5 — C O O H 
-28 1 ...352 
Ac.NSI 
Ac.NSI.F 
Ac.NSI A9 
Ac.NS1.NS2A 
1 NS1 
1 NS1 
...EENLVSSLVTfl 
...EENLVSSLVTF 
1 NS1 
...EE 
1 NS1 
1 i 
I 
i 
NS2A 
1570 
Figure 5.2 Schematic representation of the dengue virus genome and of constructs made 
for recombinant baculovirus expression of NS1 and modified NS1. 
PCR primers were designed to amplify NSI from the beginning of the signal 
sequence to the carboxy terminal VTA site or to the desired substitution or deletion. 
These are listed in Table 5.1. The sequence of each construct was confirmed prior 
to the expression of recombinant proteins. 
Table 5.1 Sequence of oligonucleotides used to amplify NS1 and produce mutant 
constructs. 
NSI CONSTRUCTS 
NS1 
NS1 
NS1.F 
NS1.F 
NS1A9 
NS1A9 
NS1.NS2 
NS1.NS2 
Forward 
Reverse 
Forward 
Reverse 
FonA/ard 
Reverse 
a Fon/vard 
a Reverse 
PRIMER SEQUENCE (5' - 3') 
GAGGGATCGAGGATGAATTGAGGCAGGAGCTCA 
GGTGGATGGGTAGGGTGTGAGGAAGGAGTTGAG 
GAGGGATGGAGGATGAATTGAGGGAGGAGGTGA 
GGGGGGATGGGTAGAATGTGAGGAAGGAGTTGAG 
GAGGGATGGAGGATGAATTGAGGGAGGAGGTGA 
GGGGGGATGGGTAGTGTTGTTTGTGTTTGAATGG 
GAGGGATGGAGGATGAATTGAGGGAGGAGGTGA 
GGGGGGATGGGATATGGTAGGTTTTGTTGGTGGTTGTTGA 
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NS1.NS2a contained the full length NSI and NS2a as it had been reported that 
NS2a was required for the correct processing of NSI (Chambers etal, 1989), and 
high molecular weight forms of NSI containing regions of NS2a, had been 
identified in YF (Chambers et al, 1990) and JE virus infected cells (Mason et al, 
1987; Mason, 1989). 
The recombinant baculoviruses were constructed by standard molecular biology 
techniques as described by Kitts ef a/(1990; 1993). The various NSI constructs 
were sub-cloned into a baculovirus transfer vector (pAcYMI) (Matsuura, 1987) and 
then co-transfected with BsaB^ linearized AcRP23-LacZ baculovirus DNA using 
Lipofectin (Life Technologies) into Spodoptera frugiperda {Sf) cells. The 
supernatants were harvested at 48 hours post-transfection and used to infect fresh 
Sf cells. After three successive plaque purifications where recombinants were 
selected on their ability to secrete high levels of NSI (by immuno-slot blot analysis), 
high titred stocks were obtained. 
(b) Biochemical characterization of recombinant derived NSI 
For a recombinant protein to be considered suitable for crystallography experiments 
it needs to be ascertained that the expressed protein resembles authentic native 
protein. To this end the known characteristics of NSI such as dimerization, 
secretion, glycosylation and antigenicity were examined. 
(i) Secretion 
The four recombinant baculoviruses were used to infect S. frugiperda cells at an 
equivalent m.o.i. of one. Tissue culture supernatants and cell extracts were 
harvested to compare expression levels. The autoradiograph in Figure 5.3 clearly 
shows that the expression levels in the Ac.NSI.F, Ac.NSIA9 and Ac.NSI.NS2a 
recombinant viruses were markedly less that that of Ac.NSI. Ac.NSI and 
Ac.NSI .F produced recombinant protein of a molecular weight of 50 kD, whereas 
Ac.NSI A9 produced a doublet probably due to incomplete glycosylation (Figure 5.3, 
open arrow). The Ac.NSI .NS2a recombinant protein was present as both the full-
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length and processed forms in the cell extract although only the processed NSI 
was secreted. 
NSI NS1.F NS1A9 NS1.2A 
C S C S C S C S 
Figure 5.3 Autoradiograph of cell extracts (C) and supernatants (S) from Sf cells infected 
with each recombinant baculovirus at an moi of 1 and immuno-precipitated 
with the anti-NS1 MAb, 1 H7.4. Cells were pulse labeled for one hour and chased 
overnight. The open arrow indicates incomplete carbohydrate processing of the 
NS1A9 expressed product; and the solid arrow, the incomplete cleavage of the 
NS1.NS2A orecursor. 
Vero C6/36 Sf 
pulse chase pulse chase pulse chase 
C S C S C S C S C S C s 
kAx 
Figure 5.4 Autoradiograph of cell extracts (C) and supernatants (S) from cells infected 
with dengue 2 virus (Vero and C6/36 cells) or Ac.NSI (Sf cells) and immuno-
precipitated with the anti-NS1 MAb, 1H7.4. Cells were pulse labeled for three 
hours and harvested immediately (pulse) or chased overnight (chase). 
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A pulse-chase experiment shown in Figure 5.4 compared the expression levels of 
the recombinant protein in S. frugiperda cells with that of dengue-2 virus infected 
cells. As has been reported previously (Mason, 1989), C6/36 cells showed very little 
secreted NSI although comparatively they produced the highest level of cell-
associated NSI. Infected Vero cells produced levels of NSI similar to that of the 
recombinant, with the secreted form being of a higher molecular weight due to 
complex glycosylation. The results of the recombinant protein chase experiment 
clearly showed the recombinant protein being chased into the supernatant after 24 
hours. 
As it was our intention to proceed towards crystallography, maximal secretion levels 
were required to maintain the viability of this approach and thus the Ac.NSI 
baculovirus recombinant was chosen as the basis of further study. 
Ac.NSI infected Sf cells 
Mock IP 1P1C 1P3C 1P6C 1P24C 
C S C S C S C S C S C S 
Figure 5.5 Autoradiograph of cell extracts (C) and supernatants (S) from Sf cells infected 
with Ac.NSI at an moi of 1 and immuno-precipitated with the anti-NSI MAb, 
1 H7.4. Cells were pulse labeled for one hour and chased for 1,3,6 and 24 hours 
as indicated. 
S. frugiperda cells were infected with recombinant virus (Ac.NSI) at an m.o.i. of 1 
to examine the kinetics of secretion over a 24 hour period. Cell extracts and tissue 
culture supernatants were assayed for the presence of secreted NSI via 
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radioimmunoprecipitation of labelled cells with an NS1 specific monoclonal 
antibody. After a one hour pulse at 24 hours post - infection, NS1 is readily 
detectable within the cell however secretion had not yet occurred to a detectable 
level (Figure 5.5). After a further one hour chase NSI became evident in the 
supernatant, albeit at low levels. Secretion continued to increase up to 24 hours 
post pulse, however the amount of cell-associated NS1 remained relatively 
constant and did not appear to chase out of the cell even after 24 hours. 
(ii) Cellular localization 
Recombinant NS1 was also present on the surface 
of infected Spodoptera frugiperda cells as shown by 
immunofluorescence in unfixed cells (Figure 5.6A 
and C), and in the cytoplasm of acetone fixed cells 
(note the large nuclei of Sf cells) ( Figure 5.6B). The 
ability of the recombinant protein to be both 
secreted and membrane-associated reflects the 
characteristics of native NSI produced in dengue 
virus infected mammalian cells. These results are in 
agreement with that of Flamand et al (1992) for JEV 
NS1, and Leblois and Young (1995) for dengue-2 
NSI, demonstrating that recombinant NS1 can be 
transported to the plasma membrane in the absence 
of any other viral protein and also that NS1 alone 
contains all of the sequence requirements for 
membrane-association and secretion. 
Figure 5.6 Immunofluorescence confocai microscopy of Ac.NSI infected Sf cells. 
Infected cells were either left unfixed (A and C) to examine cell surface 
expression of NS1 or acetone fixed (B) prior to staining with the anti-NSI 
monoclonal antibody 1H7.4. Panel C represents a computer reconstruction of 
the infected ceil surface using a Z-series sequence of confocai images. 
(iii) Glycosylation and dimerization 
On expression of wild-type dengue virus proteins in infected cells, monomeric NS1 
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undergoes a rapid conversion to a dimeric form and is glycosylated at two N-linked 
sites. The glycosylation profile of recombinant derived NSI was examined by 
endoglycosidase digestion. The western blot presented in Figure 5.7 shows the 
effect on immunoaffinity purified recombinant NSI of digestion with both 
endoglycosidase F and endoglycosidase H. 
sNSI mNS1 
M -
< dimer 
M monomer 
1 2 3 4 5 6 7 8 
Figure 5.7 Western blot of immunoaffinity purified recombinant NS1 from infected cells 
(mNS1) or supernatants (sNS1). NSI was digested with either 
endoglycosidase F (EF) or endoglycosidase H (EH), and either boiled (+) or 
not boiled (-) prior to running a 10% SDS-PAGE gel. The western blot was 
probed with the anti-NS1 MAb 1H7.4. 
The difference in migration between the samples digested with the two 
endoglycosidases, and mock treated NSI is consistent with the presence of two 
glycosylation sites in the recombinant protein and is similar to that observed for 
authentic NSI (see Chapter 4.2b (v)). Endoglycosidase F digestion removes both 
carbohydrate moieties revealing an identical polypeptide backbone for both sNSI 
and mNSI. The apparently anomalous migration of the marker proteins was a 
consistent feature of these pre-stained standards. They were not routinely used for 
molecular weight determination. Both secreted and membrane-associated 
recombinant NSI treated with endoglycosidase H exhibited an intermediate 
molecular weight when compared to the mock treated and endoglycosidase F 
treated NSI (Fig 5.7, lanes 4 & 8). This indicated that one of the two polymannose 
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sugars on both forms of NSI was trimmed to a trimannosyl core that was 
endoglycosidase H resistant (Tarentino and Maley, 1975). This modification most 
likely represents the fully processed high-mannose glycan identified in baculovirus 
infected S. frugiperda cells (Jarvis and Summers, 1989). Addition of complex 
carbohydrates that occurs in mammalian cells, does not appear to occur in insect 
cells due to the absence of the requisite glycosyltransferases (Butters and Hughes, 
1981; Jarvis and Finn, 1995). The finding that baculovirus recombinant expressed 
mNSI was partially resistant to endoglycosidae H digestion is at variance with 
observations of NSI expressed by dengue virus infection with both mammalian and 
insect cells. For native mNSI, endoglycosidase H digestion resulted in the 
complete removal of carbohydrate moieties suggesting that this form of NSI had 
not undergone any further processing beyond the linkage of two polymannose 
sugars in the ER. This discrepancy between recombinant and native forms may be 
the result of different pathways of maturation. In flavivirus infected cells, NSI is 
functionally retained in association with vesicles that are the sites of viral RNA 
replication and therefore are not likely to pass through the Golgi where processing 
occurs. The maturing recombinant NSI in contrast undergoes no such retention. 
Figure 5.7 also demonstrates that both recombinant secreted and membrane-
associated NSI formed dimers as is seen for authentic NSI, and this dimer was 
non-covalent in nature being converted to the monomeric form by heating. 
(iv) Antigenicity 
An antigenic map of both recombinant membrane-associated and secreted Ac.NSI 
was constructed in the same way as for NSI purified from dengue virus infected 
cells which was described previously in Chapter 4. Representative MAbs from each 
antigenic group (A, B, C I , C2 etc) were used in competition analyses and the 
resulting maps are shown in Figure 5.8. The high degree of correlation between the 
competition maps for both the recombinant secreted (Figure 5.8B) and recombinant 
membrane-associated NSI (Figure 5.8C) with native secreted NSI (Figure 5.8A) 
derived from dengue infected Vero cells (complete map shown in Figure 4.3), 
indicated that antigenically the proteins were very similar. This probably reflected 
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the correct processing and folding of the protein to maintain recognition by both 
linear and conformational MAbs. Preservation of structural integrity within the 
dimeric form of recombinant NSI is promising in the absence of a functional in vitro 
A B C1 C2 D1 D2 D3 D4 D5 E 
assay. An interesting observation from 
this data was that in contrast to 
membrane-associated NSI derived from 
Vero cells, A domain specific MAbs 
recognize membrane-associated 
recombinant protein. In this regard, the 
competition profile of the two membrane-
associated NSI preparations from insect 
cells (both Sf and C6/36 cells; - compare 
Figure 5.8C and Figure 4.8B 
respectively) are similar. As discussed in 
Chapter 4, this may be a consequence 
of a similar glycosylation profile leading 
to a particular protein conformation. 
Figure 5.8 Antigenic competition maps 
of A, Vero-derived sNSI; B, Sf-derived 
recombinant sNSI; C, Sf-derived 
recombinant mNS1. Shading represents 
competition between MAbs of 0-30% (clear 
boxes), 31-50% (grey boxes) and 51-150% 
(black boxes). E, Enhanced binding 
(>150% binding). NT, Not tested. Letters 
on top of the figure refer to epitope 
domains identified in Chapter 4. 
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Protection experiments in female Balb/c 
mice were performed to compare the 
immunogenicity of immunoaffinity 
purified recombinant NSI to 
immunoaffinity purified native NSI. 
Equal doses of NS1 (as determined by 
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protein concentration) afforded equal protection against challenge, to that seen with 
native protein (Qu and Young, unpublished observations). These experiments thus 
further confirmed that recombinant NSI behaves immunogenically and antigenically 
in a similar way to native protein. 
(c) Towards the crystallization of NS1 
Previous attempts in our laboratory to purify large amounts of native protein for 
crystallography have proven difficult due to the comparatively low concentrations of 
NSI produced in dengue virus infected cells. As has been described in the 
preceding section of this chapter, a recombinant protein has been expressed that 
appeared to structurally and antigenically resemble the authentic protein. This 
recombinant protein has been shown to be glycosylated and to dimerize while also 
maintaining the ability to be either secreted or to become membrane-associated in 
the infected cell. Most importantly, the previously identified antigenic domains within 
the native dimer form of dengue-2 virus NSI have also been retained. It was 
therefore considered likely that the crystal structure of this protein would accurately 
reflect that of the native protein and we therefore proceeded towards crystallization 
of recombinant NSI. 
(i) Two-dimensional gel analysis 
Two-dimensional gels were performed to allow comparison between the native and 
recombinant NSI protein. Membrane-associated ^^S - labelled NSI derived from 
dengue-infected C6/36 cells was electrophoresed on a two-dimensional gel and 
four different isoelectric points (pi) from 5.5 - 5.8 were obtained (Figure 5.9A). This 
corresponded to four different isoforms of membrane-associated NSI of very 
similar molecular weight. To confirm that these bands were indeed NSI and not 
artefacts, the gel was exposed to X-ray film. As can be seen from Figure 5.9B the 
bands in both figures correspond with each other. This result confirmed our initial 
hypothesis that the membrane-associated form of NSI would not be ideal for 
crystallography studies as revealed by the four different pis. Secreted and 
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recombinant NSI were also focussed on a two dimensional gel (Figure 5.9C) and 
the isoelectric point was determined to be approximately 5.7. This is the first report 
of a pi value for dengue virus NSI. 
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Figure 5.9 Two dimensional gels. (A) Silver stained gel of ^^S-mNS1 purified from dengue 
virus infected C6/36 cells or (C) recombinant sNSI. Arrows indicate NS1 
isoforms. B is an autoradiograph of A. pi markers are indicated with arrow 
heads. 
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(ii) Pulse-chase analysis of the recombinant protein 
Pulse-chase experiments were performed at different m.o.i.s to determine the 
optimum time points for the harvest of recombinant protein from infected cells. 
Figure 5.10 is an autoradiograph of radio-immunoprecipitations showing a 
comparison between m.o.i.s of 1 and 10 and the amount of protein produced in a 
three hour pulse. It is clear that the majority of protein was produced at 24 hours 
with an m.o.i. of 10 although protein production rapidly waned after 24 hours 
probably due to cell death. However at the m.o.i. of 1, protein production was 
maximal at 48 hours and was still detected up to 96 hours post-infection. 
hours p.i. B hours p.i. 
24 48 72 96 24 48 72 96 
Figure 5.10 Autoradiographs of radio-immunoprecipitations of supernatants from ^S-
labelled Ac.NSI infected Sf cells. Supernatants were harvested at 24,48, 72 
and 96 hours after infection (p.i.) at an m.o.i. of 10 (A) or 1 (B). 
An m.o.i. of 1 was chosen with harvests taken at 48 hours for subsequent 
experiments. 
(iii) Purification of recombinant NS1 
The development of efficient protocols for immunoaffinity column purification of 
NSI has been described previously by this laboratory (Falconar and Young, 1990). 
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In this project, initial attempts at purification were performed using tissue culture 
supernatants harvested from infected Sf cells grown in TCI 00 media (Life 
Technologies) containing 10% FCS. An SDS-PAGE silver stain profile of the 
fractions eluted from a typical immunoaffinity purification is shown in Figure 5.11. In 
addition to the purified NSI a high level of contaminating protein bands were seen. 
Elution fraction number 
M l 2 3 4 5 6 7 8 9 10 11 12 13 14 
-^NSI 
Figure 5.11 10% SDS-PAGE silver stained gel of samples from each immunoaffinity 
column elution fraction (10 \i.\Jtrack) purified from Ac.NSI infected Sf cell 
supernatants grown in TCI 00 media with 10% FCS. 
Variable levels of contaminating protein was seen in all individual purifications, with 
none yielding NSI of sufficient purity for crystallization. Given the possibility that a 
contributing factor to this contamination may be due to the high concentration of 
FCS in the medium we converted to serum free media (SF900II, Life Technologies) 
with Sf cells that had been previously adapted to serum free conditions. (Kindly 
provided by Dr Steve Reid's laboratory. Chemical Engineehng Department, 
University of Queensland, St. Lucia, Brisbane). Subsequent purifications from 500 
mL cultures gave significantly cleaner elution profiles as shown in Figure 5.12. The 
two gels shown are representative examples of numerous purifications done over 
the course of this study. 
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[Subsequent to the finding that serum free cultures were able to provide cleaner 
elution profiles a problem was experienced with the supplier, who had changed the 
media formulation. Numerous problems were encountered in terms of cell growth 
and recombinant protein production, and as time was a critical factor, media 
conditions for the final purifications reverted to TC100 with 10% FCS.] 
Elution fraction number 
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Figure 5.12 10% SDS-PAGE silver stained gels of immunoaffinity column elution fractions 
from two different batches of Ac.NSI infected cell supernatants grown in 
SF900II media. 
Cd| Oligomeric forms of NS1 
The dimeric form of NSI was originally detected by Winkler ef a/(1988) for dengue 
2 virus when infected cell lysates were left unboiled priorto analysis by SDS-PAGE. 
Crooks et al (1990) further showed that TBE secreted NSI was likely to be 
hexameric. This group also suggested that the efficiency with which NS1 acts as an 
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effective immunogen, may in part be due to the native form existing as a higher 
order oligomeric structure (Crooks etal, 1994). Indeed the dimeric form of dengue-
2 NSI had been shown to be more immunogenic than the monomer (Young and 
Falconar, 1991), and sNSI was more protective than mNSI (Young and Falconar, 
1991). The oligomerization of NSI secreted from cells infected with a defective 
adenovirus containing the gene coding for NSI alone was examined by column 
chromatography (Crooks etal, 1994). Primarily pentameric and hexameric forms 
were identified, with a small proportion of material being consistent with decameric 
and dodecameric oligomers. Flamand et al (1999) have recently confirmed that 
dengue-1 virus NSI secreted from Vero cells is indeed a hexamer form. This study 
has been able to support these findings and to verify that both the native dengue-2 
NSI and recombinant baculovirus-expressed NSI are also hexameric. 
(i) Chemical cross-linking 
Immunoaffinity-purified NSI was used in cross-linking experiments to determine 
whether evidence could be found for a higher oligomeric form of recombinant NSI 
that reflected that found for native NSI. Figure 5.13A shows the results of cross-
linking both native and recombinant NSI with BS^. SDS - PAGE analysis clearly 
shows that with increasing concentrations of BS^, both forms of NSI resolve as 
higher oligomeric species. All intermediates were observed (labelled in Fig 5.13A) 
with the highest oligomeric form detected having a molecular weight of 
approximately 300 kDa, consistent with a hexamer. 
(ii) Electron microscopy 
NSI protein derived from both dengue-2 infected Vero cells and from recombinant 
baculovirus infected S. frugiperda cells were immunoaffinity purified and examined 
by electron microscopy as described in Section 2.5 (I). Figure 5.13B and C shows 
negative stain electron micrographs of recombinant baculovirus-derived, and native 
NSI respectively. (Electron microscopy was performed by Dr. Lynne Lawrence, 
BRI, Melbourne). These preparations were shown to be composed principally of 
monodispersed particles with a size range from 10 - 12 nm (solid arrow heads). 
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The range of particle sizes suggested some breakdown of the higher oligomeric 
forms probably into tetramer and/or dimer configurations (4 - 6 nm: open arrow 
heads). However the size of the larger particles was consistent with a molecular 
weight of between 300 and 350 kDa or six times the molecular weight of sNSI. At 
high magnification (Figure 5.13D and E) these particles exhibited discernible higher 
order structure when viewed along apparent points of symmetry. 
Ac.NSI DEN2 Vero 
1 5 20 1 
NS1^ 
20 
Figure 5.13 Five-20% gradient SDS-PAGE silver stained gel of immunoaffinity purified 
recombinant NSI and native dengue-2 (Vero derived) NSI cross-linked with 
BS^ at concentrations of 1, 5 and 20 mM (A). Negative stain electron 
micrographs of recombinant sNSI (B) and infected Vero cell derived native 
dengue-2 sNSI (C) and at higher magnification (D and E respectively). 
Schematic representation of D and E (F). 
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The predominant structural form appeared to be a "bundle of rods" seen either from 
side on (Fig 5.13D) or end on (Fig 5.13E), which conceivably represent the 
assembly of three stable dimeric units (schematically represented in Figure 5.13F). 
(iii) Freeze / Thawing 
During the course of this study, aliquots of immunoaffinity purified recombinant NSI 
had been routinely stored at -80°C. Freeze - thawing however is known to 
potentially disrupt protein-protein interactions with subsequent deleterious effects 
on structural analyses (J.Martin, personal communication). Although dimeric forms 
of NSI appear to be highly stable, the fragility of the hexameric form was 
examined. 
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Figure 5.14 Analysis of retentate and filtrate samples of recombinant NSI processed 
through a 100k MW filter (centricon 100) and run on a 10% SDS-PAGE silver 
stained gel. Samples were immunoaffinity purified and stored at either 4°C or 
-80°C prior to analysis. 
Both fresh (stored for less than three days at 4°C after immunoaffinity purification) 
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and frozen samples of purified NSI were examined for retention or passage 
through a 100k molecular weight cut-off filter (centricon 100). The results shown in 
Figure 5.14 demonstrate that on freeze / thawing, the higher oligomeric forms of 
NSI are broken down sufficiently to enable them to pass through the 100k 
molecular weight cut-off filter and appear in the flow-through, whereas very little 
NSI remains in the retentate (compare tracks 6 and 5 respectively). In contrast, 
purified NSI stored at 4°C remained in the retentate with some protein being lost 
during the procedure. The lower band in lane 1 represents contaminating serum 
albumin (BSA) derived from the 10% foetal calf serum in the tissue culture 
supernatant and co-purified with NSI on the immunoaffinity column (see elution 
fractions in Figure 5.12). This contaminating species was completely removed 
during the centricon 100 filtration as shown by the analysis comparing lanes 2 and 
3, offering a convenient additional purification of NSI. 
(e) Crystallography trials 
(i) Factorial Crystal screens 
Several crystallography trials were performed using Hampton incomplete factorial 
screens I and II (See Appendix 5.1). Each screen is composed of a buffer set, and 
each individual buffer contains a combination of various salts, buffers and 
precipitants (Tables 5.2 and 5.3). The first trial involved the use of NSI purified in 
the presence of 0.1% Triton X-100 detergent. Peak fractions from three 
immunoaffinity purifications were pooled and concentrated with a centricon 30 
concentrator. The protein concentration was assayed and was determined to be 
approximately 3 mg / mL. Factorial crystal screens I and II were set up according to 
the hanging drop vapour diffusion method (McPherson, 1989) (Described in 
Chapter 2.5k (i)). At the completion of the procedure, the drops were observed and 
over 90% of wells showed phase separation of the components which suggested 
that the triton X-100 (TX-100) detergent (which had not been removed during the 
centricon procedure), was the likely cause. The drops also appeared to spread and 
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did not show the type of surface tension that is usually observed. It was therefore 
decided to avoid the use of detergent in future purification procedures to alleviate 
this problem. 
The second crystallography trial was comphsed of protein from several 
immunoaffinity purifications performed in the absence of detergent (shown in 
Figures 5.12A and B) that had been concentrated with a centricon 100 and stored 
at 4°C. Surprisingly, it can be seen that cleaner elution profiles were obtained with 
the omission of TX-100 and FCS in the media. The final protein concentration 
obtained was approximately 5 mg / mL (determined by the BCA protein assay) with 
some precipitation of the protein being observed at this concentration. Coomassie 
blue SDS - PAGE analysis of this preparation (Figure 5.15) shows the purity and 
concentration of the final protein obtained. 
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Figure 5.15 Coomassie blue stained 10% SDS-PAGE gel of 5 i^L of a 1.5 mL pool of 
recombinant NSI (start) and 5 jiL of a 200 i^L retentate after processing through 
a centricon 30 concentrator. The filtrate represents 5 \iL from the 1.3. mL filtrate. 
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Hampton factorial crystal screens I and II (the components of which are listed in 
Appendix 5.1) were set up in trays and incubated at room temperature (20°C) or at 
4°C. Examination of the trays revealed a common feature in those wells where 
precipitation and / or crystals were observed after ten weeks. A high molecular 
weight of polyethylene glycol (PEG) as the precipitant usually resulted in 
precipitation occurring and gave an indication of the next type of screen required. 
Two of the most interesting observations however were of microcrystals in crystal 
screen I (well 41) which contained 0.1 M Hopes pH 7.5, 10% v/v 2-propanol and 
20% w/v PEG 4000, and in crystal screen II (well 45) which had very small log 
shaped micro-crystals (shown in Figure 5.16A) and contained 0.01 M nickel (II) 
chloride hexahydrate, 0.1 M Tris pH 8.5 and 20% polyethylene glycol monomethyl 
ether 2000. These crystals grew after three months at 20°C however they were only 
0.05 mm long on the longest axis and therefore not large enough to use for X-ray 
diffraction studies. This preliminary screen had therefore obtained its objective 
which was to narrow down the type of conditions where the protein was starting to 
crystallize or precipitate. 
Continued observation of these crystal screen wells over nine months led to the 
observation of a larger crystal of triangular shape (1.2 mm in its longest dimension 
(Figure 5.16B)) that grew under the conditions of 0.1 M Tris pH 8.5, 20% ethanol at 
20°C (well 44, crystal screen II). Unfortunately this crystal failed to diffract which 
may have been due to the age of the crystal (Dr Tracy Arakaki, 3D Centre, UQ, 
personal communication). Achieving growth of a reasonably sized crystal however 
is indicative of a pure and highly concentrated protein preparation that, with further 
work should yield a suitable candidate for efficient X-ray diffraction studies. 
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0.05 mm 
B 
Figure 5.16 Microcrystals grown in 0.01 M nickel (II) chloride hexahydrate, 0.1 M Tris pH 8.5 
and 20% polyethylene glycol monomethyl ether 2000 (A) and 0.1 M Tris pH 8.5, 
20% ethanol (B) and observed after three months and nine months respectively. 
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5.3 DISCUSSION 
Recombinant NSI from various flaviviruses including JE (McCown et al, 1990; 
Flamand et al, 1992), Kunjin (Khromykh etal, 1996), dengue-2 (Qu et al, 1993; 
Leblois and Young, 1995), dengue-4 (Eckels etal, 1994), MVE (Blitvich etal, 1999), 
Louping III (Venugopal etal, 1994) and YF (Despres etal, 1991) viruses have been 
successfully expressed in the baculovirus expression system. In accordance with 
the findings described in this chapter, recombinant baculovirus expressed JEV NSI 
exhibited the correct molecular weight, secretion, glycosylation and dimerization 
pattern however the majority of the protein accumulated in the ER, where it formed 
insoluble aggregates (Flamand etal, 1992). Yellow fever NSI, expressed with the 
envelope protein in Sf cells exhibited similar size, folding and antigenicity to the 
authentic protein (Despres etal, 1991). In contrast YF proteins E and NSI, when 
expressed together did not produce detectable amounts of NSI in the extracellular 
medium (Despres etal, 1991). This discrepancy has been postulated to be due to 
the presence of the E protein in the construct which associates with NSI in a 
compartment preceding the Golgi in the secretory transport pathway and slows its 
passage to the surface of the cell (Flamand etal, 1992). 
Other groups have successfully used baculovirus expression systems for the 
production of recombinant flavivirus NSI. Baculovirus expression of Louping III (LI) 
virus NSI resulted in an expressed protein which reacted with LI specific MAbs and 
polyclonal antisera in immunofluorescence studies (Venugopal etal, 1994). It was 
expressed on the surface of cells but was not secreted from the cell. In agreement 
with our results with baculovirus expressed dengue-2 virus NSI, LI NSI showed the 
same antigenic reactivity as the native NSI protein (Venugopal et al, 1994) 
confirming that the baculovirus expression system is able to faithfully reproduce the 
expressed protein as with other flaviviruses. We have further confirmed this 
observation for recombinant dengue-2 NSI with our extensive competition map 
analysis (Figure 5.8). Representative MAbs from the five antigenic domains 
identified in Chapter 4, were all recognized by recombinant dengue-2 NSI with the 
pattern of cross competition being very similar between these domains. As the 
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available anti-NSI monoclonal antibodies (22 in total) had corresponding epitopes 
along the whole length of the NSI molecule this antigenic analysis is more 
extensive than those performed in other laboratories. Thus we are confident that 
this protein closely resembles the authentic secreted form of NSI. 
Previous reports have suggested that the flavivirus NSI may be hexameric (rather 
than dimeric) in its native form (Crooks etal, 1990; Crooks etal, 1994) with recent 
convincing evidence also being reported for dengue-1 virus NSI produced in Vero 
cells (Flamand ef al, 1999). We were able to confirm these observations for 
dengue-2 virus NSI derived from infected Vero cells, and also for our recombinant 
NSI derived from Spodoptera frugiperda cells by chemical cross-linking studies and 
by negative stain electron microscopy. Taken together, these findings indicate that 
our recombinant protein is a suitable surrogate for authentic NSI. 
The results described in this chapter clearly indicate that the recombinant NSI 
protein produced by baculovirus expression, and purified and concentrated using 
the methods described should be suitable for further crystallography studies. Two-
dimensional gel analysis of the recombinant protein determined that it comprised a 
single isoform with an iso-electric point (pi) of approximately 5.7 when compared 
with the marker controls, further demonstrating its suitability for crystallization. 
Along with the native NSI analysis this is the first report describing the iso-electric 
point for flavivirus NSI. Disc gel electrophoresis analysed by the Ferguson plot 
showed that each of the dengue NSI serotypes are charge isomers although the 
charge differences appeared to be small (McCloud et al, 1970). Somewhat 
surprisingly, micro-crystals formed in the incomplete factorial crystal screens in a 
buffer pH range of 7.5 - 8.5. Proteins are thought to crystallize around their pi 
because they are least soluble at that point however there is no hard and fast rule 
and this discrepancy is not considered unusual (Dr Jenny Martin, 3D Centre, UQ, 
personal communication). 
Analysis of two different m.o.i.s and the corresponding level of NSI production by 
pulse-chase labelling, showed that although NSI was secreted maximally at 24 
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hours at an m.o.i. of 10, for continuous NSI secretion it was more appropriate to 
infect at an m.o.i. of 1 and to collect supernatant harvests every 24 hours up to 72 
hours. In this way the infected cell was able to secrete more NSI before cell death 
occurred and less virus stock is utilized as inoculum. The high levels of secretion 
obtained from the baculovirus expression system meant that the protein could be 
purified exclusively from the tissue culture supernatants thereby simplifying the 
purification procedure by not having to isolate protein from cell extracts. In addition, 
it was noted that while all secreted NSI was oligomeric in nature a significant 
proportion of membrane-associated NSI remained monomeric. Presumably the 
latter represents misfolded protein retained in the ER as a consequence of over-
expression in this system. Furthermore, omission of TX-100 detergent from the 
purification procedure was found to be necessary to prevent phase - separation in 
hanging drops. Although micro-crystals were obtained in the absence of detergent, 
the failure to form suitable crystals for X-ray diffraction analysis could be due to a 
level of microheterogeneity arising from the different states of oligomerization / 
aggregation during the crystallization process (McPherson et al, 1986). This was 
also evident from the electron microscopy observations. The addition of a neutral 
detergent such as (3 - octyl-glucoside has been shown by McPherson ef a/(1986) to 
give more reproducible and rapid crystal growth at the expense of microcrystals 
especially for glycoproteins. This is a parameter that needs further investigation 
however these experiments were difficult due to the expense of this detergent. 
Significantly, this detergent at 0.5% was successfully used in the purification of the 
TBE envelope protein (Heinz etal, 1991) from which a crystal structure was derived 
with a protein concentration of 6 mg / mL (Rey ef al, 1995). Preliminary studies 
have indicated that detergent exchange (TX-100 for octyl-glucoside) could be made 
on the immunoaffinity column and further studies are undenway to test the products 
of this exchange. PEG was found to be an important constituent of buffers in which 
crystals / microcrystals were observed. Interestingly, PEG 8000 was a component 
of the buffer conditions required for crystallization of the TBE E protein (Heinz etal, 
1991). The use of serum free media (SF900II, Life Technologies) was also found to 
be preferential to medium containing foetal calf serum. Despite ultimately having to 
continue the study with TCI 00 + 10% FCS due to supplier problems, we were able 
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to obtain microcrystals of 0.05 mm in length and a crystal of 1.2 mm on its longest 
axis, from protein produced in TCI 00 media. Ideally crystals need to be of the order 
of 0.5 mm before they can be used in X-ray diffraction studies (Dr. Tracy Arakaki, 
3D Centre, UQ, personal communication). It was demonstrated in section 5diii that 
one cycle of freeze / thawing was able to disrupt the higher oligomeric forms of 
NSI. Purified protein destined for crystallization trials was therefore stored at 4°C 
prior to use and was never permitted to go through any cycles of freeze / thawing. 
Endoglycosidase analysis (Maley ef al, 1989) of the recombinant protein 
demonstrated that both of the N-glycosylation sites were utilized when expressed in 
S. frugiperda cells, in accordance with the reports of other researchers (Flamand et 
al, 1992; Qu etal, 1993). The maintenance of glycosylation of the recombinant NSI 
may be relevant to the preservation of the overall structure of the protein as the loss 
of the carbohydrate moiety on the second glycosylation site of NSI has been 
reported by other researchers to significantly decrease dimer stability and secretion 
of the protein (Pryor and Wright, 1994; Flamand etal, 1999). Additionally, previous 
experiments by Muylaert ef a/(1996) and Pletnev ef a/(1993) showed that removal 
of the complex-type oligosaccharide correlated with a decrease in mouse 
neurovirulence. This may imply that the carbohydrate structure may be significant in 
the formation of the mature secreted form of NSI (Flamand etal, 1999). Crooks ef 
a/(1994) also commented that the increased level of glycosylation seen in secreted 
NSI appeared to assist stabilization of the dimer. Because of these findings 
examination of a deglycosylated form of NSI for structural studies was not 
considered to be an option. 
As with other RNA viruses (Harrison, 1989), such as poliovirus (Hogle etal, 1989), 
rhinovirus and mengovirus (Rossman ef al, 1987) and other viral glycoproteins 
(Laver etal, 1990; Weis etal, 1988; Wiley and Skehel, 1987; Rey etal, 1995) the 
resolution of the three dimensional structure of the dengue virus NSI will have a 
significant impact on the elucidation of the functional properties of this molecule as 
well as potentially providing a target for rational drug design. 
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APPENDIX 5.1 
Table 5.2 Components of Hampton Factorial Crystal Screen I buffers 
TUBE 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
SALT 
0.02 M Ca Chloride 
None 
None 
None 
0.2 M Na Citrate 
0.2 M Mg Chioride 
None 
0.2 M Na Citrate 
0.2 M NH4 Acetate 
0.2 IVI NH4 Acetate 
None 
0.2 M IVIg Chloride 
0.2 M Na Citrate 
0.2 M Ca Chloride 
0.2 M NH4 Sulfate 
None 
0.2 M Li Sulfate 
0.2 M Mg Acetate 
0.2 M NH4 Acetate 
0.2 M NH4 Sulfate 
0.2 M Mq Acetate 
0.2 M Na Acetate 
0.2 M Mq Chloride 
0.2 M Ca Chloride 
None 
0.2 M NH4 Acetate 
0.2 M Na Citrate 
0.2 M Na Acetate 
None 
0.2 M NH4 Sulfate 
0.2 M NH4 Sulfate 
None 
None 
None 
None 
None 
None 
None 
None 
None 
None 
0.05 M K Phosphate 
None 
None 
0.2 M Zn Acetate 
0.2 M Ca Acetate 
None 
None 
1.0 M Li Sulfate 
0.5 M Li Sulfate 
BUFFER 
0.1 M Na Acetate pH 4.6 
None 
None 
0.1 M Tris HCI pH 8.5 
0.1 M Na Hopes pH 7.5 
0.1 M Tris HCI pH 8.5 
0.1 M Na Cacodylate pH 6.5 
0.1 M Na Cacodylate pH 6.5 
0.1 M Na Citrate pH 5.6 
0.1 M Na Acetate pH 4.6 
0.1 M Na Citrate pH 5.6 
0.1 M Na Hepes pH 7.5 
0.1 M Tris HCI pH 8.5 
0.1 M Na Hepes pH 7.5 
0.1 M Na Cacodylate pH 6.5 
0.1 M Na Hepes pH 7.5 
0.1 M Tris HCI pH 8.5 
0.1 M Na Cacodylate pH 6.5 
0.1 M Tris HCI pH 8.5 
0.1 M Na Acetate pH 4.6 
0.1 M Na Cacodylate pH 6.5 
0.1 M Tris HCI pH 8.5 
0.1 M Na Hepes pH 7.5 
0.1 M Na Acetate pH 4.6 
0.1 M Imidazole pH 6.5 
0.1 M Na Citrate pH 5.6 
0.1 M Na Hepes pH 7.5 
0.1 M Na Cacodylate pH 6.5 
0.1 M Na Hepes pH 7.5 
None 
None 
None 
None 
0.1 M Na Acetate pH 4.6 
0.1 M Na Hepes pH 7.5 
0.1 M Tris HCI pH 8.5 
0.1 M Na Acetate pH 4.6 
0.1 M Na Hepes pH 7.5 
0.1 M Na Hepes pH 7.5 
0.1 M Na Citrate pH 5.6 
0.1 M Na Hepes pH 7.5 
None 
None 
None 
0.1 M Na Cacodylate pH 6.5 
0.1 M Na Cacodylate pH 6.5 
0.1 M Na Acetate pH 4.6 
0.1 M Tris HCI pH 8.5 
None 
None 
PRECIPITANT 
30% v/v 2-methyl-2,4-pentanediol 
0.4 M K / Na Tartrate 
0.4 M NH4 Phosphate 
2.0 M NH4 Sulfate 
30% v/v 2-methyl-2,4-pentanediol 
30% w/v PEG 4000 
1.4 M Na Acetate 
30% v/v 2-propanol 
30% w/v PEG 4000 
30% w/v PEG 4000 
1.0 NH4 Phosphate 
30% v/v 2-propanol 
30% v/v PEG 400 
28% v/v PEG 400 
30% w/v PEG 8000 
1.5 M Li Sulfate 
30% PEG 4000 
20% PEG 8000 
30% v/v 2-propanol 
25% w/v PEG 4000 
30% v/v 2-methyl-2,4-pentanediol 
30% w/w PEG 4000 
30% v/v PEG 400 
20% v/v 2-propanol 
1.0 M Na Acetate 
30% v/v 2-methvl-2,4-pentanediol 
20% v/v 2-propanol 
30% w/v PEG 8000 
0.8 M K / Na Tartrate 
30% w/v PEG 8000 
30% w/v PEG 4000 
2.0 M NH4 Sulfate 
4.0 M Na Formate 
2.0 M Na Formate 
1.6 M Na / K Phosphate 
8% w/v PEG 8000 
8% w/v PEG 4000 
1.4 M Na Citrate 
2% v/v PEG 400 & 
2.0 M NH4 Sulfate 
20% v/v 2-propanol & 
20% w/v PEG 4000 
10% v/v 2-propanol & 
20% w/v PEG 4000 
20% w/v PEG 8000 
30% w/v PEG 1450 
0.2 M Mq Formate 
18% w/v PEG 8000 
18% w/v PEG 8000 
2.0 M NH4 Sulfate 
2.0 M NH4 Phosphate 
2% w/v PEG 8000 
15% w/v PEG 8000 
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Table 5.3 Components of Hampton Factorial Crystal Screen II buffers 
TUBE 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
SALT 
2.0 M Sodium chloride 
0.01 M Hexadecyltrimethylammonium 
Bromide 
None 
None 
2.0 M Ammonium Sulfate 
None 
None 
1.5 M Sodium Chloride 
None 
0.2 M Sodium Chloride 
0.01 M Gobaltous Chloride 
hexahydrate 
0.1 M Cadmium Chloride dihydrate 
0.2 M Ammonium Sulfate 
0.2 M Potassium Sodium Tartrate 
tetrahydrate 
0.5 M Ammonium Sulfate 
0.5 M Sodium Chloride 
None 
0.01 M Ferric Chloride hexahydrate 
None 
None 
0.1 M Sodium dihydrogen phosphate 
mono / 0.1 M mono-Potassium 
dihydrogen Phosphate 
None 
1.6 M Ammonium Sulfate 
0.05 M Cesium Chloride 
0.01 M Cobaltous Chloride 
hexahydrate 
0.2 M Ammonium Sulfate 
0.01 M Zinc Sulfate heptahydrate 
None 
0.5 M Ammonium Sulfate 
None 
None 
0.1 M Sodium Chloride 
None 
0.05 M Cadmium Sulfate hydrate 
None 
None 
None 
None 
0.2 M Magnesium Chloride 
hexahydrate 
None 
0.01 M Nickel(ll) Chloride 
hexahydrate 
1.5 M Ammonium Sulfate 
0.2 M mono Ammonium dihydrogen 
Phosphate 
None 
0.01 M Nickel(ll) Chloride 
hexahydrate 
0.1 M Sodium Chloride 
None 
2% v/v Dioxane 
BUFFER 
None 
None 
None 
None 
None 
None 
None 
None 
0.1 M Sodium Acetate trihydrate pH 4.6 
0.1 M Sodium Acetate trihydrate pH 4.6 
0.1 M Sodium Acetate trihydrate pH 4.6 
0.1 M Sodium Acetate trihydrate pH 4.6 
0.1 M Sodium Acetate trihydrate pH 4.6 
0.1 M tri-Sodium Citrate dihydrate pH 5.6 
0.1 M tri-Sodium Citrate dihydrate pH 5.6 
0.1 M tri-Sodium Citrate dihydrate pH 5.6 
0.1 M th Sodium Citrate dihydrate pH 5.6 
0.1 M tri-Sodium Citrate dihydrate pH 5.6 
0.1 M tri-Sodium Citrate dihydrate pH 5.6 
0.1 MMESpH6.5 
0.1 MMESpH6.5 
0.1 MMESpH6.5 
0.1 MMESpH6.5 
0.1 M MES pH 6.5 
0.1 MMESpH6.5 
0,1 MMESpH6.5 
0.1 MMESpH6.5 
None 
0.1 M HEPES pH 7.5 
0.1 M HEPES pH 7.5 
0.1 M HEPES pH 7.5 
0.1 M HEPES pH 7.5 
0.1 M HEPES pH 7.5 
0.1 M HEPES pH 7.5 
0.1 M HEPES pH 7.5 
0.1 M HEPES pH 7.5 
0,1 M HEPES pH 7.5 
0.1 M HEPES pH 7.5 
0,1 M TRIS pH 8.5 
0.1 M TRIS pH 8.5 
0.1 M TRIS pH 8.5 
0.1 M TRIS pH 8.5 
0.1 M TRIS pH 8.5 
0.1 M TRIS pH 8.5 
0,1 M TRIS pH 8,5 
0.1 M BicinepH9.0 
0.1 MBicinepH9.0 
0.1 M Bicine pH 9.0 
PRECIPITANT 
10%w/v PEG 6000 
0.5 M Sodium Chloride, 0,01 M 
Magnesium Chloride hexahydrate 
25% v/v Ethylene Glycol 
35% v/v Dioxane 
5% v/v iso-Propanol 
1,0 M Imidazole pH 7,0 
10% w/v Polyethylene Glycol 1000 
10% w/v Polyethylene Glycol 8000 
10% v/v Ethanol 
2,0 M Sodium Chloride 
30% v/v MPD 
1,0 M 1,6 Hexanediol 
30% v/v Polyethylene Glycol 400 
30% w/v Polyethylene Glycol 
Monomethyl Ether 2000 
2,0 M Ammonium Sulfate 
1.0 M Lithium Sulfate monohydrate 
4% w/v Ethylene Imine Polymer 
35% v/v tert-Butanol 
10% v/v Jeffamine M-600 
2.5 M 1,6 Hexanediol 
1,6 M Magnesium Sulfate heptahydrate 
2.0 M Sodium Chloride 
12% w/v Polyethylene Glycol 20,000 
10% v/v Dioxane 
30% v/v Jeffamine M-600 
1.8 M Ammonium Sulfate 
30% w/v Polyethylene Glycol 
Monomethyl Ether 5000 
25% v/v Polyethylene Glycol 
Monomethyl Ether 550 
1.6 M tri-Sodium Citrate dihydrate pH 
6.5 
30% v/v MPD 
10% w/v Polyethylene Glycol 6000, 
5% v/v MPD 
20% v/v Jeffamine M-600 
1.6 M Ammonium Sulfate 
2.0 M Ammonium Formate 
1.0 M Sodium acetate 
70% v/v MPD 
4.3 M Sodium Chloride 
10% w/v Polyethylene Glycol 8000, 
8% v/v Ethylene Glycol 
20% w/v Polyethylene Glycol 10,000 
3.4 M 1,6 Hexanediol 
25% v/v tert-Butanol 
1.0 M Lithium Sulfate monohydrate 
12% v/v Glycerol anhydrous 
50% v/v MPD 
20% v/v Ethanol 
20% w/v Polyethylene Glycol 
Monomethyl Ether 2000 
30% w/v Polyethylene Glycol 
Monomethyl Ether 550 
2.0 M Magnesium Chloride 
hexahydrate 
10% w/v Polyethylene Glycol 20,000 
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CHAPTER 6 
CONCLUSIONS AND FUTURE DIRECTIONS 
This thesis describes many new characteristics of the dengue virus NSI 
glycoprotein in terms of antigenicity and structure, its presence in patient sera 
and also provides a basis for the purification and screening conditions required 
to ultimately determine the crystal structure of the molecule. 
6.1 NS1 in dengue patient sera and its role in pathogenesis 
The development of an antigen capture ELISA for the detection of NSI in patient 
sera has described for the first time an assay for the detection and quantitation 
of NSI in the serum of dengue patients (Young etal; 2000). NSI was able to be 
detected in dengue patients experiencing primary and secondary infections with 
the concentration of NSI increasing in secondary infections. Specific antibody to 
NSI was detected in dengue patients also with increased concentrations being 
detected in secondary infections. These combined results have hinted at a 
correlation between relatively high levels of NSI in acute sera in combination 
with high levels of antibody to NSI in the convalescent sera of patients with 
severe grades of disease (grades III and IV). On the basis of this work, a 
collaborative study between this laboratory and AFRIMS in Bangkok, Thailand, 
has utilized the NSI capture ELISA to examine NSI levels in dengue infected 
children in serum taken daily during the course of the illness. The results showed 
that NSI levels greater than or equal to 600 ng / mL on presentation was an 
excellent prognostic marker for the subsequent development of DHF (Libraty ef 
al, 2002). Utilizing the assay to determine which dengue patients are at risk of 
developing DHF, using NSI as a marker, should be extremely beneficial in terms 
of clinical management and disease outcome. 
The pathogenesis of dengue haemorrhagic fever / dengue shock syndrome has 
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remained largely unexplained. Many of the sequelae including plasma leakage, 
complement depletion and thrombocytopenia are not accounted for in the 
models suggested by Kurane and Ennis (1994) and Halstead (1998). Any 
proposed mechanism must account for all the clinical manifestations of the 
disease, especially the lack of pathology in major organs observed at autopsy 
and the rapid recovery, without significant sequelae for survivors. These 
obsen/ations suggest that these clinical manifestations are mediated by the local 
release of quick acting biological mediators capable of causing severe illness 
with little resulting structural injury. Although our initial results are preliminary in 
their findings we have hypothesized that the presence of NSI immune 
complexes may contribute to the pathogenesis of dengue disease. Immune 
complexes have been reported in DHF patients (Theofilopoulos et al, 1976) and 
other researchers have reported that there is a direct correlation between the 
level of immune complexes and complement consumption in severe disease 
(Bokisch et al, 1976a, Malasit, 1987; Rothman and Ennis, 1999; Boonpucknavig 
et al, 1976b). We have suggested that it is circulating NSI immune complexes 
that are able to be deposited in tissues resulting in complement activation and 
tissue injury. Complement may also lead to lysis of dengue infected 
mononuclear phagocytes via complement-mediated cytolysis, resulting in the 
release of potent biological mediators that could affect vascular permeability 
(Bhadki and Kazatchkine, 1990). NSI immune complexes may also interact with 
cellular receptors resulting in the release of biologically active mediators through 
natural killer cell activity or ADCC (Hill et al, 1993; Kurane ef al, 1984; Jacobs 
and Young 1998). Despite the evidence for the pivotal role of immune complexes 
and complement it does not explain the disease manifestations in infants 
undergoing primary infection who have low antibody levels. This scenario 
provides evidence for mechanisms elicited by cell-mediated immunity in 
pathogenesis. Although progress is being made towards understanding 
individual aspects of dengue pathogenesis, further work is required to analyse 
how each immune mechanism interplays in contributing to severe DHF and DSS 
especially with the increasing number of outbreaks occurring throughout the 
world. 
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6.2 The antigenicity and structure of NS 1 
Five antigenic domains and up to ten distinct epitopes on NSI have been 
identified, described and putatively mapped to the tertiary structure of the 
protein. This is the first time that such a comprehensive antigenic map has been 
presented for dengue virus NSI. Other groups have described antigenic 
epitopes for NSI of various flaviviruses (Henchal et al, 1987; Putnak et al, 1988; 
Mason etal, 1990; Yao et al, 1995; Garcia etal, 1997; Huang etal, 1999; Hall ef 
al, 1990; Wu ef al, 2001; Bugrysheva ef al, 2001) however the large panel of 
anti-NSI monoclonal antibodies previously produced in this laboratory (Falconar 
and Young, 1991) have enabled the collation of this extensive map. By 
examining the monoclonal antibody competition profile for different forms of NSI 
derived from different cell lines, several differences were noted. The lack of 
recognition by MAbs of an important protective epitope on membrane-associated 
NSI derived from Vero cells (the A epitope) is the likely reason for the previous 
observation by Falconar and Young (1990) that sNSI generated higher levels of 
protection to lethally challenged experimental animals than mNSI derived from 
dengue infected Vero cells. The lack of reactivity by MAbs to the epitope was 
found not to be a consequence of steric hinderance by an adjacent carbohydrate 
moiety although we did not discount the possibility that it could be due to 
conformational effects of carbohydrate addition and / or modification. To 
definitively address these possibilities would require further experimentation, 
either with the glycosylation inhibitor tunicamycin, or with recombinant 
constructs. Another possible reason for the differential recognition of the A 
domain, is that in mNSI, the region encompassing the A epitope is involved in 
membrane association and may therefore be hidden within the tertiary structure. 
TX-114 phase extraction experiments with proteolytic fragments supports this 
theory as the N-terminal third of the molecule was shown to exhibit hydrophobic 
properties. 
A structure prediction algorithm suggested that the three alpha-helices present in 
the N-terminal region of flavivirus NSI are amphipathic in nature. The 
hydrophobic residues comprising these helices are highly conserved implying a 
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functional role. Coincidently, one of these helices forms a component of the A 
epitope which was found to be differentially displayed in secreted and 
membrane-associated forms and between oligomeric forms. On this basis it is 
speculated that this hydrophobic domain may determine the fate of newly 
synthesized NSI (Figure 6.1). 
signalase 
B 
mNS1 sNS1 
0 
ts 
V 
Dimerization 
domain 
Hydrophobic 
region 
NS1 
Figure 6.1 Hypothetical model for the formation of mNS1 and sNSI. A, Schematic 
diagram highlighting key stages in the intra-cellular maturation pathway 
of NSI. NSI is expressed in the context of a polyprotein which is post-
transiationally cleaved to yield the individual viral proteins. Signalase 
cleavage at the N-terminus and cleavage by an as yet unidentified ER 
resident host-cell protease at the C-terminus yields full-length NS1 (1). 
Reflecting its hydrophilic profile, this species is found initially as a 
monomeric soluble protein (2). Dimerization occurs within 10-20 
minutes after synthesis via the interaction between a domain (light blue 
sphere) located in the C-terminal region of the protein. Dimerization is 
accompanied by the acquisition of a hydrophobic character which the 
present study has suggested is located in the N-terminal region (yellow 
sphere) of the protein. This induced hydrophobicity commits the dimer 
to either membrane-association (4) or association with other dimers (5) 
in order to stabilize the exposed hydrophobic domain. B, Electron 
micrographs of purified sNS1 highlighting apparent correlates of the 
hypothetical sNS1 structure viewed either from the side (top panel) or 
end on (bottom panel). 
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Once NSI is cleaved from NS2A in the ER by a resident protease, it is 
essentially a soluble monomeric hydrophilic protein. After dimerization has 
occurred through interaction of a domain at the highly conserved C-termini, the 
dimer acquires a hydrophobic character that this thesis has shown to be 
localized to the N-terminal third of the molecule. It is the induction of this 
hydrophobicity that we speculate may commit the molecule to membrane-
association and its subsequent role as a component of the replication complex. 
In this way the hydrophobic region is stabilized by membrane-association, 
implying that the functional form of NSI within the infected cell may be dimer. As 
NSI levels increase to concentrations higher than that required for RNA 
replication, it is tempting to speculate greater chance of dimer interactions may 
predominate thereby stabilizing the exposed hydrophobic domain through 
association with two other dimers (Figure 6.1) to generate the secreted 
hexameric form of NSI. This hypothesis implies that the hexameric form of NSI 
may simply be the result of over-expression and serves as a way of removing 
unwanted levels of protein from the cell. This would in turn explain why 
hexameric forms are readily generated by NSI over-expressed in the 
baculovirus expression system as shown in Chapter 5 of this thesis. The 
possibility that the secreted form of NSI also has a functional role either in vitro 
or in vivo cannot be discounted. It is proposed that future work examine some of 
these possibilities by mutating the conserved amino acids in the hydrophobic 
region and assaying the expressed protein for oligomer formation, secretion and 
hydrophobicity. It would also be critical to determine which oligomeric form of 
NSI exists on cellular membranes however these experiments are inherently 
difficult, as detergent solubalization is usually required to purify the protein away 
from the membranes. 
Evidence from the competition analyses that C and D domain reactive MAbs 
were able to compete with each other, although they are known to be located 
distally in the primary sequence suggests that these regions may be in close 
proximity in the native folded structure. This was also supported by results 
indicating that intermolecular competition occurs between these epitopes. Some 
of the data presented here is also consistent with the possibility that the 
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interaction between the C and D domains is hydrophobic in nature. This may 
explain the decrease in integrity of these domains for mNSI that had been 
prepared by detergent solubalization. Further evidence is provided by a lack of 
passive protection provided by MAbs in the C I , C2, Dl and D2 domains, which 
suggests that their orientation on, or near, the infected cell surface is not optimal 
to provide effective ADCC or complement-mediated lysis to confer such 
protection. 
A structural model for NSI was provided in Figure 4.20 by collating the data from 
this study. We now await the three dimensional resolution of the crystal structure 
of native NSI as a basis on which to compare our model. 
It would also be interesting in future work to apply the competition analysis to 
serum from dengue patients to determine which NSI epitopes antibody 
responses are directed to. In terms of vaccine development it would be 
invaluable to know whether specific epitope responses vary between individuals 
and according to the severity of subsequent disease. 
6.3 Recombinant baculovirus expressed NS1 and its suitability for 
crystallography studies. 
Recombinant baculovirus-expressed secreted NSI was immunoaffinity purified 
and, in the absence of a functional assay was assessed for antigenic and 
biochemical integrity. It was found to resemble native NSI in terms of cellular 
localization, secretion, oligomerization, glycosylation and antigenicity. The 
extensive antigenic map that had been established for native NSI in Chapter 4, 
was invaluable in analyzing the structure of recombinant NSI and determining 
that antigenically, the expressed protein had retained authentic antibody 
reactivity. This was reinforced with protection experiments using this 
recombinant protein that suggested that it may be suitable for further vaccination 
studies. Cross-linking and electron microscopy studies provided support for the 
reported hexameric structure of both native and recombinant sNSI. Crystal 
screens were performed with purified recombinant NSI and several crystal 
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structures were obtained. Although too small for diffraction analysis the 
approximate buffer conditions for crystallography and methodology for purifying 
protein have been determined. 
Future attempts at NSI protein purification for crystallography should ideally be 
carried out in serum free media and protein fractions stored at 4°C as freeze / 
thawing was found to be detrimental to the hexameric structure. Nevertheless 
recombinant protein produced in serum containing media (due to supply 
problems) did ultimately give some crystal structures. Due to time limitations, 
further crystal screens could not be performed in this study but future work 
should focus on production of recombinant secreted NSI from large-scale 
cultures of Spodoptera frugiperda cells. A recent collaborative study between 
ourselves and the Chemical Engineering Department, UQ has optimised fed-
batch cultures in the presence of an insect moulting hormone to increase 
recombinant NSI production (Chan et al, 2002). The application of this 
technique to recombinant NSI production is likely to increase the yields and 
concentration of expressed protein and assist in the successful production of 
crystals suitable for structural analysis. It is envisaged that solving the crystal 
structure of NSI will shed some light on the elusive biological function of the 
dengue-2 virus glycoprotein, NSI and allow verification of the accuracy of our 
proposed structural model. 
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